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v Preface 
The first monograph on haemorrhagic septicaemia (HS) 
was published by the Food and Agriculture Organization 
(FAO) in 1962. Two decades later, following a 
recommendation of the Third International Workshop on 
Haemorrhagic Septicaemia (December 1979), this 
monograph was revised and  updated and a new edition 
was published in  1982. During the 1980s and  1990s, 
there has been a considerable amount of research  on  HS 
and a vast amount of new information has become 
available. A significant feature of this period was the 
collaborative work by Australian scientists with scientists 
in many Asian countries, supported by the Australian 
Centre for International Agricultural Research  (ACIAR). 
This has led to the introduction of new technologies into 
haemorrhagic septicaemia research and development. 
The FAO has also funded a number of projects on  HS in 
the Asian  region. 
This monograph attempts to capture all  the new 
information generated through these projects - to 
enrich and add to the available information and present 
it in a form that will address the needs of a wide 
readership.  It seeks to satisfy multiple roles,  including 
that of a textbook, a review and a laboratory manual. 
It is,  therefore, targeted for veterinary students, 
practising veterinarians, research  workers and also 
animal health administrators and policy makers. 
I have endeavoured to incorporate into this monograph 
all accessible published and  unpublished information, 
as well as  my own experiences with the disease. 
The information on enzyme-linked immunosorbent 
assay (ELISA) and molecular techniques (Appendixes 
3-6) was kindly contributed by Dr Kirsty Townsend of 
the School of Veterinary Science and Animal 
Production, The University of Queensland. The 
photographs were contributed by Dr Neil Horadagoda 
of the Faculty of Veterinary Medicine and Animal 
Science,  University of Peradeniya, and the staff of the 
Veterinary Research  Institute, Peradeniya, Sri  Lanka 
(the FAO Regional Reference Centre for Haemorrhagic 
Septicaemia). These contributions, and the interest and 
support of ACIAR, are gratefully acknowledged. 
Dr M .C.L.  De Alwis 
Veterinary Research  Institute 




Dr Malcolm De Alwis is  Head of the Veterinary 
Research  Institute (VRI) in  Sri  Lanka.  He graduated 
with a bachelor of veterinary science degree from the 
University of Peradeniya, Sri  Lanka in  1963 and he has 
a PhD from the University of Liverpool. After a short 
time as a provincial veterinarian he joined the VRI, 
where he has worked for the last 33 years,  initially as a 
research  officer, then as  Head of the Division of 
Bacteriology and currently as  Head of the VRI.  During 
this time, Dr De Alwis has specialised in  bacterial 
diseases of agricultural animals, particularly 
haemorrhagic septicaemia. Introduction 
Haemorrhagic septicaemia (HS)  is an  acute, fatal, 
septicaemic disease of cattle and buffaloes caused  by 
specific serotypes of the bacterium 
Pasteurella multocida. The numerous serotypes of 
P.  multocida are associated with a variety of disease 
syndromes in a wide range of agricultural, domestic 
and feral animal species.  In  many instances pasteurella 
plays a secondary role in the pathogenesis of the 
disease or acts in combination with other agents. HS, 
on the other hand, is a primary pasteurellosis and is 
reproducible in  susceptible host species using pure 
cultures of the causative organism alone. This  is 
comparable to typhoid fever, for example, which is  a 
specific form of salmonellosis caused  by a specific strain 
of salmonella in  a specific host species. 
HS can  be controlled by vaccination and most countries 
where the disease  is endemic resort to routine 
prophylactic vaccination. The vaccines currently in 
routine use are satisfactory and strategic vaccination 
programs have resulted in  substantial reduction in  the 
losses.  However, research  is  in  progress for the 
development of an  improved vaccine, to overcome 
some remaining weaknesses in  the current vaccines. 
HS occurs most commonly in cattle and buffaloes. 
Buffaloes are more susceptible than cattle and the disease 
occurs more frequently in  poor husbandry conditions. 
Clinical symptoms are often not observed but include 
high temperature, loss of appetite, nasal discharge, 
increased salivation and laboured breathing, with 
swellings in the submandibular region. Death usually 
occurs quickly and mortality is virtually 100% in infected 
animals. True recovery from clinical disease occurs only if 
the animal  is treated in the very early stages, which is 
often impossible under prevailing field conditions. 
HS has been recorded  in almost all  parts of the world 
except for Oceania, including Australia, where it has 
never occurred. Its distribution is related to climatic 
conditions, husbandry practices and the types of animals 
reared.  The disease is of great economic importance in 
Asia where cattle and buffaloes are abundant and are 
vital for draught power and  milk production. It is  less 
important in Africa where there are relatively few cattle 
and  buffaloes and  because other animal diseases cause 
relatively more severe economic losses. 
Although the conventional host species are cattle and 
buffaloes, P.  multocida has been reported or suspected 
in  Bali  cattle, pigs, goats, sheep, horses, donkeys, 
African buffaloes, camels, yaks and  poultry. 
Explosive outbreaks of HS  may occur when it is first 
introduced to areas that have previously been free of 
the disease, or when it occurs as sporadic outbreaks in 
non endemic areas.  In endemic areas,  large numbers of 
animals that survive after an  outbreak of disease 
become latent carriers. They intermittently shed the 
organisms but, since the herd immunity is also high, 
there are no fresh clinical cases. A new outbreak occurs 
when a shedder comes into contact with a susceptible 
animal, which may be one born after the previous 
outbreak or one introduced into the herd from 
elsewhere. The chance of a fresh outbreak increases 
with time with an  increase in  size of the susceptible 
population. 
Movement of animals can  precipitate new outbreaks of 
disease in  two ways.  Firstly, the animals moved may be 
carriers and may infect susceptible stock. Secondly, the 
animals moved may be susceptible to the disease and 
become infected from native immune carriers.  In  either 
case,  explosive outbreaks can  result. 
Once the first clinical case occurs, more bacteria are 
shed and disseminated. Their survival in  the 
environment and  transmission to other animals depend 
on factors such  as closeness of contact, hygiene and 
climate (wet conditions prolong the survival of the 
causative bacteria outside the animal, making an 
outbreak more likely). The size  of the outbreak 
depends on the proportion of immune to non immune 
animals in the herd. Occasional sporadic outbreaks 
allow the build up of nonimmune animals and a major 
outbreak may occur.  Regular seasonal outbreaks result 
in  much higher herd immunity (through frequent 
exposure) and outbreaks that do occur therefore tend 
to be  less significant. 
Several international organisations have played a 
significant role in assisting in the control of HS.  These 
are the Food and Agriculture Organization (FAO) of 
the United Nations, the Office International des 
Epizooties (OlE, a world organisation for animal health) 
and the Australian Centre for International Agricultural 
Research  (ACIAR). The assistance provided by these 
organisations includes encouragement and funding of 
ix research, development of diagnostic techniques and 
vaccine production technologies and facilitating control 
of the disease through strengthening and establishment 
of diagnostic and vaccine production facilities in the 
countries where the disease exists. 
Outline of monograph 
In this monograph an  attempt has been made to bring 
together all the current information on HS.  This 
includes the global distribution and economic 
importance of the disease (Chapter 1); a review of the 
causative organism (Pasteurella)  and its relationship to 
HS and other animal diseases of economic importance 
(Chapter 2); and the mode of infection, clinical signs 
and pathology (Chapter 3), epidemiology (Chapter 4), 
diagnosis (Chapter 5), and treatment and control 
(Chapter 6) of HS.  Chapters 7,  8 and 9 are devoted to 
the types of vaccines currently available, vaccination 
programs and vaccine research  and development, 
respectively. Some priority areas for future research  are 
identified in  Chapter 10. 
The appendixes give details of laboratory techniques 
for diagnosis and technologies for production and 
quality control of vaccines. These include simplified 
methods that can  be carried out in any modestly 
equipped laboratory in the developing countries where 
the disease  is endemic, and  sophisticated molecular 
techniques that are mainly research  tools at present but 
may,  in  time, emerge as  routine procedures. 
x Global Distribution and Economic Importance 
Overview 
Global distribution 
Haemorrhagic septicaemia (HS) has a wide global 
distribution. In most Asian and African countries, it is 
endemic. Other countries have recorded a low sporadic 
or exceptional occurrence. I  n a few other countries the 
disease has been suspected clinically but has not been 
confirmed by serology. HS has never been reported in 
a few countries, including the United Kingdom, 
Oceania (including Australia) and some European 
countries. 
Economic importance 
Most Asian countries rank HS as one of the most 
economically important diseases or the most 
economically important bacterial disease. The Office 
International des Epizooties (OlE) classifies HS with 
a number of other bacterial and parasitic diseases as a 
List B disease. 
1.1  Global Distribution 
Haemorrhagic septicaemia (HS)  has been recorded 
in almost all  parts of the world except for Oceania, 
including Australia, where it has never occurred 
(see Table  1.1). 
It occurs in South and Southeast Asia,  including 
Indonesia, the Philippines, Thailand and Malaysia. The 
disease was first reported as early as the 1880s in 
Malaysia (FAa 1991). In  Sri  Lanka, it was first reported 
in  1911  but assumed epidemic proportions in the mid-
1950s and routine vaccination was introduced in  1957. 
It is believed to have been  introduced into the 
Philippines in  buffaloes (carabaos) imported from Hong 
Kong in  1902 and  in  a shipment of cattle imported 
from Shanghai in  1903. However, the first authentic 
reports of the disease in the Philippines were from the 
Visayas and in Bulacan, Luzon. After this, sporadic cases 
were reported until the mid-1950s when the disease 
had spread to 40 of the 54 provinces (FAa 1959). 
HS  has been reported in the Near and Middle East, 
southern Europe and North, Central and East Africa. 
There are records of HS in  Iran dating back to the 
1930s, and a serious study of the disease was  made at 
the Razi  Institute in  1935. A saponin adjuvanted vaccine 
has been  used  as an  immunising agent in  Iran since 
1938 (FAa 1959). There  is  a report of HS occurrence 
in  South Africa (Bastianello and Jonker 1981). 
In the United States, the disease was reported among 
bison in  national parks in  1912, 1922 and 1965-67. 
Outbreaks were also reported among dairy cattle in 
New Jersey in  1969 and among beef calves in 
California in  1993 (Heddleston et al.  1967; Carter 
1982; Blanchard et al.  1993). In summer 1993, an 
outbreak was reported among beef calves in  New 
Brunswick, Canada (Rimier and Wilson 1994). Cultures 
from these outbreaks are still available in  collections 
and confirm the diagnosis. However, apart from these sporadic outbreaks, the disease has not become 
endemic in  North America. 
HS was recognised  in Japan  as early as  1923 but has 
not been  recorded since  1954 and was never endemic 
(Carter 1984; FAO 1959). 
The disease has never been  reported in Oceania 
(including Australia), or most of western Europe. There 
have been some reports suggestive of HS from some 
Central and South American states, and from southern 
and eastern  European countries (FAO-WHO-OIE 
Animal Health Yearbook 1994) but these reports are 
not supported by serotype identification for 
confirmation. Table  1.1  gives  a summary of the global 
distribution of the disease.  It is  likely that HS  may occur 
in  some South American countries with high water 
buffalo populations, and  where conditions are 
somewhat similar to those prevailing in tropical Asia. 
1.2  Economic Importance 
1.2.1  Asia 
Asia has 423 million cattle and 145 million buffaloes-
33 % and 95 %, respectively, of the world's populations 
of these species. 
Cattle and buffaloes are reared  mainly for use as 
draught animals in the rice fields, but in  India and, to a 
lesser extent, Pakistan, milk production is  also important 
(FAO 1994, 1995). In Asia as a whole, buffaloes 
contribute 37% of milk production but in  India, where 
the production of milk is the highest in Asia,  nearly 50% 
of the milk is produced from buffaloes. 
Where animals are used  for draught power, which is a 
seasonal activity, they are managed in  an extensive, 
free-range system for most of the year.  Such conditions 
are an  ideal environment for the spread of diseases 
such  as  HS because herds of animals belonging to 
different owners roam together in common grasslands, 
drink in  common village tanks and are often even 
paddocked together at night. Such animals are often 
less well managed, with lower vaccination coverage, 
than more intensively farmed animals. 
2 
The relatively high buffalo population in Asia,  together 
with the higher susceptibility of this species to the 
disease and the high case fatality (see  Chapter 4), all 
highlight the significance of the economic losses caused 
by  HS  in the Asian  region. 
Diseases such  as  rinderpest have now been effectively 
controlled or eradicated, while foot-and-mouth disease 
(FMD) has a low mortality (particularly among animals 
indigenous to the region). Hence, HS  has emerged as a 
disease of considerable economic importance in the 
Asian  region. 
1.2.2 Africa 
HS  is of less economic importance in the African region 
than in Asia.  This  is  because Africa has  less of the 
world's cattle and  buffalo populations, with only 15% 
and 2 % for cattle and  buffaloes, respectively (FAO 
1995). Also, many other animal diseases cause more 
severe economic losses. These include the African 
endemic diseases, such  as trypanosomiasis (nagana), 
theilleriosis (East Coast fever) and contagious bovine 
pleuropneumonia; and also  rinderpest and  FMD, which 
are common to both Africa and Asia.  Published  reports 
on economic losses in the African region are scarce. 
1.3 Economic Losses  in Asia 
The actual economic losses due to HS are difficult to 
determine. The prevalence of HS and the morbidity 
and mortality rates are known in most Asian  countries 
and a few countries have attempted to quantify the 
losses.  However,  since the methods used  have varied 
from one country to another, the findings are not 
strictly comparable. 
The problem is that many factors need to be 
considered in  computing economic losses.  For example, 
HS occurs mainly in  situations where husbandry 
practices are poor and animals are reared  under a free-
range system.  In such situations, disease-reporting 
systems,  particularly passive systems that depend on 
the owner or farmer notifying the relevant authorities, 
are poorly developed. Thus,  a wide discrepancy is Table 1.1.  Summary of the global distribution of haemorrhagic septicaemia. 
Disease endemic 
ASIA 
Bhutan, China,  India, 
Indonesia, Malaysia, 
Mongolia, Myanmar, 
Philippines, Sri  Lanka 
AFRICA 
Central African Republic, 
Chad, Ivory Coast, Ghana, 
Guinea, Kenya, Mozambique, 
Niger, Nigeria, South Africa, 
Zimbabwe 
AMERICA 
Argentina, Brazil  (part), 
















Antigua and  Baruda, 
EI  Salvador (1990), 
Paraguay (1985), 
St Kitts and  Nevis 
Estonia,  Latvia,  Albania, Austria, 
Portugal,  Croatia, Greece 




Hong Kong (1984), 
Israel (1948), 
Singapore (1930) 
Algeria, Republic of Congo, 
Egypt (1970), Eritrea (1993), 
Mauritius (1989), Morocco, 
Namibia (1988), Seychelles, 
Sudan, Tunisia 
Barbados,  Belize 
Bolivia, Chile, 








Sweden,  Switzerland, 

















a The year indicated within brackets is the known year of last occurrence. In other instances, year of last occurrence is  unknown. 
Source:  FAO-OIE-WHO Animal Health Yearbook 1994. Only countries which submitted information on  haemorrhagic septicaemia for 
the year are  included. 
3 bound to exist between actual deaths and  reported 
deaths. This  is  borne out by the findings of an  active 
surveillance study carried out in  Sri  Lanka (De Alwis 
and Vipulasiri 1980) compared to the reported deaths 
in that country (see Section 1.3.1). 
Secondly,  losses cannot merely be restricted to the 
market value of the animal at the time of death. The 
productive potential of the animal, its reproductive 
capacity and,  in  the case of draught power loss, the 
cost of alternate sources of draught power have to be 
taken into account. Singh et al.  (1987) in  India and 
Ahmed (1996) in  Bangladesh attempted to quantify 
these losses. The  Indian study was location-specific, 
restricted to one village and covered all animal diseases 
including HS.  The Bangladesh study covered several 
selected diseases in the entire country. 
A summary of the economic studies that have been 
reported in  South and  Southeast Asian countries is 
given below. However, all the available information 
indicates that the actual losses are considerably higher 
than the values calculated in  the studies. 
1.3.1  South Asia 
India has a sizeable cattle and buffalo population of 
192 million and 70 million, respectively.  From 1936 to 
1944, there were an  average of 700 reported 
outbreaks of HS and 40000 deaths per year.  During 
the 1950s, the average reported deaths per year 
ranged from 30000 to 60 000. In the 1960s and 
1970s this figure dropped to approximately 4000 per 
year,  presumably due to improved control measures 
(FAO 1991). 
Dutta et al.  (1990) estimated that in  India during the 
past four decades  HS  has accounted for 46-55% of all 
bovine deaths. They also reported that from 1974 to 
1986, HS accounted for 6.3 deaths per year for every 
100000 bovine population. This amounted to 58.8% 
of the aggregate of bovine deaths due to the five 
epidemic diseases FMD, rinderpest, black quarter, 
anthrax and  HS.  Before 1939, the corresponding figure 
ranged from 13.4 to 20.9%. Thus,  it appears that HS 
has increased in economic importance in  relation to the 
other four epidemic diseases. 
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In a location-specific study in  India, Singh et al.  (1987) 
computed all of the losses from mortality and 
productivity, as well as  reproductive losses and  losses 
incurred in  disease control programs, and concluded 
that FMD, HS and gastrointestinal parasitism were the 
most economically important diseases of cattle. 
Pakistan ranks  HS  as a disease of considerable 
economic importance, with 34.1  % of all deaths in 
susceptible animals caused  by  HS  (FAO 1979). Pakistan 
has a cattle population of 17.7 million, and a buffalo 
population of 18.8 million, the latter being 
proportionately higher than most other countries in the 
region.  In  1978, annual economic losses from HS were 
estimated at 1.89 billion Pakistan rupees  (PKR) or 
US$189 million (Chaudhry and  Khan  1978; Sheikh et 
al.  1994). In a study conducted in  10 of the 95 villages 
in  the district of Lahore, Khan  et al.  (1994) found HS, 
FMD and gastrointestinal diseases to be the main 
causes of economic losses. The annual financial loss 
due to disease was estimated as  PKR 19 million, of 
which PKR 6.8 million was attributed to HS. 
Nepal, with 6.3  million cattle and 3.0 million buffalo, 
ranked HS  as the second most important infectious 
disease after rinderpest and the most important 
bacterial disease.  In a retrospective study of veterinary 
hospital records maintained in four districts of Nepal 
during 1985-90, Thakuri et al.  (1992) found that 
parasitic diseases and  infectious diseases accounted for 
54% and 24% of all cases,  respectively, and  HS was 
the most frequent infectious disease. 
In 1978 the Food and Agriculture Organization and 
United Nations Development Program coordinated a 
survey on the impact of disease on production in the 
Azad  State of Jammu and  Kashmir,  near the border of 
India and  Pakistan. The survey was carried out as part 
of the National Program for Livestock and  Dairy 
Development. It showed that nutritional disorders and 
parasitism were the greatest sources of loss in  livestock. 
Of the bacterial diseases,  however, HS and  black 
quarter made the most significant contribution to losses. 
In  Sri  Lanka, an  island of 65 000 km2,  HS first assumed 
epidemic proportions in  1955-56, with around 5000 
reported deaths from a cattle and  buffalo population of 
around 2.5 million. Thereafter, through various control 
measures, the losses were reduced to about 1200 reported deaths per year in the early 1980s and had 
declined further to 269 in  1990 (FAO 1991). These 
reports were derived from a passive reporting system. 
Of the 24 administrative districts in  the country, the 
disease is endemic in all of 13 districts and parts of four 
other districts, covering around two-thirds of the total 
land area. There has been  an  active surveillance study 
in  six selected locations within the endemic zone (De 
Alwis and Vipulasiri 1980) covering 22 297 buffaloes in 
803 herds and 20 878 cattle in 870 herds. This study 
has indicated that 15.2 % of buffaloes and 8.1 % of 
cattle die of HS each  year.  When these findings were 
extrapolated to the entire endemic zone, considering 
the carcase value alone, a modest estimate of 
economic loss was 90 million Sri  Lankan rupees  (SLR), 
equivalent to US$6 million at that time. 
Bangladesh has 23.4 million cattle and 0.8 million 
buffaloes. When only the production of milk, meat and 
eggs was considered, the contribution of the livestock 
sector to the economy was calculated to be about 9%. 
When the value of draught power, rural transport and 
the use of dung as fertiliser and domestic fuel were also 
computed, it was reported to be around 15%. Of the 
bacterial diseases of cattle and buffaloes present in 
Bangladesh,  black quarter was ranked as the most 
important, with anthrax and HS equal second  in 
economic importance (Ahmed 1996). 
Ahmed (1996) also estimated that of a total economic 
loss of US$148.6 million each  year due to these three 
diseases, direct losses account for only US$2.3 million. 
Direct losses include the market value of animals that 
died and the cost of treatment for those that 
recovered.  Indirect losses in this computation took into 
account the value of the rice that would have been 
produced from the land left uncultivated as a result of 
lack of draught power. 
However, it did not include potential productive (milk 
and meat) and  reproductive capacities of the animals.  It 
is  also noteworthy that this study used  retrospective 
computerised data, which were probably the product 
of a passive,  routine reporting system. The difference 
between losses computed from such  an  information 
system and an  active surveillance study was very 
evident in a project carried out in  Sri  Lanka (De Alwis 
and Vipulasiri 1980). 
1.3.2  Southeast Asia 
Indonesia has 9.5 million cattle and nearly 3.3  million 
buffaloes, of which around 97% are used  for draught 
power. The livestock sector contributes around 10% to 
total agricultural output (ACIAR 1993: Country 
Reports).  Estimates of economic losses due to HS have 
ranged from US$3500 to US$6000 (FAO 1991; ACiAR 
1993: Country Reports).  In a study of diseases affecting 
animals used for draught power in  Indonesia 
(Partoutomo et al.  1985), which included large 
ruminants and horses,  HS was ranked fourth, after 
fascioliasis, trypanosomiasis and FMD. 
Malaysia has a relatively small population of 735 000 
cattle and  186000 buffaloes (FAO 1994). In the early 
years,  an average of 28.7 outbreaks per year were 
reported, with an  average mortality of 12.6% per 
outbreak (FAO 1979). During 1967-76, 287 outbreaks 
were recorded in  peninsular Malaysia with 3605 deaths 
(FAO 1991). During 1980-89, the losses due to HS 
were estimated as 2.25 million Malaysian ringgit 
(US$0.85 million). 
The Philippines has 1.67 million cattle and 2.65 million 
buffaloes (ACIAR 1993). In  1990, the Philippines 
reported 14331 cases of HS  in cattle, with 1057 deaths; 
and 17 720 cases in  buffaloes, with 1725 deaths. 
Myanmar lists FMD, HS,  black quarter and anthrax as 
the four most important diseases that cause economic 
losses in  its 11.5 million cattle and  buffaloes (of which 
6.3  million are used for draught). It has been estimated 
that 50% of the government's effort in disease control 
is for the control of HS.  Through regular,  high 
vaccination coverage, the disease has been effectively 
controlled in  middle and lower Myanmar. In the 
northern and eastern regions, however, the disease 
remains endemic and 20-30 outbreaks are  reported 
each year, with around 1000 deaths (ACIAR 1993). 
Thailand has 5.5 million cattle and 4.7 million 
buffaloes, spread over 513 115 km2  Only 35 
outbreaks of HS  have been  reported, with 3.64 deaths 
per outbreak. It is believed that losses may have been 
unreported (FAO 1991; ACIAR 1993). 
Vietnam, the Lao People's Democratic Republic (Laos) 
and Cambodia rank HS  as one of the most 
5 economically important diseases.  In  Laos,  however, the 
number of reported deaths has dropped from 16 000 in 
1981  to 7500 in  1990. The economic losses from HS 
were estimated at US$1.4 million in  1990 (FAO 1991, 
ACIAR 1993). 
1.4  The Role of International 
Organisations 
Several  international organisations have played a 
significant role assisting in  the control of HS.  These are 
the Food and Agriculture Organization (FAO) of the 
United Nations, the Office International des Epizooties 
(OlE) and the Australian Centre for International 
Agricultural Research  (ACIAR). The assistance provided 
by these organisations includes encouragement and 
funding of research, development of diagnostic 
techniques and vaccine production technologies and 
facilitating control of the disease through strengthening 
and establishment of diagnostic and vaccine production 
facilities in the countries where the disease exists. 
1.4.1  Office International des 
Epizooties 
The OlE, or World Organisation for Animal Health, was 
established in  1924. The main activities of the 
organisation are: 
•  to collect and disseminate to its member countries 
information on the occurrence, course and 
treatment of animal diseases; 
•  to provide guidelines and standards of health 
regulations applicable to international trade in 
animals; and 
•  to promote and coordinate research  on  pathology, 
diagnosis, treatment and  prevention of animal 
diseases when international collaboration in such 
research  is desirable. 
For the purpose of the above activities animal diseases 
are classified into two categories, Lists A and  B.  List A 
consists of those diseases that spread rapidly, and the 
scope of which extends beyond national borders. These 
diseases have particularly serious socioeconomic or 
public health consequences and are of major 
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importance in  the international trade of animals and 
animal products. 
List B includes diseases that are also considered to be of 
socioeconomic andlor public health importance within 
countries, and which are also of significance to the 
international trade in  animals and animal products. HS 
is  included in  List B.  This classification largely influences 
the priority status given to livestock diseases by 
respective governments in  endemic countries in their 
allocation of resources for disease control. 
The OlE does not have any regional programs for the 
controll eradication of HS  as for rinderpest and  FMD. 
These two latter diseases are in List A (see above). 
Where necessary,  however, there are opportunities for 
regular vaccination against HS linked with FMD 
vaccination since simultaneous vaccination against both 
diseases has been shown to be effective. 
1.4.2  Food and Agriculture 
Organization 
During the last five decades of this century, the FAO 
has  helped Sri  Lanka, Thailand, Zambia and Myanmar 
to control HS.  This assistance has included the services 
of consultants, training opportunities, equipment and 
supplies to strengthen national diagnostic and vaccine 
production laboratories. In  Asia, a better focus on the 
assistance provided was made through the Animal 
Production and Health Commission for Asia and the 
Far East (APHCA) - a regional wing of the FAO, 
formed in  1973. Initially, the FAO sponsored two 
international meetings on  HS, the first in Manila in 
1959 and the second  in  Kuala Lumpur in  1962. The 
Manila meeting was attended by delegates from Burma 
(Myanmar), Ceylon (Sri  Lanka), France,  India, Iran, 
Iraq, Japan,  Liberia, Malaya (Malaysia), Pakistan, 
Philippines, Thailand, United I<ingdom, United States 
and Venezuela. The second  meeting was equally well 
represented, with delegates from Australia, Burma, 
Ceylon, France,  RepubliC of Guinea,  India, Indonesia, 
Italy, Laos, Malaya, Philippines, Singapore, Sudan, 
Thailand and the United States. At these two early 
meetings on  HS,  a consensus was  reached on a number 
of broad areas,  including: •  that increased cooperation be established between 
research workers in different countries and that the 
coordination of research  and investigational efforts 
directed towards control of the disease be 
strengthened; 
•  that facilities for training in specialised techniques be 
made available; 
•  that the diagnostic tests and vaccine production 
techniques be standardised; 
•  that due recognition be given to the need for 
combined vaccines and effective simultaneous 
vaccination against other diseases present in the 
region; 
•  that arrangements be made for collection and 
dissemination of information relating to the disease 
within the relevant countries. 
It was also agreed that these objectives could  be met 
by the following means: 
•  designate an  institution in the Asian  region as a 
reference centre for HS,  and also examine the 
possibility of recognising such centres in other 
regions; and 
•  convene regular meetings on  HS,  to be held at the 
invitation of member countries. 
After a decision was made by APHCA at its annual 
sessions  in  1978, the third international meeting on  HS 
was held in Colombo, Sri  Lanka in  December 1979. 
Prof. RVS. Bain  was commissioned to visit all APHCA 
member countries, to assess the status of the disease 
and to submit a report, which formed the basis for the 
meeting. This meeting was attended by delegates from 
India, Indonesia, Iraq, Malaysia, Nepal, Sri  Lanka and 
Thailand. Country reports were also submitted by 
Bangladesh and Pakistan. 
The recommendations made at this meeting are 
summarised  below. 
•  That the offer made by the Government of Sri  Lanka 
to establish the regional reference centre in  Sri  Lanka 
be considered favourably by the FAO. A special 
subcommittee recommended that this centre should: 
- make available strains of known serotype and 
immunogenicity as vaccine seed; 
- provide a serotyping service for cultures 
associated with HS  in  particular and also other 
pasteurelloses; 
- provide national laboratories with reference 
cultures, reagents and vaccines; 
- provide training facilities in diagnostic 
procedures, including serotyping, vaccine 
production and testing. 
•  That further trials be carried out on  the double 
emulsion vaccine, which has an  improved 
syringeability. 
•  That the monograph on  HS published by the FAO in 
1963 (Bain  1963) be revised  by a group of authors. 
•  That besides implementing the present knowledge 
on  the disease, further research  be encouraged on 
the following aspects: 
- carrier state of serotype 6:B in cattle, buffalo, 
pigs, sheep, goats and  poultry; 
- vaccine strain selection; 
formulation of media for dense culture 
production for vaccines,  using locally available 
ingredients; and 
- development and testing of vaccines based  on 
newer microbiological concepts. 
•  That the APHCA secretariat serve as a centre for 
collection and dissemination of information. 
•  That in  recognition of the usefulness of a uniform 
system of serotype designation, the capsular typing 
system of Carter and the somatic typing system of 
Namioka and Murata be adopted. 
In  pursuance of the recommendation of the third 
international meeting, the FAO designated the 
Veterinary Research  Institute, Peradeniya,  Sri  Lanka as a 
regional reference centre for HS for the Asian region in 
1985. The FAO provided some support to upgrade the 
facilities at this institute. A reference centre for the 
African region was in  existence in Senegal in West Africa. 
7 At the 1986 annual sessions of APHCA, a decision was 
made to set up an  HS subgroup. This subgroup 
consisted of members from Indonesia, Malaysia, Sri 
Lanka and Thailand. The main task entrusted to the 
subgroup was to accelerate and coordinate the work 
aimed towards improving the quality of the vaccines. 
Two meetings of the subgroup were held in  Bangkok, 
in September 1987 and  February 1990. Priority areas 
for research  and development on vaccines were 
identified as follows: 
•  the formulation of improved oil adjuvant vaccines 
with low viscosity and  high stability without 
affecting potency; 
•  development of the double emulsion vaccine; 
•  development of vaccines based  on  the identification 
and characterisation of the protective antigens; 
•  development of live vaccines using strains which are 
avirulent or are of low virulence; and 
•  evaluation of all  HS vaccines produced in the region 
at the regional reference centre. 
These areas of vaccine research  are described in  more 
detail in Chapter 9. The fourth international meeting 
on  HS was held in  I<andy,  Sri  Lanka in  February 1991 
and  was attended by delegates from India, Indonesia, 
Iran, Laos, Malaysia, Nepal, Philippines, Sri  Lanka and 
Thailand. Additionally, with support received from the 
British Council and ACIAR,  as well as APHCA, it was 
possible to obtain the participation of several  resource 
personnel. These included two scientists from the 
United Kingdom, closely associated with the Moredun 
Research  Institute, where considerable advances have 
been  made on  pasteurella vaccines, one from the 
CSIRO, Australia, and one from Japan. 
The discussions at this meeting led to the identification 
of some important areas warranting further research 
and  investigation: 
•  studies on pathogenesis of HS; 
•  investigations into the factors that determine 
virulence of the organism; 
•  comparison of serotyping systems and adoption of 
the most appropriate system; 
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•  an evaluation of the usefulness of new laboratory 
techniques such  as enzyme-linked immunoserbent 
assay (ELISA), polyacrylamide gel electrophoresis 
(PAGE),  immunoblotting etc; 
•  determination of the criteria for declaration of 
disease-free status to a given area; 
•  studies on the carrier status of vaccinated animals; 
•  further confirmation as to whether naturally immune 
animals (also carriers) are resistant to challenge; 
•  investigations into thinner emulsions, and  non-oil 
based adjuvants; 
•  studies on  live vaccines and  in vivo antigens. 
•  development of combined vaccines; and 
•  development of simplified methods for evaluation 
of vaccines. 
In addition to supporting countries that needed 
assistance and organising scientific meetings, the FAO 
has produced a number of publications directly on  HS 
or on a broader field including this disease: 
•  The control of haemorrhagic septicaemia. 
In: FAO-OIE Animal Health Yearbook 1958. 
•  Haemorrhagic Septicaemia.  R.V.S  Bain,  FAO 
Agricultural Studies No.  62, 1963. 
•  Haemorrhagic Septicaemia of Cattle and Buffaloes. 
R.v.S Bain,  South  East Asia Treaty Organisation, 
Bangkok, Thailand 1961. 
•  Haemorrhagic Septicaemia.  R.v.S Bain,  M.C.L. 
De Alwis G.R.  Carter and  B.K.  Gupta, FAO Animal 
Production and Health Paper No. 33, 1982. 
•  Manual of Production of Haemorrhagic Septicaemia 
Vaccine.  R.P.  Misra. Nong Teng,  Laos,  FAO,  1985. 
•  A Manual of Laboratory Procedures for Selected 
Diseases of Livestock.  G.G. Alton, G.R.  Carter, A.c. 
Kibor and  L.  Pesti,  FAO,  1990. 1.4.3  Australian Centre for 
International Agricultural 
Research 
ACIAR is a statutory authority established in  Australia 
under an  Act of Parliament. It has a mandate to 
facilitate collaborative research  on  high priority 
problems of developing countries that offers good 
prospects for mutual benefits with Australia. This  is 
achieved by linking Australian research  institutions with 
overseas research  groups.  In  keeping with its mandate, 
ACIAR has maintained an  interest in  HS,  which is a 
major animal health problem in the region.  During the 
past decade, ACIAR has funded two projects 
specifically on  HS, another dealing with a variety of 
diseases including HS, and another in the related field 
of pasteurellosis in  pigs and poultry. A brief description 
of these projects is  given below. 
Development of  an improved 
haemorrhagic septicaemia vaccine 
This was a collaborative project between the CSIRO 
Division of Animal Health in Australia and the 
Veterinary Research  Institute in  Ipoh, Malaysia. This 
project broadly aimed at producing improved vaccines 
and developing and  evaluating existing as well as 
newly developed tests for determining the efficacy of 
vaccines.  Broadly two types of vaccines were 
developed. These were improved emulsion type 
vaccines which had  low viscosity and easier injectability 
as well as vaccines based  on  the identification and 
characterisation of the cell  components with a view to 
determining the protective antigens (see Chapter 7). 
Conventional tests such  as the indirect 
haemagglutination test (lHA) and the passive mouse 
protection test (PMPT) were compared with a newly 
developed ELISA test and direct challenge. 
Diagnosis and control of  haemorrhagic 
septicaemia in Indonesia 
This was a collaborative project between the Victorian 
Institute of Animal Science in Australia, the Research 
Institute for Veterinary Science in  Bogor,  Indonesia and 
the Disease  Investigation Centre in  Denpassar, 
Indonesia. This project covered a wide spectrum of 
areas connected with the diagnosis and control of HS. 
•  Improvement of techniques to detect the organism, 
including the development of special transport 
media and their evaluation in comparison with the 
conventional culture techniques. 
•  Development of molecular tests for detection of the 
organism as well as for characterisation with special 
emphasis on  strain variation. 
•  Review of management and vaccination strategies. 
•  Retrospective and  prospective studies of the 
epidemiology of the disease,  as  well as sero-
epidemiological studies using the ELISA test. 
Establishment of  improved methods for 
the diagnosis and control of  livestock 
diseases in Southeast Asia using ELISA 
This project was a collaboration between four 
institutions: the CSIRO  Division of Animal Health and 
the Victorian Department of Agriculture and  Rural 
Affairs in  Australia; the Research  Institute for Veterinary 
Science in  Bogor,  Indonesia; and  University of Pertanian 
in Malaysia. Amongst other diseases, this project aimed 
at developing and evaluating the ELISA technique for 
identification of Pasteurella multocida strains causing 
HS  as  well as for detection of antibody against 
P.  multocida in  animals. 
Control of  pasteurellosis in pigs 
and poultry 
This project had five participating institutions. These 
were Monash University and The University of 
Queensland in  Australia; the Veterinary Research 
Institute in  Peradeniya,  Sri  Lanka; and the National 
Institute of Veterinary Research  and the National 
Veterinary Company in Vietnam. Though the project 
did not directly deal with bovine pasteurellosis, 
technologies developed may have future applications in 
the field of HS. 
9 International workshops 
ACIAR has also organised international meetings to 
enable scientists working on their research  projects to 
present their findings. During the past decade, two 
such  meetings sponsored by ACIAR were the 
International Workshop on  Pasteurellosis in  Production 
Animals, held  in  August 1992 (ACIAR 1993), and the 
International Workshop on  Diagnosis and  Control of 
Haemorrhagic Septicaemia in  May 1996. Both 
workshops were held  in  Bali,  Indonesia, with the 
participation of other scientists in the field  as well. 
These workshops provided an excellent opportunity for 
those working in the field of HS  in  the region to 
exchange their views and  share their experiences. 
Additionally, the participation of scientists from outside 
the region enabled the infusion of new ideas and 
technologies into this problem of utmost economic 
importance to the region. 
10 The Organism: Classification and Diseases 
Overview 
History and nomenclature 
Haemorrhagic septicaemia (HS) is caused by specific 
serotypes of the bacterium Pasteurella. The organism is 
named after Louis Pasteur in recognition of his 
pioneeri ng work in the 1880s. The genus Pasteurella 
belongs to a large family of bacteria - the 
Pasteurellaceae, which includes two other important 
genera, Actinobacillus and Haemophilus. Two members of 
the genus Pasteurella - P multocida and P haemolytica -
cause a variety of important diseases in domestic, 
agricultural and wild animals. 
Pasteurella multocida 
Several methods have been developed to identify 
different serotyopes of P multocida. These can be broadly 
grouped into methods that identify five 'capsular' 
antigens (based on components of the outer cell layer) 
and up to 16 'somatic' antigens  (based on core 
components).  Using a combination of capsular and 
somatic typing, the two common HS serotypes 
(popularly known as  the Asian and African serotypes) 
are designated B:2  and E:2, respectively. 
Pasteurella haemolytica 
P haemolytica  can be distinguished from P multocida by 
several biochemical characteristics.  Two biotypes have 
been identified, based on sugar fermentation (A and T), 
while 16 types have been identified based on capsular 
polysaccharides. 
2.1  History and Nomenclature 
Haemorrhagic septicaemia (HS)  is caused  by specific 
serotypes of the bacterium Pasteurella multocida in 
cattle and buffaloes. According to current classification, 
the family Pasteurellaceae (Pohl 1981) includes a large 
group of gram-negative bacteria that are 
chemoorganotrophic, facultatively anaerobic and 
fermentative. The family has three genera: Pasteurella 
(Trevisan  1887), Actinobacillus (Brumpt 1910) and 
Haemophilus (Winslow et al.  1917). Several other 
species that exhibit complex phenotypic and genotypic 
relationships with these genera are also included. Most 
members of the family cause disease in  mammals 
(including humans), birds and reptiles. 
The first description of the bacterium was in  1878-79 
when Rivolta and  Revolee reported an  outbreak of 
disease in  fowl. About the same time, a disease in 
cattle and  buffaloes was described by Bollinger in 
Germany. Its causative organism was isolated by Kitt in 
1885. Gaffky described a septicaemic disease in  rabbits 
in  1881  and  Loeffler described a similar disease in 
swine in  1886. It was the German pathologist Hueppe 
who, in  1886, observed similarities in all of these 
diseases and also similarities in the bacteria associated 
with these disease conditions. Later,  in  1887, Oreste 
and Armani described a similar disease called  'barbone' 
in  buffaloes in  Italy, also caused  by a similar organism; 
they proposed the name Bacillus septicaemiae for this 
bacterium. However, in  1887, Trevisan  proposed the 
name Pasteurella to commemorate the work of Louis 
Pasteur on the aetiology of fowl cholera, which is 
caused  by the same organism. Human infections 
caused  by the same organism were described for the 
first time in  1920. 
Since this bacterium caused  disease in  many species of 
animals, species names were initially given according to 
the host species  in  which it caused  disease. Thus, 
11 isolates from cattle were named boviseptica; pigs, 
suiseptica; poultry, aviseptica; and so on. Subsequently, 
there were several complex name changes for the 
organism until 1929 when Topley and Wilson 
introduced the name Pasteurella septica.  In  1939, 
Rosenbach and Merchant proposed the name 
Pasteurella multocida. A summary of the historical 
evolution of the nomenclature of Pasteurella multocida 
is shown in Table 2.1. 
On the basis of phenotypic similarities, more serotypes 
were added to the genus: Pasteurella haemolytica in 
1932, P.  pneumotropica in  1950, P.  gallinarum in  1955, 
P.  ureae in  1962 and the gas-producing P.  aerogenes 
isolated from pigs in  1974. 
More recent classification of the genus Pasteurella  is 
based  on genetic relationships, which have been 
determined by DNA:DNA hybridisation, rRNA:DNA 
hybridisation and  16S rRNA sequencing. On this basis, 
11  species have been  identified: Pasteurella multocida 
(with three subspecies: multocida, septica and 
gallicida), P.  dagmatis,  P.  gallinarum, P.  voluntium, 
P.  stomatis,  P.  avium, P.  langaa,  P.  anatis and 
Pasteurella subspecies A and  B (Mutters et al.  1989; 
Sawada 1991; Bisgaard 1994). 
Several species that were previously classified under the 
genus Pasteurella have now been  excluded as they 
were found to be genetically more closely related to 
the Actinobacillus group. These are  P.  ureae, 
P haemolytica biotypes A and T,  P.  testudinis, 
P.  aerogenes and P.  pneumotropica, biotypes Heyl and 
Jawetz. Since the genus was redefined on a genetic 
basis, six  new species have been  included in the group: 
P.  granulomatis, P.  caballi,  P.  bettii, P.  Iymphangitidis, 
P.  mairi and  P.  trehalosi (Bisgaard  1994). 
Two members of the genus Pasteurella are of 
veterinary importance - P.  multocida and 
P.  haemolytica. These species cause a variety of disease 
syndromes (pasteurelloses) in  agricultural, domestic and 
wild animals. A brief description of the common 
pasteurelloses in animals is given in  Section 2.4 and the 
associated organisms, host species and diseases caused 
are shown in  Table 2.7. 
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2.2  Pasteurella multocida 
2.2.1  Morphology and staining 
P.  multocida is a nonmotile, nonspore-forming short rod 
or coccobacillus, 0.2-0.4 by 0.6-2.5 mm  in size. 
Repeated laboratory subcultures of old cultures or 
cultures grown under unfavourable conditions tend to 
be pleomorphic and longer rods and filamentous forms 
appear.  In tissues, exudates and recently isolated 
cultures, the organism shows the typical coccobacillary 
forms. It is a gram-negative organism and, in fresh 
cultures and animal tissues, gives typical bipolar staining, 
particularly with Leishman or methylene blue stain. 
2.2.2  Growth characteristics and 
colony morphology 
P.  multocida grows in  most common laboratory media 
such as  nutrient agar.  Special  media such  as 
dextrose-starch agar and casein-sucrose-yeast (CSY) 
medium support an  abundant growth. Blood agar and 
CSY agar with 5% blood (bovine, sheep) are 
convenient media for routine laboratory culture. The 
optimum growth temperature is 35-37°C. In enriched 
media at 37°C, colonies 1-3 mm in diameter are 
produced after 18-24 hours culture. 
The organism shows different types of colonies, which 
are related to the capsular type. Capsular type A 
produces the largest colonies, which are translucent, 
greyish in  colour, and  mucoid in  conSistency.  There may 
be considerable variation in  colony size,  ranging from 
rounded, convex, discrete colonies with circular edges 
to large watery colonies with flowing margins.  In  this 
type of colony, the capsules consist,  in  part, of 
hyaluronic acid.  Occasionally, type D strains may also 
produce mucoid colonies. Colonies of capsular types D 
and F and  the rounded colonies of type A display a 
pearl-like iridescence in  oblique transmitted light. 
Colonies of types Band E may also vary in  size, 
depending on the degree of capsulation. They will 
range from larger greyish colonies, when freshly isolated 
or when grown in  media containing blood serum, to 
smaller colonies that give a yellowish-green or bluish-
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Table 2.2.  Early attempts at serological classification of Pasteurella multocida. 
Authors  Basis  Types identified 
Cornelius (1929) 
Yusef (1935) 
Rosenbach and Merchant (1939) 
Little and Lyon (1943) 




Groups I,  II,  III and IV 
Groups I,  II,  III and IV 
Groups I,  II  and III 
Types  1, 2 and 3 
Types  I,  II,  III and IV  Roberts (1947)  Passive  mouse protection 
Rough colonies may be produced by old cultures. 
These are the smallest colonies of all forms, and are 
noniridescent in oblique light. Production of rough 
colonies is the result of loss of capsular material, a 
process referred to as  'dissociation'. Dissociation may 
take place to different degrees, giving rise to 
intermediate colony forms.  Passage of rough cultures in 
natural host animals or laboratory animals, or 
subculture in  media containing animal tissues, causes 
reversion to the capsulated, iridescent colony forms. 
Dissociation also occurs during storage of stock cultures 
either in stock culture media or in a Iyophilised form. In 
such  instances, an  animal passage should be carried out 
upon reconstitution of the stock culture. 
Colony morphology is also related to virulence. 
Dissociation is associated with reduction or loss of 
virulence and also with loss of antigenicity. Well-
capsulated cultures make good vaccines;  for this reason, 
vaccine seed  cultures are passaged in laboratory animals 
or even in  natural host species periodically. However, 
the relationship between the capsule and virulence is 
13 not absolute. There are capsulated variant cultures that 
are of low virulence or are avirulent, whilst 
non capsulated strains may be virulent. 
Maintenance of  stock cultures 
Stock cultures may be maintained conveniently in 
nutrient agar containing 0.75% agar to give a 
semisolid consistency. Stab cultures should be made, in 
semisolid nutrient agar in tightly screw-capped bottles 
to prevent drying on storage. After incubation for 
18-20 hours at 37°C they can  be stored at room 
temperature for several years. 
For lyophil ising, a confluent growth of an  18-20-hour 
culture from CSY agar with blood may be washed and 
suspended in  an  equal volume of 5% skimmed milk. 
Alternatively, the WHO medium recommended for 
Iyophilising brucella cultures, consisting of 2.5% 
tryptone, 5% sucrose and  1 % glutamate, has been 
found to be satisfactory. 
2.2.3  Serological classification 
Early attempts at serological classification of 
P.  multocida date back to the 1920s (Cornelius 1929; 
Yusef 1935; Little and  Lyon  1943). Roberts (1947) 
developed a system of serological classification based 
on  passive protection tests in  mice.  He used antisera 
prepared in  rabbits to protect mice against challenge 
with a wide range of strains. On the basis of mouse 
protection, he was able to identify four types, which he 
designated types I,  II,  III and  IV. This was the first 
classification to meet some degree of acceptance. Since 
all  HS strains fell into Roberts type I,  this designation 
became fairly well established. Subsequently, Hudson 
(1954) added a fifth serotype. The basis of these early 
attempts at serological classification and the types 
identified are shown in Table 2.2. 
Carter used a precipitation test (Carter 1952) and 
subsequently an  indirect haemagglutination test (Carter 
1955) and was able to identify four serological types. 
These were based on agglutination of human '0' 
erythrocytes coated with crude extracts of outer cell 
components from the bacterial cultures. These crude 
'capsular' extracts were supernatants prepared by 
heating suspensions of the bacteria at 56°C for 
30 minutes and  removing the cells by centrifugation. 
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He designated these four capsular types A,  B,  C and D 
(Carter 1952,1955). The strains that caused  HS were 
grouped into Carter type B.  Subsequently, he found 
that the strains that caused  HS  in Africa did not fall 
strictly into any of these groups, though they were 
related to type B,  and they were included in a separate 
group designated type E (Carter 1961). Subsequently, 
however, he found that type C was not a consistent 
type and it was deleted (Carter 1963). 
This method of identifying serotypes has become 
established as the Carter indirect haemagglutination 
test (IHA). Three decades later, Rimier and Rhoades 
(1987) isolated a consistent type from turkeys which 
did not fit into any existing serogroups; this was 
designated serogroup  F. 
Since fresh  human '0' erythrocytes may not always be 
available in a laboratory, the IHA test has been  modified 
by various workers for practical convenience. Carter and 
Rappay (1962) used formalinised human '0' cells, which 
could be stored in a laboratory for long periods. More 
recently,  Sawada et al.  (1982) used glutaraldehyde-fixed 
sheep erythrocytes. The test has now been modified for 
the detection of antibodies as well, using erythrocytes 
coated with cell extracts from known reference cultures. 
Wijewardana et al.  (1986a) used fresh sheep 
erythrocytes, and adopted the test both for identification 
of serotype and for antibody detection. 
In the early 1960s, Namioka and Murata (1961 a) 
described a simplified and rapid method of identifying 
the capsular types using a slide agglutination test in 
which fresh cultures are agglutinated with 
hyperimmune rabbit sera.  Namioka and Murata 
(1961 b,c,  1964) and Namioka and  Bruner (1963) later 
developed what is described as a 'somatic' typing test, 
based  on  releasing core ('somatic') bacterial 
components by agglutinating acid (HCI)-treated cells 
with rabbit antiserum. Using this method, 11  somatic 
types were identified. Type-specific antiserum was 
produced by a complicated system of absorptions, as 
shown in Table 2.3. Another drawback to this system is 
that some cultures undergo autoagglutination after the 
HCI treatment and therefore are  rendered  untypeable. 
Heddleston et al.  (1972) developed an  agar gel 
precipitation test also for somatic typing. In this test, 
the antigen used  was the supernatant of culture 
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Volume (mL)  for absorptionb  No. of YPC platesd 
0.5  P8  15 
0.3 
0.2 
0.6  Kobe 5  15 
0.4 
1.0  M  17  15 
0.6  M4  15 
0.4 
0.5  Kobe 6  10 
0.5 
1.0  Kobe 6  10 
1.0  TS  8  15 
1.0  Kobe 5  10 
P8  10 
1.0  P 27  10 
1.0  R 479  10 
• Somatic group  b Local strain designations  c All antisera were diluted 1  :10 in saline  d YPC = yeast extract-protease peptone-casein medium 
Note: This table illustrates the complexity of the Namioka and Murata somatic typing system; it can  be  used for typical HS  serotypes 
only, since the number of 0  groups within capsular groups Band E are  limited. 
Source:  Namioka (1978) 
antiserum was prepared in chicken. Using this method, 
16 different somatic types were recognised. This test 
was originally used to type avian strains from fowl 
cholera but is now extended to strains from all  host 
species.  The typing systems that are currently in  use 
are summarised in Table 2.4 
2.2.4  Designation of serotypes 
Currently, the most acceptable and widely used 
serotype designation system  is a combination of Carter 
capsular typing and  Heddleston somatic typing. Using 
this method, the Asian and African HS serotypes are 
designated 8:2 and E:2,  respectively, and  a non-HS 
type 8 strain of Australian origin as  8:3,4 (this strain 
was originally isolated from a bovine wound but has 
subsequently been associated with occasional  HS-like 
septicaemic disease in cattle in  North America and  deer 
in the United Kingdom; see Section 4.3). 
Since there are only two of Namioka's types (6 and 11) 
among the capsular type 8 strains, and only one (6) 
among the capsular type E strains, a combination of 
capsular and  Namioka typing is  also used occasionally 
(i.e. 6:8 and 6:E for the Asian and African strains, 
respectively). Under this system, the avirulent 
Australian strain  is designated 11 :8. Since both systems 
are used  in the literature, to avoid confusion, it is 
desirable to adhere to a standard system of expression. 
In the Carter-Heddleston system, the capsular type is 
expressed first, followed by the somatic type. In the 
Namioka-Carter system, expression  is  made in  the 
reverse order.  In this monograph, the 
Carter-Heddleston system  is generally used,  unless 
otherwise indicated. 
Limitations of  serotyping systems 
The serotyping systems provide a convenient method 
of grouping isolates from a diagnostic point of view 
15 Table 2.4.  Current systems of serological classification of Pasteurella multocida. 





Indirect haemagglutination (lHA) 
IHA 
A, B,  C,  0 
E 
Namioka and Murata (1961a) 
Rimier and Rhoades (1987) 
IHA and passive mouse protection 
Slide agglutination of fresh cultures 
IHA 
Excluded type C 
A, B,  0, E 
F 
Somatic typing 
Namioka and Murata (1961 b,c) 
Namioka and Bruner (1963) 
Namioka and Murata (1964) 
Heddleston et al. (1972) 
Agglutination of HCI-treated cells  1-11 
Agar gel precipitation test using 
1-hour boiled supematant 
1-16 
but are not an  absolute method of classification of the 
species.  All of the methods described above have their 
limitations. 
A rough correlation exists between Roberts' types I,  II, 
III  and IV (1947) and Carter's capsular types B,  A, C 
and  D,  respectively (Carter 1955). However, the 
Roberts method, which is  based on  mouse protection, 
does not differentiate between the Asian and African 
HS strains (B:2 and  E:2,  respectively) and the Australian 
avirulent strain, identified as  11 :B (Namioka-Carter) 
and subsequently as  B:3,4 (Carter-Heddleston). It will 
probably not differentiate the types B:1  and B:4 either 
(these have recently been found to be associated with 
HS-like syndromes in feral animals). 
Brogden and  Packer (1979) compared the Namioka and 
Heddleston serotyping systems and observed that 
serotypes identified by one system did not generally 
correlate with those of the other. There were instances 
where one serotype identified by one method 
corresponded to two or more serotypes identified by the 
other. For example, serotypes that cause HS belonged to 
a single Namioka or Heddleston type (type 6 or type 2, 
respectively) but two Carter types (B  and E). 
De Alwis (1987) observed that what Heddleston called 
the 'somatic' antigen was closer to Carter's 'capsular' 
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antigen, in that both were surface components that 
were liberated into the supernatant by heat treatment, 
only the temperature and treatment time being 
different. Namioka's 'somatic' antigen, on the other 
hand, was the residue left after a more drastic HCI 
treatment. He found that when Carter's and 
Heddleston's antigens were prepared according to the 
methods described by the respective workers using the 
Asian  B:2  strain, and used to coat erythrocytes in  IHA 
tests or in  precipitation tests using a counter-
immunoelectrophoresis technique (see Section 5.8.2), 
both antigens gave the same results. Further, Carter's 
antigen (56°C/30-minute supernatant), and the same 
antigen subsequently heated to 100°C for one hour, 
also gave the same results. These observations 
appeared to suggest that the two preparations shared 
common reactive components. It was also found that 
when phenol-water extracts (Westphal type) prepared 
from HCI-treated cells were coated onto sheep 
erythrocytes in  IHA tests, the results parallelled 
Namioka's somatic typing. 
These findings led to the conclusion that the so-called 
'capsular' and  'somatic' antigens are empirical entities 
that serve the need for a convenient practical 
classification to identify different serotypes associated 
with different disease conditions, purely from a diagnostic point of view. The actual cell  structure is 
much more complex, as becomes evident from a more 
detailed study of cell  components. 
In  situations where a wide range of isolates of 
P multocida from a variety of sources are examined, a 
substantial proportion remain untypeable (Namioka 
and Bruner 1963; Chandrasekaran et al.  1981; Jones et 
al.  1988). When strains associated with clinical  HS are 
considered, however, almost 100% of isolates are 
typeable with group B or E antisera (De Alwis and 
Panangala 1974; Shigidi and Mustafa 1979). In  Sri 
Lanka,  all of 50 isolates associated with clinical HS were 
typeable, but out of 49 abattoir isolates from tonsils, 
only 67% were typeable by Carter's capsular typing 
and  80% by Heddleston's somatic typing (De Alwis 
and  Panagala 1974; Wijewardana et al.  1993). In 
another study (Wijewardana et al.  1986a), biochemical 
and serological uniformity was observed among 17 
isolates of P.  multocida associated with clinical disease, 
but there was considerable diversity among 23  isolates 
from the nasopharynx and associated lymph nodes of 
apparently healthy cattle and buffaloes. 
2.2.5  Nonserological tests 
Several  nonserological tests have been described for 
the identification of specific types of pasteurellae. The 
acriflavine test of Carter and Subronto (1973) 
specifically identifies type D strains. Carter and  Rundell 
(1975) described a hyaluronidase decapsulation test 
that used a hyaluronidase-producing staphylococcus to 
identify mucoid type A strains. A hyaluronidase 
production test has been described by Carter and 
Chengappa (1981) for the identification of type B 
strains that cause  HS.  These tests can  be  used to 
supplement the serotyping systems rather than as 
substitutes for them. 
2.2.6  Cellular components 
The limitations and the lack of correlation between the 
different serotyping systems can  be  understood on the 
basis of cellular components. 
Capsule 
The capsule (or outer layer) of the cell  is  believed to be 
responsible for the serogroup specificity. It is composed 
of polysaccharides, lipopolysaccharides (LPS)  and a 
variety of proteins. Both LPS and polysaccharides are 
absorbed onto erythrocytes and are believed to playa 
role in  passive  haemagglutination. Studies on purified 
capsular extracts have given somewhat conflicting 
results and this may be due to the incomplete 
separation of the constituents in the different 
purification processes used  (Dhanda 1960; Knox and 
Bain  1960; Bain and  Knox 1961; Rimier and Rhoades 
1989). More recently,  Penn  and Nagy (1976) separated 
a nontoxic polysaccharide capsular antigen by 
fractional precipitation from aqueous solutions with 
polar solvents. When tested in comparison with crude 
capsular extracts, this capsular polysaccharide was 
nontoxic in chick embryo lethality and rabbit 
pyrogenicity tests.  It was nonimmunogenic in  rabbits 
but produced mouse protective antibodies in cattle. 
Muniandy et al.  (1993), using an  improved procedure 
for purification of polysaccharide, prepared an  extract 
which gave a final yield of 3.5%, with minimal 
contamination with proteins and  nucleic acids and free 
of LPS.  This product was also nontoxic and 
nonimmunogenic in  rabbits. These workers also found 
that the Penn and  Nagy type of polysaccharide 
extracts, which were contaminated with 20% LPS, 
displayed a high degree of anti phagocytic activity in an 
in vitro phagocyte uptake assay. 
Prince and Smith (1966a,b), described three antigen 
complexes - alpha,  beta and gamma-
corresponding to a polysaccharide-protein complex, a 
serogroup-specific polysaccharide and  LPS,  respectively 
(Mosier 1993). 
Proteins are believed to be important immunogens and 
are likely to playa vital role  in the protective 
mechanism. With the exception of a few serogroup A 
and D strains that produce protein toxins, proteins of 
P multocida are nontoxic. Johnson et al.  (1991) 
examined a wide range of P multocida strains of 
different serogroups by electrophoretic techniques and 
found a high degree of homogeneity in protein profiles 
among 14 strains associated with HS.  Strains of Asian 
and  North American origin (B:2) displayed a major 
protein band of molecular mass 32  kDa.  Strains of 
African origin (E:2), on the other hand, gave a similar 
band at 37 kDa. Other bands at 27,45 and 47 kDa 
were shared  by all strains, irrespective of serotype. 
Using monoclonal antibodies and an  immunoblotting 
technique, Ramdani and Adler (1993) identified protein 
17 fractions of 29 and 36 kDa in the cytoplasmic and 
periplasmic fractions and 42  kDa in the membrane 
fraction. These fractions were shown to give only 
variable protection in  mice (25-67%; see Section 9.2.3). 
The association of outer membrane proteins (OMPs) 
with protective immunity has been  widely investigated. 
Muniandy and Mukkur (1993) observed that the 
immunogenicity of certain  LPS  preparations was due to 
the presence of contaminating OMPs. Kennett et al. 
(1993) grew P.  multocida serotype B:2  (Malaysian C82) 
cultures in  BHI  medium under iron-restricted or iron-
replete conditions. An iron chelator (2.2-dipyridyl) was 
added to the iron-restricted medium, while 0.1  M  FeCI3 
was added to the iron-replete medium. They found 
that the OMPs produced under iron-restricted 
conditions gave a higher degree of protection in  mice 
than OMPs produced under iron-replete conditions. 
This was attributed to a high molecular mass protein of 
over 84 kDa, which was expressed  in abundance under 
iron-restricted conditions. 
In  Sri  Lanka, T.G.  Wijewardana, Veterinary Research 
Institute, Peradeniya (personal communication) found a 
similar protein (116 kDa), which was produced by B:2 
strains in vivo and when grown under iron-restricted 
conditions in vitro but was absent from cultures grown 
in  normal media. The analysis of total membrane 
proteins by sodium dodecylsulfate polyacrilamide gel 
electrophoresis (SDS-PAGE),  in cells of serotype B:2 
strains grown under iron-replete and iron-restricted 
conditions (Veken et al.  1994, 1996), also revealed 
different specific protein components that were 
expressed  by the same strain, depending on the culture 
conditions (see also Section 9.2.3). A variety of protein 
components of various molecular weights have also 
been  isolated from the Indian vaccine strain  P52,  by 
various extraction methods including sonication and 
precipitation with ammonium sulfate gel. Their 
immunogenic merits have been tested in  rabbits and 
mice (Pati et al.  1996; Srivastava 1996). 
The  LPS of P.  multocida are similar to those of other 
gram-negative bacteria. They constitute the 'endotoxins' 
of the organism, and are the basis of somatic typing. The 
best LPS preparations are obtained from ethanol-killed 
cells that have been washed and dried. Killing with 
formalin alters certain properties of the LPS.  Extraction  is 
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done by the phenol-water (Westphal) method or the 
phenol-chloroform-petroleum method (Rimier and 
Rhoades 1989). 
LPS are largely responsible for the toxicity in  the HS-
causing serogroup B:2  and  play an  important role in the 
pathogenesis of the disease (Rebers et al.  1967; 
Rhoades et al.  1967). Purified LPS extracts have been 
shown to have anti phagocytic activity in  in vitro 
phagocytic uptake assays (Muniandy et al.  1993). 
Serological relationships exist between LPS of 
serogroups Band E (Mosier 1993). Electrophoretic 
analysis of purified LPS  preparations has also 
established relationships between Band E and some 
type A strains (Rimier 1990). This  is  not surprising since 
all strains of both Asian and African origin possess the 
Namioka somatic antigen type 6 and  Heddleston 
type 2, although in  the two serotyping procedures the 
LPS components used are different (De Alwis 1987). 
Although crude LPS  preparations are associated with 
immunity, it has been shown that highly purified LPS 
are nonimmunogenic to mice and  rabbits (Muniandy 
et al.  1993). Muniandy and Mukkur (1993) showed 
that Westphal extracts were protective in  mice, and 
that treatment with phenol or digestion with proteinase 
K abolished the protection. This latter observation 
suggests that the protectivity of crude LPS extracts is 
due to contaminating proteins. 
Common antigens 
P.  multocida shares common antigens with other 
closely related  gram-negative bacteria. Antigenic 
relationships with Yersinia paratuberculosis, 
P.  haemolytica, Haemophilus canis, H.  influenza, 
Actinobacillus lignieresi, Escherichia coli and Neisseria 
catarrhalis have been  reported (Bain  1963; Prince and 
Smith 1966b; Schryvers et al.  1986). Cross-protection 
has been detected in a study of 11  isolates of 
P.  multocida from cases of HS,  bovine pneumonia and 
fowl cholera and  belonging to various serotypes 
(Rimier 1996). A serotype A:5 strain and a fowl cholera 
strain were found to protect against a number of other 
strains,  irrespective of the disease caused.  This 
protection was attributed to antigen components of 
molecular weight 20-120 kDa. Enzymes 
P.  multocida has been found to produce a number of 
enzymes.  Neuraminidase is produced by members of 
serogroups A,  B,  D and E (Rimier and  Rhoades 1989). 
Its activity is found to be highest in  strains of serogroup 
A and  D.  Activity of neuraminidase of type E was 
inhibited by homologous antiserum only, whilst that of 
types Band D were inhibited by antisera against 
serogroups A,  B,  D and  E. 
The production of hyaluronidase and  chondroitinase by 
serotype B:2  associated with HS  is well documented 
(Carter and Chengappa 1980; Rimier 1993; Rimier and 
Rhoades  1994). Hyaluronidases are enzymes that are 
normally associated with invasive mechanisms in 
bacteria, helminths and  snake venoms. Type B strains, 
bearing other somatic antigens, such  as the B:3,4 cattle 
and deer strains, fail to produce hyaluronidase. Whilst it 
may be concluded that hyaluronidase production is a 
character exclusively restricted to serotype B:2  strains 
that cause  HS,  De Alwis et al.  (1996, 1998) described a 
type B:2  mutant that was of low virulence to mice and 
rabbits and avirulent to cattle and  buffaloes but 
produced hyaluronidase. No clear relationship has been 
established  between the ability to produce 
hyaluronidase or any other enzyme and virulence. 
Toxins 
Serogroups A and  D have been found to produce 
protein toxins, more toxigenic strains being present in 
serogroup D.  These toxins are directly involved in the 
pathogenesis of disease,  as  in  naturally occurring 
atrophic rhinitis in swine.  No correlation has been 
found between toxin production and somatic types. 
Toxins of serogroups A and  D are similar,  if not 
identical, and antiserum produced against one 
neutralises the other (Rimier and Rhoades 1989). 
True exotoxins are not produced by strains of the B 
group associated with HS.  Toxic effect (endotoxic 
shock) can  however be produced by injection of culture 
supernatants (which contain free endotoxins) or 
endotoxin preparations. 
Bacteriocins 
Bacteriocins are bacteriocidal proteins produced by 
many species of bacteria and which are active against 
members of their own species or closely related species. 
Production of bacteriocins is  believed to be determined 
by a genetic element. Bacteriocin activity has been 
demonstrated in  bovine and avian strains of 
P.  multocida (Rimier and Rhoades 1989). Thirty-three 
bovine and  bison strains belonging to serotypes A,  B 
and  D were tested for bacteriocin activity by 
Chengappa and  Carter (1977); 14 were found to 
produce bacteriocins. Seventeen strains were 
susceptible to bacteriocins. Except in special 
investigations, their role as a diagnostic tool is of 
limited value. The role of bacteriocins in the 
pathogenesis of disease has not been investigated. 
2.2.7  Genotype analysis 
With the advent of molecular biology, it has been 
possible to characterise isolates on a genotypic basis, 
providing a firmer and  more stable basis than 
groupings based on phenotypic characteristics. 
Molecular techniques have now been  developed both 
to identify bacterial types, and for further strain 
differentiation within serotypes, the latter being useful 
for epidemiological studies. 
Dawkins et al.  (1990) described strains of P.  multocida 
that were known to cause  HS  but gave a negative 
result in the HS-specific ELISA.  When analysed by 
immunoelectron microscopy, these isolates were shown 
to express a mixture of phenotypes with less than 
10%, and often less than 2 %, of the population 
expressing HS-associated epitopes (Dawkins et al. 
1991 a).  The phenotypic dichotomy observed by these 
workers within individual strains provides a further 
indication for characterisation on a genetic basis. 
Polymerase chain  reaction (PCR) tests have been 
developed to detect strains of P.  multocida associated 
with HS from material having low numbers of the 
organism (Thomas 1996; Brickell 1996; Natalia 1996; 
Townsend et al.  1998). A PCR-based fingerprinting 
method has also been developed for identification of 
strains causing HS,  irrespective of serotype (Townsend 
et al.  1997a) 
19 Ribotyping and field alternation gel electrophoresis are 
also techniques developed to characterise strains of 
P.  multocida that cause  HS (Adamson et al.  1993; 
Townsend et al.  1997b). A large number of genetic 
fingerprint profiles have been  identified by restriction 
endonuclease analysis (REA) among isolates of 
serotype B:2  that cause  HS.  These profiles are valuable 
as  markers in epidemiological work (Rimier 1997). 
These genomic typing methods are discussed  in greater 
detail in Section 5.10; details of the methods are shown 
in Appendixes 4 and 5. 
2.2.8  Biochemical properties 
Some of the biochemical properties are stable and 
consistent within the species but some characters are 
variable. The consistent characteristics of the species 
are shown in  Tables 2.5 and 2.6. 
Classification of the species into groups or biotypes 
based  on biochemical reactions has not been 
successful. Although some fermentation reaction 
patterns have been associated with isolates from a 
particular host species, such  relationships have not 
been consistent enough to form the basis for 
classification of the species. 
2.2.9  Virulence to experimental 
animals 
The type B:2  strains that cause  HS are highly virulent 
for mice and  rabbits. The  minimum lethal dose (LD50) 
is between 1 and  10 viable organisms. Guinea-pigs are 
also susceptible but to a considerably lower extent. 
Even  0.1  mL of an  undiluted broth culture containing 
around 107 viable bacteria fails to kill consistently. The 
B:2  serotype is also nonpathogenic to birds. 
The type B:3,4 strains show a similar pattern of 
virulence to laboratory animals.  No specific information 
on  type E is available and  it is  believed that this 
serotype will act in a similar way to B:2. 
2.3  Pasteurella haemolytica 
Pasteurella haemolytica is a small,  nonmotile, 
nonspore-forming bacillus, often showing 
coccobacillary forms, sometimes pleomorphic, with 
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occasional bipolar staining.  It can  be differentiated from 
P.  multocida by the following characteristics: 
•  ability to produce a narrow zone of haemolysis on 
ovine or bovine blood agar; 
•  ability to grow on McConkey agar,  where lactose 
fermenting strains produce pink colonies; and 
•  inability to produce indole. 
In  some strains, haemolysis may be detected only in 
thinly poured plates, and  may be visible after scraping 
off a colony from the surface of the plate. 
Based  on sugar fermentation reactions, two distinct 
biotypes have been  identified, designated the A and T 
types.  In the A type, most strains ferment arabinose 
but not trehalose. The converse is true of the T type. 
Serologically, based  on  an  IHA test and differences in 
capsular polysaccharides, 16 types have been 
identified. Of these,  12 are distributed within the A 
biotype and four in  the T biotype. Thus, the strains are 
identified on the basis of biotype and  serotype (A  1, 
A2, T1, T2  etc). 
2.4  Animal Diseases Caused 
by Pasteurella 
Specific serotypes of P.  multocida and  P.  haemolytica 
are associated with disease conditions in  cattle, 
buffaloes, sheep and goats, pigs,  poultry and other 
animals. These diseases and the aetiological agents 
involved are shown in Table 2.7. 
2.4.1  Haemorrhagic septicaemia 
HS,  which is the subject of this book, is the most 
economically important of the pasteurelloses (see 
Chapter 1).  It is  an  acute, fatal septicaemic disease 
caused  in cattle and buffaloes by one of two specific 
serotypes of P.  multocida belonging to the serogroups 
B or E,  commonly in cattle and buffaloes and also  in 
pigs and feral  ruminants.  Unlike other pasteurelloses, 
where the pasteurella organism plays a secondary 
and opportunistic role,  HS  is a primary pasteurellosis 
(see Section 3.1  for further details and  definition of 
the disease). Table 2.5.  Summary of common biochemical properties of Pasteurella multocida. 
Biochemical property 
Haemolysis 
Growth on  McConkey medium 
Gelatin hydrolysis 
Indole production 
Hydrogen sulfide production 
Nitrate reduction 
Methyl red  reaction 
Voges-Praskauer reaction 

















• Detectable using lead acetate paper,  but does not show up in  media such  as triple sugar iron agar (Difco) or SIM medium (Difco) 

































Note: The fermentation process  is slower than with some other gram-negative bacteria, particularly the Enterobacteriaceae. 
V+ =  Variable - more often positive 
V- = Variable - more often negative 









Haemorrhagic septicaemia (HS) 
Occasionally, HS·like septicaemic disease 
Bovine pneumonic pasteurellosis 
Pneumonic pasteurellosis, 
Septicaemic pasteurellosis 





P multocida serotypes B:2  and E:2 
P multocida serotype B:3,4 
P haemolytica A 1 
P multocida A 
P haemolytica A 
P haemolytica T 
P multocida serotype B:2 
Toxigenic strains of P multocida type D,  occasionally, 
type A 
P multocida type A 
P multocida type A 
Common serotypes are A:1, A:3, A:4. Other serotypes of 
groups A and D are less common (and type F in turkeys) 
Note: For P multocida 'A' refers to the capsular serogroup whereas for P haemolytica 'A' refers to the biotype. 
2.4.2  Bovine pasteurellosis 
Bovine pasteurellosis is  known by a number of 
synonyms that are descriptive of the condition and are 
relevant in specific circumstances. The terms shipping 
fever, transit fever,  bovine enzootic pneumonia, and 
bovine respiratory disease (BRD) complex are all very 
meaningful terms used to describe the disease.  It is 
believed that in  the United States, the losses to the 
beef and dairy industries from this disease complex are 
greater than the losses due to all other diseases put 
together. In the BRD  complex, more than one species 
and serotype of pasteurellae are incriminated as playing 
a role that is secondary to respiratory viruses and 
'stress'. This  is  unlike HS,  which is a primary 
pasteurellosis caused  by specific serotypes of the 
species  P.  multocida. The pasteurellae associated with 
BRD are predominantly P.  haemolytica type A, and 
P.  multocida capsular serogroup A.  There is no 
consistency in  the somatic types involved. 
The pasteurellae that cause  pneumonic pasteurellosis 
are carried in the upper respiratory tract (URT) of 
calves.  In  the case of P.  haemolytica type A  1, the 
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bacterium is  not easily detected in the URT of healthy 
calves,  but is  shed and can  be easily isolated in  calves 
that are stressed in some way or affected with another 
concurrent infection. The URTs of stressed or otherwise 
diseased calves can  be easily colonised by 
P.  haemolytica A 1. In the case of P.  multocida, no such 
relationship between stress and ability to colonise has 
been observed. The explosive multiplication of 
P haemolytica that results from stress leads to two 
processes.  Firstly, there is the invasion of the lungs, 
resulting in  pneumonia. Secondly, there is excessive 
shedding resulting in dissemination of infection to 
healthy incontact calves. The exact mechanisms 
underlying the rapid proliferation are not completely 
understood. 
The most effective preventive method is good 
management and avoidance of stress. Vaccines are of 
limited use,  since a multiplicity of other causative 
agents such  as viruses are also involved. Vaccines 
against the pasteurellae involved will help to reduce the 
severity of the disease, since it is the secondary bacterial 
phase of the disease that contributes to both its severity and fatality. Treatment with appropriate antibiotics 
helps to reduce the severity of the disease and prevent 
death. In  problem herds where the condition occurs 
frequently, a knowledge of the antibiotic sensitivity 
patterns of the strains involved is  useful. 
2.4.3  Pasteurellosis 
in  sheep and goats 
This is probably the most economically irnportant 
bacterial disease of sheep and goats. The predominant 
organism that causes pasteurellosis in sheep and goats in 
temperate climates is  P.  haemolytica. Biotype A causes 
pneumonia in all ages of sheep, and septicaemia in 
young lambs. Biotype T,  on the other hand, is associated 
with a distinct septicaemic syndrome in young adult 
sheep.  P.  haemolytica is carried  in the nasopharynx and 
tonsils of apparently healthy sheep.  Lambs acquire 
infection soon after birth, presumably by contact. The 
carrier rate  is low in normal healthy flocks and there is an 
assortment of serotypes.  In flocks undergoing outbreaks, 
on the other hand, the carrier rate  is high and a few 
specific serotypes dominate. The carrier status has also 
been found to display seasonal variations. 
Predisposing factors undoubtedly playa vital role in 
most outbreaks. Climatic changes and stressful 
management practices such  as transport, dipping and 
shearing may precipitate outbreaks. Proper 
management and the use of vaccines help to reduce 
the prevalence of the disease. 
2.4.4  Pasteurellosis in  pigs 
Apart from occasional outbreaks of septicaemic disease 
caused  by the HS serotype (B:2), two well-defined 
syndromes occur in  pigs. These are atrophic rhinitis 
and  pneumonia. 
Atrophic rhinitis is a disease associated with intensive 
pig breeding in  most parts of the world. It was 
originally described in  Germany nearly 160 years ago, 
but it was only during the last decade that its complex 
aetiology and  pathogenesis were revealed.  Economic 
losses due to this disease are due not only to deaths, 
but also to reduced weight gains. The disease  is 
characterised by the atrophy of the nasal turbinates 
resulting in a shortening and sometimes twisting of the 
snout. It is accompanied by sneezing and epistaxis. Two 
bacterial organisms have been  incriminated in  the 
disease. These are Bordetella bronchiseptica and 
P.  multocida. The former organism is a normal 
inhabitant of the URT of pigs. Turbinate atrophy that 
occurs in atrophic rhinitis is preceded by a rapid 
proliferation of certain toxigenic strains of P.  multocida 
type D.  Concurrent infection with B.  bronchiseptica or 
the action of certain irritants creates an  environment 
favourable for such  proliferation. Vaccines used  in  the 
past were bacterins containing both organisms. 
Modern vaccines are a combination of 
B.  bronchiseptica bacterin with pasteurella toxoids 
prepared from toxigenic strains.  Both components play 
a role in  the protective mechanism. 
2.4.5  Fowl cholera 
This  is a disease of considerable economic importance 
to the poultry industry in  the developed countries of 
the world. In the developing countries, where the 
poultry industry is rapidly changing from a scenario 
dominated by village chicken and smallholder 
operations to one of large-scale commercial 
undertakings, it has become an emerging disease of 
economic importance. In 1986, one estimate gave the 
worldwide losses due to fowl cholera as  US$200 
million. The disease in wild birds is often referred to as 
avian cholera or avian pasteurellosis and  is considered 
to be a threat to the survival of some endangered birds. 
The earliest historical record of what is  now known to 
be fowl cholera dates back to the year 1600. Much of 
the earliest work on the role of microorganisms in 
infectious diseases, the use of immunising agents and 
the contribution of Louis Pasteur in this regard was 
related to Pasteur's work on  fowl cholera in the 1880s. 
Fowl cholera is caused  by P.  multocida and most 
serotypes involved belong to serogroup A.  Serotypes 
A:1, A:3 and A:4 appear to be the common ones in 
most countries, although all of the 16 somatic 
serotypes of capsular group A, and  some types of 
group D,  have also been implicated. In turkeys, 
capsular serogroup F has been  incriminated. Fowl 
cholera is  a primary pasteurellosis resulting in 
septicaemia and death. A chronic form has also been 
described and chronically affected birds may serve as 
reservoirs of infection. 
23 The disease is associated with poor sanitation. 
The most important control measure is to improve 
sanitation. Chemotherapeutic agents are used for 
treatment as well as on  a prophylactic basis at low dose 
levels in situations of high prevalence. The latter use, 
however,  is not encouraged. Vaccines are also used. 
Polyvalent vaccines containing the commonly occurring 
serotypes as  bacterins, with or without adjuvants, are 
available commercially. Their efficacy is variabie. 
2.4.6  Other animals 
In addition to these diseases of economic importance 
caused  by pasteurella organisms in agricultural and 
domestic animals, occasional, sporadic outbreaks of 
disease have been  reported in a variety of host species. 
Some of these are summarised in Table 2.8. Carter 
(1959) recorded pasteurellae associated with disease 
in  deer,  cats,  dogs, horses, mink and monkeys. More 
recent reports of disease in donkeys and horses (Pavri 
and Apte 1967), and deer (Jones and  Hussaini 1982; 
Carrigan et al.  1991), are available. Pasteurellosis has 
also been reported among elephants in  Sri  Lanka,  bison 
in the United States, camels in Sudan and  in  a snow 
leopard in the Himalayas (Carter 1957; De Alwis and 
Thambithurai 1965; Bain et al.  1982; De Alwis 1982a; 
Wickremasuriya and  Kendaragama 1982; Chaudhuri 
et al.  1992). 
The types of infections recorded are highly varied and 
range from septicaemias and respiratory infections, 
which are the most common forms, to wound 
infections, abscesses,  mastitis, peritonitis and 
encephalitis. The most common form of infection in 
the human occurs as a result of animal bites. 













Country  Serogroup 
United States  B 
China  B 
England, Australia  B 
Sri Lanka  B 
Sudan 
India, Egypt, Sudan  B,D 
India  F 
United States, France 
United States  A,D 
United States  A The Disease:  Infection, Clinical Signs and Pathology 
Overview 
The disease 
Haemorrhagic septicaemia is  a primary pasteurellosis in 
cattle and buffaloes caused by Pasteurella multocida 
serotypes B:2 and E:2. More recently, disease syndromes 
indistinguishable from HS have been found in other 
host species associated with other B serotypes. 
Infection 
Clinically affected animals and active carrier animals 
serve as a source of organisms in outbreaks, and 
infection occurs by inhalation or ingestion. Although 
the virulence factors responsible for the pathogenesis 
are not yet completely understood, recent work has 
thrown considerable light on this aspect. There are no 
permanent reservoirs of infection outside susceptible 
animals but carcases, freshly infected pasture, bedding 
etc. may be infective, particularly in moist conditions. 
Clinical signs and pathology 
Clinical signs, including increased temperature and 
respiratory distress, appear after a brief incubation period. 
The disease lasts a few hours to a few days and most 
animals die with septicaemia in the terminal stages. 
Recovery from clinical disease is rare and occurs only when 
animals are treated in the initial stages of the disease. 
Subcutaneous oedema and widespread petechial 
haemorrhages are seen at postmortem examination, as 
well as with congested lungs and enlarged lymph nodes. 
Pathogenesis and bacteriology 
The bacteria appear to multiply in  the tonsils. During 
the terminal phase of the disease, pasteurellae can be 
isolated from blood and rapid multiplication occurs in 
the carcase. The nature of the bacterium's virulence is 
not fully understood but lipopolysaccharides in the 
outer membrane have been implicated, as  they inhibit 
phagocytosis enabling rapid multiplication. Some 
animals can become immune carriers. 
3.1  The Disease 
Haemorrhagic septicaemia (HS) was previously defined 
as:  an  acute, fatal septicaemic disease caused  in cattle 
and buffaloes by one of two specific serotypes of the 
bacterium Pasteurella multocida. 
The two serotypes are popularly known as the Asian 
and African serotypes, but were designated 6:B and  6:E 
by the Namioka-Carter system and  more recently B:2 
and  E:2  by the Carter-Heddleston system,  respectively 
(see Section 2.2). Occasionally, these same serotypes 
cause septicaemic disease in other species (e.g. sheep 
and goats). In such  instances, the term 'septicaemic 
pasteurellosis' has been  used to describe the condition 
(see Table 2.7). 
More recently, a re-examination of the bacterial strains 
associated with the classical  HS syndrome, using 
modern serotyping or DNA fingerprinting techniques, 
has indicated that type B strains of P multocida, other 
than serotype B:2,  have also been  involved in  some 
instances (Rimier and Wilson 1994). In view of the 
wider spectrum of serotypes of the Band E groups 
incriminated in the disease, and the involvement 
(though rarely) of species of animals other than cattle 
and buffaloes, it may now be appropriate to give the 
disease a somewhat broader definition. Hence,  HS may 
now be considered as: an acute,  fatal,  septicaemic 
disease caused by strains of P.  multocida belonging to 
the serogroups B or E,  commonly in cattle and 
buffaloes and also in pigs and feral ruminants. 
Unlike other pasteurelloses, where the pasteurella 
organism plays a secondary and opportunistic role,  HS  is 
a primary pasteurellosis. It is  reproducible experimentally 
using pure cultures of the causative organism alone, and 
is preventable by vaccines incorporating the specific 
serotypes. Thus,  HS  is a specific form of pasteurellosis, 
occurring mainly in  cattle and buffaloes. This is similar 
to the situation of typhoid in  humans, and pullorum in 
poultry, which are both caused by a specific strain of 
salmonella in a specific host species. 
25 It must be stressed, however, that only the classical 
serotypes B:2  and E:2  are capable of producing disease 
consistently and predictably upon experimental 
subcutaneous transmission. The other serotypes 
occasionally encountered are  B:1,  B:3,4 and  B:4  (see 
Section 2.2). In  the author's experience, B:3,4 fails to 
produce disease consistently, even upon experimental 
transmission. No information is  available on  types B:1 
and  B:4 in this regard but these serotypes have been 
associated with occasional sporadic outbreaks of 
disease,  indistinguishable from the classical  HS 
syndrome, mainly in  wild animals and, in a few 
instances, in domestic cattle. 
Buffaloes are generally more susceptible than cattle, 
and young animals are  more prone to the disease than 
adults (De Alwis et al.  1976; De Alwis and Vipulasiri 
1980; De Alwis 1981; FAO 1979, 1991). (See Chapter 
4 for further details on  host and age susceptibility.) 
3.2  Source of Infection 
In general, P.  multocida does not survive long enough 
outside the animal to become a significant source of 
infection, although survival may be longer in  moist 
conditions. 
Some experiments have shown that the organism can 
survive in sterilised soil for 2-3 weeks (Bain et aI1982). 
It was shown in  Malaysia, however, that when sterilised 
earth and mud from rice fields were artificially infected, 
bacteria could not be recovered after a few hours 
exposure to sunlight (FAO 1959). When deposited in 
mud where buffaloes wallow, bacteria could not be 
recovered after 24 hours (Bain et al.  1982). 
Carcases dumped into rivers and waterways and 
carried downstream are often incriminated as  a likely 
method of spread  of the disease and it is believed that 
pasteurellae can  survive in animal tissues, and perhaps 
in decomposing carcases, for a few days. Freshly 
infected pasture, bedding etc.  may also be  infective. 
However, no permanent reservoirs of infection have 
been established outside the animal. 
Outbreaks of HS  begin when clinically affected or, 
more likely, carrier animals are introduced into the herd. 
Once an  outbreak has occurred, decomposing carcases 
not promptly buried or burnt serve as  a source of 
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infection. In  experimental transmission, it has been 
found that large numbers of organisms - in the region 
of 107 to 1012 colony forming units (CFU) - are 
required to set up an infection by the natural routes 
(De Alwis et al.  1990). 
How an  active carrier animal transmits such a large dose 
to an incontact animal  is not completely understood. It 
can  be speculated that organisms directly shed from a 
carrier may be more virulent than cultures grown in 
vitro and used in experimental transmission studies. 
Alternatively, unknown circumstances may alter the 
susceptibility of animals so that a smaller infecting dose 
can cause disease. When isolates from clinical cases and 
from latent carrier animals were compared, however, no 
difference in virulence was demonstrated as judged by 
the median lethal doses (LD50s) for mice (Wijewardana 
et al.  1986a). 
3.3  Routes of Infection 
It is believed that the natural routes of infection are by 
inhalation and/or ingestion, and successful transmission 
has been  made experimentally using intranasal aerosol 
sprays or oral drenching. However, the dose required to 
produce clinical disease has not been consistent, and 
the results obtained with a given dose are not always 
predictable. Subcutaneous inoculation of bacterial 
cultures grown in vitro, with doses ranging from 104 to 
107 CFU,  has produced more consistent results. In 
experimental transmission, the route of infection is 
loosely related to the course of the disease, the clinical 
syndrome and the extent of pathological lesions. 
Intranasal infection by aerosols and oral drenching 
results in  a longer course of disease and more profound 
lesions; subcutaneous inoculation results in  rapid onset 
of disease, a shorter course and less marked 
pathological lesions. 
3.4  Clinical Signs 
Figure 3.1  shows a buffalo calf with clinical symptoms 
of HS.  The disease occurs mainly in  regions where 
husbandry practices are primitive and the animals are 
reared  under free-range conditions. In such 
circumstances, the animals are not under constant 
observation and the only reported sign  may be sudden death. Indeed, first-hand descriptions of the clinical 
syndrome under natural conditions are scarce. 
Generally, the observed signs are temperature 
elevation, loss of appetite, nasal discharge, salivation 
and  laboured breathing, with swellings in the 
submandibular region spreading to the brisket area and 
even down to the forelegs. 
Figure 3.1. A buffalo calf clinically affected with 
haemorrhagic septicaemia. Note the dull appearance and 
rough coat and the prominent submandibular swelling. 
Some descriptions of the syndrome arising from 
experimental transmission have been  made in  Sri 
Lanka. These include experimental transmission of the 
disease by subcutaneous inoculation of in vitro cultures, 
intranasal or oral transmissions, or natural infections 
occurring in animals housed in close contact with 
clinically affected animals, the last being the closest 
equivalent to naturally occurring disease (M.CL. De 
Alwis, unpublished data; Horadagoda et al.  1991). The 
results of these studies are described below. 
3.4.1  Incubation period 
On exposure to experimental or natural infection, 
clinical signs appear after a brief incubation period. The 
following incubation times were observed in  Sri  Lanka 
for indigenous buffalo calves, 4-10 months of age 
(M.CL. De Alwis, unpublished data): 
•  subcutaneous infection (n=1) - around 
12-14 hours (i.e.  when observed at about 12 hours 
the animal appeared normal and  when observed at 
14 hours it was sick); 
•  aerosol or oral infection (n=7 and 2,  respectively) -
average of 30 hours; 
•  naturally exposed animals (n=4) - 46-80 hours 
after initial contact. 
In a further study (Horadagoda et al.  1991) using 18 
indigenous buffalo calves aged between 7 and  12 
months, the incubation period recorded was 
approximately 24 hours for oral infection (n=2) and 
ranged from 18 to 66 hours for aerosol infection (n=12). 
3.4.2  Duration 
The duration of the clinical course of disease is  highly 
variable. In  experimental infections by the 
subcutaneous route, the clinical course lasted only a 
few hours.  In  experimental transmissions by natural 
routes (oral or aerosol), and  in  natural exposure 
experiments, M.CL. De Alwis recorded a clinical course 
ranging from two to five days (unpublished data). 
Horadagoda et al.  1991  recorded a clinical course of 
14-19 hours after experimental oral infection (n=2), 
25-110 hours after aerosol infection (n=12) and 19-70 
hours after natural exposure (n=4). 
In  field observations of five outbreaks of disease 
involving 37 buffaloes and 7 cattle, Saharee and Salim 
(1991) recorded a clinical course of 4-12 hours in  per 
acute cases and 2-3 days in acute and subacute cases. 
On a herd basis, the outbreaks usually occur very fast 
and do not persist for long. The observations of Saharee 
and Salim  (1991) in west Malaysia indicated that 75% 
of outbreaks lasted for less than 15 days within a herd. 
3.4.3  Progression of the disease 
The clinical syndrome may broadly be divided into 
three phases  as follows. 
•  Phase  1 is dominated by increased temperature, loss 
of appetite, general apathy, and depression.  If 
closely monitored, a rise  in  rectal temperature to 
40-41°( is recorded, which lasts throughout the 
course,  dropping to subnormal levels during the 
terminal phase, a few hours before death. 
•  Phase 2 is dominated by a respiratory syndrome. 
There will be an  increased respiration rate 
(40-50/minute), laboured breathing, clear nasal 
discharge and salivation. Submandibular oedema 
27 may also begin to show during this phase.  As the 
disease progresses, the nasal discharge becomes 
opaque and  mucopurulent. 
•  Phase 3 is dominated by recumbency. The 
respiratory distress becomes more acute, the animal 
lies down, terminal septicaemia sets in and death 
follows: case fatality is  nearly 100%. 
In  many instances, there are varying degrees of overlap 
between the phases, and the shorter the course, the 
less distinct are the three phases.  Unless a close 
vigilance is  maintained, the first phase may be easily 
overlooked. The course of the disease arising from field 
reports is  often shorter than experimental observations, 
probably due to the failure to detect the first phase 
under free-range conditions. 
In general, it has been observed that the disease is 
more acute and  has a shorter course in  buffaloes than 
in  cattle. Graydon et al.  (1993) observed that upon 
experimental subcutaneous inoculation, buffaloes died 
24-31  hours after inoculation, whereas the time of 
death for cattle was 60 hours. 
3.4.4  Atypical syndromes 
Atypical syndromes caused  in the natural hosts by HS-
causing pasteurella serotypes have been  recorded from 
time to time. An outbreak of pneumonia was reported 
in  a batch of buffalo calves 4-10 months of age in  Sri 
Lanka (De Alwis et al.  1975). The course of the disease 
was somewhat longer than usual and  a few cases 
lingered on  for up to 10 days.  Pneumonia was the 
dominant feature. Out of 33 affected animals, 30 died 
and all showed a terminal septicaemia.  It was 
postulated that this protracted pneumonic syndrome 
was the result of a heavy burden of infection on 
buffalo calves with low levels of immunity. Syndromes 
have been described in literature as  'septicaemic form', 
'respiratory form' or 'cutaneous, pectoral or 
oedematous forms' (presumably based on the 
dominant symptoms). 
Dhanda and  Nilakanthan (1961) reported the 
occurrence of paraplegia in  189 cattle from 28 villages 
in  India following a vaccination campaign against 
rinderpest, where a total of 48 603 animals in  71 
villages in  the Andhra Pradesh  were vaccinated. Of 
these animals, 135 died. The cerebrospinal fluid was 
collected from two animals, and P multocida was 
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isolated from cultures. The authors typed the isolate as 
Roberts type I but it is  now known that Roberts type I 
includes the Asian  and African strains B:2 and E:2, 
respectively,  as  well as the Australian strain 989 (11:B 
by Namioka-Carter; B:3,4 by Carter-Heddleston). It is 
therefore not certain whether the report is  one of an 
atypical syndrome caused  by the Asian serotype, or one 
with a variant serological configuration. It is  also 
significant that in this outbreak, there was no terminal 
septicaemia, a feature characteristic of infection with 
the Asian  B:2  serotype. 
3.5  Pathology 
3.5.1  Gross pathology 
Upon opening a carcase of an  animal that has died of 
HS, the most obvious lesion  is subcutaneous oedema -
subcutaneous infiltration with yellow serosanguinous 
fluid, particularly in the submandibular and  brisket 
regions.  Subcutaneous petechial haemorrhages are also 
evident. There are also widespread petechial 
haemorrhages in the thoracic cavity,  particularly on the 
base of the ventricles and  the auricles. There may be 
excessive fluid in the pericardial sac and  pericarditiS 
with marked thickening of the pericardial wall may be 
present. The lungs may be congested with varying 
degrees of consolidation and with a marked thickening 
of the interlobular septa.  In the abdominal cavity, 
petechial haemorrhages are widespread in all tissues. 
Massive ecchymotic or petechial haemorrhages may be 
Figure 3.2. Heart of  an animal that died of haemorrhagic 
septicaemia showing ecchymotic and petechial haemorrhages 
on the subepicardial adipose tissue. Figure 3.3. Heart and pericardium of an infected buffalo. 
The parietal pericardium is markedly thickened. Note the 
fibrinous strands between the two layers of  pericardium and 
the excessive pericardia  I effusion. 
Figure 3.5. Abomasum of  a buffalo calf that died of 
haemorrhagic septicaemia, showing severe diffuse 
haemorrhages on the mucosa. 
seen on the abomasal wall, as well as on the 
mesentery. The lymph nodes are usually enlarged. 
Figures 3.2 to 3.6 show typical lesions. 
In experimental transmissions, De Alwis et al.  (1975) 
observed that the pathological picture depended upon 
the duration of the syndrome.  In animals that died 
within 24-36 hours of experimental inoculation, the 
gross pathology was  limited to widespread petechial 
haemorrhages and generalised congestion of the lungs. 
When the duration was 36-72 hours, haemorrhages 
were petechial or ecchymotic, and  more pronounced. 
Fibrinous pericarditis was present. 
Figure 3.4. A lateral view of the thoracic and abdominal 
viscera of  a buffalo calf that died of haemorrhagic septicaemia. 
Figure 3.6. A slice of the affected cardiac lobe of  the lung in 
a buffalo calf that died of haemorrhagic septicaemia. Note 
the demarcation between the pneumonic (arrow) and 
congested areas. 
When the course was longer than 72 hours, there was 
extensive consolidation of the lungs, with marked 
lobulation, pleuritis, pericarditis with marked thickening 
of the pericardial wall and, in later stages,  pleural 
adhesions (De Alwis et al.  1975). The pleura overlying 
the pneumonic lungs are sometimes thickened, forming 
a sheet of fibrin, often adhering to the costal wall and 
pericardium (De Alwis et al.  1975; Horadagoda et al. 
1991). Rhoades et al.  (1967) found similar lesions, and 
further reported that the nature of the lesions 
depended on the route of infection. 
29 Figure 3.7. Histological appearance of the lung of  a buffalo calf that died of  haemorrhagic septicaemia.  (a)  Thickened pleura and 
interlobular septa stained with haematoxylin and eosin (HE)(X25).  Note the congested alveolar capillaries and alveolar oedema.  (b) 
Congestion of  alveolar capillaries, oedema fluid and infiltration of  polymorphonuclear leucocytes in an area of early pneumonia 
(HEx100).  (c) An area of  acute inflammation of the lung (HEx100).  The alveolar capillaries are infiltrated with numerous 
polymorphonuclear leucocytes.  (d)  Vacuolated alveolar macrophages in alveolar spaces (arrow) stained with 
immunoperoxidase/haematoxylin (X400). Some of the alveoli demonstrated a strong immunoreaction. 
3.5.2  Histopathology 
Early reports on the histopathological changes in  HS 
include that of Rhoades et al.  (1967) who produced the 
disease experimentally in  a calf using the bison  B:2 
strain. The histopathological lesions observed included 
small haemorrhages involving the peritracheal adventitia 
and submucosa, generalised interstitial pneumonia, 
hyperaemia, oedema and cellular responses most 
prominent in the anterioventral portions of the lung, 
increased lymphocytes and macrophages in the 
thickened alveolar septa.  Lymph nodes were 
hyperaemic, and there were subserous haemorrhages 
and hyperaemia in the spleen.  In the gastrointestinal 
tract, hyperaemia and subserous haemorrhages were 
evident. The liver showed hyperaemia, cloudy swelling 
and fatty degeneration. The kidney showed cloudy 
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swelling and pyknosis of tubular epithelial cells.  Sections 
of the heart showed marked hyperaemia with 
subepicardial and subendocardial haemorrhages. Figure 
3.7 shows the histological appearance of the lung of a 
buffalo that died of HS. 
In experimental transmission, Horadagoda et al.  (1991) 
found close similarities between microscopic lesions in 
animals infected experimentally by the intranasal route 
and those infected by natural exposure. There was 
fibrinous bronchopneumonia, with a marked dilatation 
of the pleura, interlobular septa and  lymphatics with 
fibrinous exudate. Fibrin clots were present within the 
distended lymphatics. The alveoli were filled with fibrin 
with varying amounts of inflammatory cells consisting 
mainly of polymorphonuclear leucocytes. With immunoperoxidase labelling, it was possible to 
demonstrate P.  multocida antigens in subpleural 
lymphatics and interlobular septae, and within blood 
vessels of visceral organs. 
The only available report on  the pathological lesions in 
HS outbreaks occurring naturally in Africa is that of 
8astianello and Jonker (1981). 
3.6  Pathogenesis 
Upon entry of the pasteurella organism into the animal, 
it is believed that the initial site of multiplication is the 
tonsillar region. The outcome of this infection depends 
on an interaction between the virulence of the organism 
and its rate of multiplication in vivo, on the one hand, 
and the specific immune mechanisms and nonspecific 
resistance factors of the host animal, on the other. Thus, 
the dose of infection is a vital factor and if the organism 
overcomes the host's defence mechanisms, clinical 
disease will result.  If the defence mechanisms dominate 
over the organism, what is  described as an  'arrested 
infection' occurs, and the animal becomes an  immune 
carrier. Such  animals possess solid immunity, and the 
presence of large numbers of such  immune animals 
following an  outbreak of disease contributes to 'herd 
immunity' (De Alwis et al.  1986). 
There is currently no evidence that the HS-causing 
strains of P.  multocida produce any exotoxins. It has 
however been observed that serotype 8:2 strains that 
cause  HS produce hyaluronidase (Carter and Chengappa 
1980), whilst a few known 8:2 strains not associated 
with HS fail to produce this enzyme. It is equally true 
that other type 8 strains such  as 8:3,4, which are known 
to produce a syndrome indistinguishable from the typical 
HS, also do not produce hyaluronidase. It is, therefore, 
uncertain whether this enzyme is of any significance in 
the pathogenesis. 
It is significant that with some type 8 (8:2) and type E 
strains (E:2), disease can  be predictably reproduced 
experimentally. Other type 8 strains (8:3,4, 8:1, 8:4) 
have been associated with sporadic outbreaks of 
disease,  but pathogenicity cannot always be 
demonstrated experimentally. It is still  uncertain 
whether the former strains possess any specific 
virulence factors, and, if so,  whether they are merely 
phenotypic characters or have a genetic base. 
Whatever the virulence factor(s), it is  logical to expect 
it to allow the organism to initially multiply against the 
defence mechanisms of the body and then produce the 
lesions that are characteristic of the disease. At present, 
there is some circumstantial evidence to indicate what 
these factors might be. 
It has been found that the classical Asian serotype (8:2) 
is capable of causing vacuolation and eventually lysis of 
macrophages, a property that will diminish 
phagocytosis and promote multiplication of invading 
bacteria. This activity of cytoplasmic vacuolation 
leading to macrophage lysis and death has been 
demonstrated using HS-causing type 8 strains,  but not 
with the non-HS 8 strains, in a model using mouse 
peritoneal macrophages and in  in  vitro studies using a 
mouse macrophage cell  line (Shah et al.  1996). This 
activity has also been demonstrated using culture 
supernatants of the same strains, but not for those of 
the non-HS strains.  In the absence of a true exotoxin, it 
might be expected that free endotoxin would be found 
in  the culture supernatants, a feature also common to 
other gram-negative bacteria. 
Using an ovine mammary neutrophil system and [3Hl-
labelled type 8 strain of P.  multocida, Muniandy et al. 
(1993) found that capsular polysaccharide extracts 
known to contain 20% lipopolysaccharides (LPS), 
potassium thiocyante extracts and Westphal type LPS 
extracts inhibited phagocytosis. These workers also 
found that when encapsulated cells and de-encapsulated 
cells were used, the percentage of de-encapsulated cells 
phagocytosed was significantly higher than when 
encapsulated cells of P.  multocida were used. These 
observations indicated that HS-causing strains of 
P.  multocida appeared to possess a factor in their capsule 
that inhibited the ability of phagocytes to engulf and 
destroy invading bacterial cells. 
It is well established that the endotoxins of gram-
negative bacteria consist predominantly of LPS.  The toxic 
effects of the LPS of P.  multocida associated with HS 
have been amply demonstrated (Rebers et al.  1967; 
Rhoades et al.  1967). These workers prod uced 
experimental HS in calves and  pigs by different routes 
using type 8 strains. They also administered endotoxin 
prepared from this strain to a calf. The symptoms and 
lesions produced in the calf given endotoxin resembled 
those of experimental infection. More recently,  N.U. 
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studied the acute phase response (APR)  in  buffaloes 
infected experimentally with HS.  The APR is a 
nonspecific, systemic host response that is cytokine-
mediated; it results from tissue injury or infection and is 
an  integral part of the host defence mechanism. The 
APR is characterised by changes in  body temperature, 
endocrine changes and changes in trace mineral levels, 
leucocytes and serum proteins. Horadagoda et al. 
observed a rapid  rise in serum haptoglobin and a more 
delayed increase in  a1-acid glycoprotein. A rapid  rise  in 
serum iron and zinc was accompanied by a delayed rise 
in copper levels.  Leucocyte counts dropped progressively 
with advancement of the clinical syndrome, reaching 
their lowest immediately before death. Serum cortisol 
increased progressively, reaching its peak just before 
death, or in the terminal moribund stage. Endotoxin 
levels in the serum remained unchanged throughout the 
course of the disease and displayed a spectacular rise 
immediately before death. These changes are typical of 
the APR in any infection and the terminal rise  in 
endotoxin level coincides with the observed terminal 
septicaemia (M.C.L.  De Alwis, unpublished data; 
Horadagoda et al.  1991). When a group of buffaloes 
were injected with endotoxin prepared from an  HS-
causing strain of P.  multocida, the APR was strikingly 
similar to that following infection (N.U.  Horadagoda et 
al. t(personal communication 1998). 
Whilst the presence of other virulence factors cannot be 
discounted, there is sufficient evidence to implicate LPS as 
an entity largely responsible for the disease. The evidence 
supports its role in  inhibiting phagocytosis, thereby 
enabling rapid multiplication, and further reinforces the 
role of the capsule in the virulence mechanism (the 
inhibitory effect is greater in encapsulated strains). It also 
accounts for the APR and the typical lesions observed in 
HS. This hypothesis is further supported by the findings 
of Shah et al.  (1996) that sera from buffaloes recovering 
from HS inhibited the vacuolating cytotoxic activity of 
type B strains as well as of culture supernatants known to 
contain free endotoxin. 
t N.U. Horadagoda (Faculty of Veterinary Medicine and Animal 
Science, University of Peradeniya; ).C. Hodgson and C.M. Moon 
(Moreton Research Institute,  Edinburgh, UK); PD. Eckersall 
(Department of Veterinary Clinical Studies, Clasgow Veterinary 
School, UK);  and T.C. Wijewardana (Veterinary Research 
Institute,  Peradeniya, Sri Lanka) . 
32 
3.7  Bacteriology 
Septicaemia is  essentially a terminal event and 
pasteurellae can only be isolated from blood during the 
terminal phase of the disease. At the time of death, 
around 105-106 CFU/mL of organisms appear in  the 
blood. Rapid  multiplication occurs in  the carcase;  under 
tropical conditions counts in the range of 
1011_1012 CFU/mL have been recorded in carcases 
20-21 hours after death (M.C.L. De Alwis, unpublished 
data). Apart from animals infected by aerosol, the 
appearance of pasteurellae in  the nasopharynx was 
inconsistent, and the chances of isolation increased 
with the progress of the disease. 
In an outbreak of what was described as  HS in beef 
cattle in Zimbabwe, heavy growths of nearly pure 
cultures were made from heart blood, lung, pericardium, 
spleen, liver, kidney and brain. Organisms were not 
recovered from the foetal tissue (Lane et al.  1992). 
3.8  Recovery 
Once clinical signs are established in typical field 
outbreaks, death invariably occurs.  Recoveries may 
occur only if the disease is treated in the early stages of 
the clinical syndrome. When the disease occurs in  an 
organised farm, losses can  be  minimised by regularly 
checking the rectal temperatures of all incontact 
animals and giving antibiotic treatment to any animals 
showing increased temperatures. 
Spontaneous recovery without treatment is extremely 
rare,  but it may occur in a few animals towards the end 
of an outbreak. Such instances are presumably due to the 
animal possessing some degree of immunity at the time 
of exposure. In a controlled exposure of buffaloes to 
experimental infection with a view to producing carrier 
animals, some animals showed early signs, followed by 
recovery (De Alwis et al.  1990). This phenomenon is 
referred to as 'arrested infection', and invariably leads to 
an  immune carrier state (see Section 4.7). 
There are some instances of high recovery rates on 
record but these are likely to be due to inconsistencies 
in  routine disease notification systems. Epidemiology 
Overview 
Global distribution 
The global distribution of haemorrhagic septicaemia 
(HS) includes almost all  parts of the world  .. The disease 
is generally associated with wet, humid weather 
conditions, extensive farming practices that do not allow 
for good disease prevention management strategies, and 
areas where buffaloes and cattle are abundant. 
Distribution of serotypes 
Of the classical serotypes, B:2  is  found in Asia and E:2 
in Africa while some Middle Eastern and East African 
states record both. A few other B serotypes have been 
associated with sporadic outbreaks of disease resembling 
HS, particularly in wild animals. 
Host susceptibility, morbidity and mortality 
Of the conventional host species, buffaloes are more 
susceptible than cattle. The morbidity is  highly variable 
and is influenced by a variety of factors. When first 
introduced, explosive outbreaks occur. In endemic 
situations, few deaths occur at a time, mainly among 
young adult animals. When clinical disease is 
established, however,  death invariably occurs and case 
fatality is  near 100%. 
Carriers 
A variable proportion of animals in a given population 
are latent carriers. These animals intermittently become 
active and shed virulent pasteurellae. 
Disease outbreaks 
New outbreaks occur when a shedder comes into 
contact with a susceptible animal (e.g. one introduced 
from elsewhere or born since the previous outbreak). 
Once the first clinical case occurs, more bacteria are 
shed and disseminated. The size of an outbreak depends 
on the proportion of immune to nonimmune animals in 
the herd. 
4.1  Geographic Distribution 
of Disease 
The global distribution of HS (which was described in 
Chapter 1)  is  related to climatic conditions, husbandry 
practices and the types of animals reared. This is shown 
in  Sri  Lanka, an  island of 65 000 km 2 with a variety of 
agroclimatic zones and  related husbandry practices and 
distinct endemic and  nonendemic areas for HS. 
In the hill country, where the climatic conditions are 
mild (elevation over 1000 m, temperature range 
1  a-24°C) and temperate dairy breeds are reared 
intenSively, the disease  is almost nonexistent. In the 
warmer dry plains, on  the other hand, with heavy 
seasonal  rains,  where indigenous cattle and  buffaloes 
and  zebu cattle are reared  under a free-grazing 
extensive system of management, the disease  is 
endemic. Intermediate areas experience occasional 
sporadic outbreaks. A similar geographic distribution is 
also well documented in  India (Sharma et al.  1982; 
Dutta et al.  1990). It is likely that HS may occur in 
some South American states, with high water buffalo 
populations, and  where conditions are somewhat 
similar to those prevailing in  tropical Asia. 
4.2  Seasonal Effects on 
Distribution 
HS  is generally associated with wet, humid weather 
conditions. Massive outbreaks recorded in  Sri  Lanka 
(Perumalpillai and Thambiayah 1957; Dassanayake 
1957) and in  Zambia (Francis et al.  1980) were all 
associated with heavy rains.  In  Sudan,  outbreaks are 
reported to occur during rainy seasons (Mustafa et al. 
1978). Seasonality has been well documented in  India, 
with the majority of outbreaks occurring during the 
wet season  (from July to September), with the peak in 
August. The correlation with wet weather conditions 
33 was further evident from studies on geographical 
distribution of the disease in  India. The disease 
occurred more frequently in states that received a 
higher annual mean rainfall (Dutta et al.  1990; Saini et 
al.  1991). Sharma et al.  (1982) has similarly reported 
that 83% of all  cases in  Uttar Pradesh,  India occurred 
during the wet monsoon months of July, August and 
September. Seasonal occurrence has also been 
confirmed in  Pakistan (Sheikh et al.  1996). 
Active surveillance studies in  Sri  Lanka (De Alwis and 
Vipulasiri 1980; De Alwis 1981), however, have shown 
clearly that outbreaks occur throughout the year. Whilst 
dry season outbreaks appear to be contained, outbreaks 
occurring during wet seasons tend to spread, presumably 
due to the longer survival of the causative organism 
outside the animal.  In Asian countries, there are other 
wet season associated factors that promote spread of the 
disease. With the start of the rainy season, considerable 
movement of animals occurs for draught power to 
plough the rice fields. The outbreak in Northern Samar in 
the Philippines in  1993-94 was attributed, amongst 
other factors, to movement of new animals into the area 
from Mindanao (Molina et al.  1994). 
4.3  Distribution of Serotypes 
The classification of Pasteurella multocida serotypes 
was described in Chapter 2.  In Asian countries, the 
only serotype that has been  reported is type B:2. 
Perreau  (1961) first recognised that outbreaks of 
acute septicaemic pasteurellosis recorded in  Africa 
were typical HS and Carter (1961) showed that the 
causative organism was a new type of P.  multocida, 
which he designated as type E,  to distinguish it from 
the Asian type B. 
The African states of Senegal, Mali, Guinea, Ivory 
Coast, Nigeria, Cameroons, Central African Republic 
and Zambia have all  reported serotype E:2  (Perreau 
1961; Francis et al.  1980). Egypt and Sudan  have 
recorded the presence of both E and B serotypes 
(Shigidi and  Mustafa 1979), and there is one record of 
an outbreak caused  by the B (Asian) strain in Cameroon 
(Martrenchar 1993). There are indications that serotype 
B:2  may be present in some East African countries. 
All the North American isolates were originally 
identified as the Asian serotype (B:2). More recently, 
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Rimier and Wilson (1994) re-examined these isolates 
using the Carter-Heddleston serotyping scheme and 
DNA fingerprinting methods. This revealed that the 
bison strain isolated from Montana in  1965 was 
serotype B:3,4, not B:2  as earlier reported. A dairy calf 
strain isolated in  1969 was also B:3,4. No distinction 
could be made between these strains by DNA 
fingerprinting. On re-examination, the 1993 isolate 
from beef calves in California was confirmed as  B:2, 
whilst the Canadian strain was B:3,4. DNA 
fingerprinting showed that the latter two strains were 
distinct from each  other as  well as from all  other strains 
in  the culture collection. Recently, Rimier (1997) has 
examined a global collection of over 200 isolates 
associated with classical  HS and related syndromes, and 
identified a large number of DNA fingerprint profiles 
(see Section 5.10.3). 
HS  is  not known to be present in the United Kingdom. 
However, in  1982 a strain was isolated from deer with 
a septicaemic disease and was found to be serotype 
B:3,4 (Jones and  Hussaini 1982; Myint et al.  1987; 
Rimier et al.  1987). Other serotypes associated with 
sporadic septicaemic pasteurellosis resembling HS  in 
feral ruminants include serotype B:1  isolated from 
antelope in the United States, and  B:4 from bison in 
Canada. Serotype B:3,4 has also been associated with 
septicaemic disease in elk in  the United States (Rimier 
1993). Genetic fingerprinting has established that the 
North American B:2 strains possess a DNA profile 
different from that of the Asian  B:2  strains.  From an 
epidemiological standpoint, DNA fingerprinting serves 
as an  additional tool (to serotyping) in  strain 
identification. 
4.4  Host Susceptibility 
The conventional host species are cattle and  buffaloes. 
There is general agreement that buffaloes are more 
susceptible than cattle.  In Malaysia, it was reported 
that 73% of all  deaths due to HS during the period 
1970-79 and 90% during the period 1980-89 were 
among buffaloes, despite the fact that the buffalo 
population in  Malaysia is  half that of cattle (FAa 1979, 
1991). The higher losses  in  buffaloes have also been 
quantified and clearly shown in  epidemiological studies 
in  Sri  Lanka (De Alwis and Vipulasiri 1980; De Alwis 
1981). An island-wide study covering endemic as well as  nonendemic areas revealed that mortality in 
buffaloes was three times higher than in cattle. This 
difference was more marked in  the sporadic outbreaks 
that occurred in  nonendemic areas and  less evident in 
endemic areas, where outbreaks occurred regularly.  In 
the latter case,  there were other factors that partly 
masked the host susceptibility. In contrast to the 
general results, one of the Sri  Lankan investigations 
indicated that the percentage of cattle and buffalo 
herds that experienced outbreaks during a given period 
was not significantly different. Once the disease was 
introduced to a herd, however, mortality within a herd 
was higher in  buffaloes. In  India, Ramarao et al.  (1991) 
recorded a higher incidence of HS  in districts where the 
buffalo population was higher. Bali cattle (B05 banteng) 
in  Indonesia are believed to be highly susceptible to HS 
(Bain  1979a; Bain  et al.  1982). 
There is evidence of type B infection in  pigs in Malaysia 
and India (FAO 1959, 1979; Murthy and  Kaushik 
1965; Pillai et al.  1986). Verma and Sexena (1987) and 
Verma (1988) established clearly that septicaemic 
pasteurellosis in  pigs in India was caused  by serotype 
B:2.  For many years, strains identified as type 6:B have 
been  reported from pigs in  Sri  Lanka. These isolates 
have been used to successfully reproduce a typical HS 
syndrome in cattle (M.CL. De Alwis, unpublished 
data). Gamage et al.  (1995) reported an  outbreak of 
acute septicaemic pasteurellosis in  pigs in a farm in  Sri 
Lanka, caused  by serotype B:2. Thus, although the pig 
is not a conventional host, it displays susceptibility. 
Although type B strains have also been associated with 
poultry (Gupta 1973; Gupta and Kumar 1973; FAO 
1979), it is generally accepted that serotype B:2  is 
nonpathogenic to poultry. 
Sporadic cases of P.  multocida infection have been 
recorded in goats (which are a common small ruminant 
in the Asian  region) in  India and Malaysia (FAO 1959, 
1979, 1991). The isolates have been  identified as 
Roberts type I,  Carter type B, or serotype 6:B, according 
to the available serotyping methods in use at the time. 
Investigations on the susceptibility of goats carried out 
in  Sri Lanka, however, provided ample evidence of the 
low susceptibility of goats to HS.  No natural 
transmission occurred when goats were housed in close 
contact with clinically affected buffaloes and the goats 
did not even elicit an antibody response.  Goats were 
also subjected to intranasal as well as subcutaneous 
inoculation, with doses in the range of 
1010 to 1012 colony forming units (CFU).  Only 10% of 
the goats died. Others showed merely a transient rise in 
temperature and swelling at the site of inoculation 
(Wijewardana et al.  1986b). 
Wijewardana et al.  (1986c) did not identify any carriers 
among 254 goats in  an  abattoir study.  For 494 cattle 
slaughtered in the same abattoir during the same 
period, 3.4% were found to be carriers.  Loganathan 
and Chandrasekaran (1995) produced a pneumonic 
syndrome in transport-stressed, six-month-old goats 
experimentally infected with the Asian serotype by the 
intranasal route and simultaneously given a three-day 
course of dexamethazone. All of four animals died in 
five days. A B:3,4 deer isolate was also tested for its 
pathogenicity to goats. Four goats were inoculated 
subcutaneously, and two intranasally, with doses 
ranging from 109 to 1011  CFU,  but showed no signs of 
disease (M.CL. De Alwis, unpublished data). Thus, 
there is no evidence to incriminate the goat as a 
susceptible host or a reservoir of infection for the Asian 
serotype B:2 or serotype B:3,4. 
It was also reported that Rahmani sheep in  Egypt 
resisted  all  attempts at experimental infection by the 
subcutaneous or intranasal routes, using an  organism 
that caused classical  HS  in calves by similar methods 
(Barakat et al.  1976). 
There are numerous other species in which septicaemic 
sporadic disease caused  by HS serotypes is  recorded. 
Pavri and Apte (1967) have reported the disease in 
horses and donkeys in  India. Gevedze (1986) reported 
an  acute septicaemic pasteurellosis among horses in 
Belorussia,  believed to have been acquired from cattle. 
There is evidence of the disease in the African buffalo 
Synceru5 nanU5 (Kasali 1972). Feral  buffaloes in  Sri 
Lanka are known to possess very high antibody levels 
that are normally associated with arrested infections and 
often present in survivors from outbreaks (M.CL De 
Alwis, unpublished data). This supports the suspicion 
that the disease is present in feral buffaloes in Asia. 
HS has been  reported among camels in Sudan (Bain et 
al.  1982) but Awad et al.  (1976) found that camels 
resisted  experimental infection with doses lethal to 
buffaloes. HS has been well documented in wild 
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among cattle and  buffaloes in the locality (De Alwis and 
Thambithurai 1965; De Alwis 1982a; Wickremasuriya 
and Kendaragama 1982). There are indications that 
septicaemic disease associated with type B occurs 
among yak in China and  Nepal, although these are 
unconfirmed. In the United States, septicaemic disease 
caused  by serotype B:1  has been  recorded in antelope 
and that caused  by B:3,4 in elk; Canada has recorded 
disease caused  by B:4 in  bison  (Rimier 1993). 
4.5  Morbidity, Mortality 
and Case  Fatality 
4.5.1  Rates of morbidity, 
mortality and case fatality 
When HS  is first introduced to virgin areas, or when it 
occurs as sporadic outbreaks in nonendemic areas, 
morbidity is  high. These once-typical, explosive 
outbreaks no longer occur in  most countries where the 
disease has become endemic. When clinical disease  is 
established, however, mortality invariably occurs and 
case fatality is  nearly 100%. True recovery from clinical 
disease occurs only if the animal is treated in the very 
early stages (see Section 3.8). Conditions prevailing in 
the field often prevent such  treatment. 
Reports of high recovery rates do exist, however. An 
analysis of records in  India from 1949 to 1987 shows a 
recovery rate varying between 10% and 50%. Nepal 
records  recovery rates of 60% to 90% and the 
Philippines over 90% (FAO 1979). These apparently 
high recovery rates  have not been  based  on  scientific 
study and  may be due to routine local reporting 
systems in which the number said to be affected may 
be the total number exposed (hence at risk)  rather than 
the number actually with the disease. 
In  Pakistan, observations from nine districts in  Punjab 
showed an  11 % morbidity with 9% mortality and 
hence a 78% case fatality for buffaloes.  In the same 
study, the corresponding figures for cattle were 4 %, 
2.5% and 62% respectively (Sheikh, et al.  1996). A 
study of an  outbreak in Zimbabwe in a beef cattle farm 
revealed an  unusually high recovery rate with 77% 
morbidity and only 5% mortality (Lane et al.  1992), 
but this study had  some  noteworthy features. Though 
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the clinical picture and  pathology resembled  HS the 
isolate had  not been serotyped. It was presumed to be 
type E,  based on  the location. Further, the outbreak 
occurred in  an  organised farm, and  intensive antibiotic 
therapy was given together with a bacterin. All of these 
factors could influence the normal course and  pattern 
of clinical disease and  mortality. 
4.5.2  Factors influencing 
morbidity and mortality 
A variety of factors and their interactions influence 
morbidity and  mortality. These have been well 
documented in two epidemiological studies in  Sri  Lanka 
(De Alwis and Vipulasiri 1980; De Alwis 1981). 
Host species and age 
The susceptibility of different host species was 
discussed  in Section 4.4. Morbidity is  higher in  buffalo 
herds or mixed herds with a high buffalo population. 
In  many Asian  countries young animals have been 
observed to be more susceptible than adults but 
quantitative estimates are scarce.  In one study covering 
HS endemic areas  in  Sri  Lanka, 77% of HS cattle 
deaths and 65% of HS buffalo deaths were of animals 
under two years old. Another study of two outbreaks 
in  neighbouring farms showed that the most vulnerable 
age group was six months to two years (De Alwis et al. 
1976). The age distribution of deaths for one farm in 
this study is shown in  Figure 4.1 . The disease rarely 
occurred in calves  under six  months of age. As these 
studies were carried out in endemic areas, a large 
percentage of the adult population would have had 
high antibody levels.  It is therefore likely that very 
young calves (under six months) possessed  sufficient 
levels of maternal immunity. 
On a second farm, located in close proximity to the 
first, vaccination was started immediately. The disease 
broke out in this farm two days after vaccination, but 
the mortality was 2.3% of the susceptible population, 
compared to 8.2% in  the first farm, and the peak 
mortality was in the 6-12-months age group. There 
has only been one noteworthy case of HS in a very 
young calf in  Sri  Lanka (two months of age). This was a 
calf born to a cow imported from a country free from 
HS and  hence without maternal antibodies (M.C.L. De 
Alwis, unpublished data). A study of buffaloes in  Pakistan showed that 
maternal antibodies appeared soon after colostrum 
feeding, remained constant up to day 28 and then 
diminished, reaching undetectable levels by day 56 
(Sheikh et al.  1994). 
>4 years  0% 
2-4 years  0.7% 
18-24 months 
12-18 months  41.0% 
6-12 months 
0-6 months  0.7% 
0%  10%  20%  30%  40%  50% 
Deaths 
Figure 4.1. Age distribution of  deaths in an outbreak of 
haemorrhagic septicaemia. 
Immunological factors 
Once clinical disease is established in a herd, morbidity 
depends upon the herd immunity. The immune status 
of a herd  is  influenced by either the extent of naturally 
acquired immunity or the efficiency of vaccination. In 
the former case,  it has been established that the 
percentage of animals that have acquired natural 
immunity depends on the frequency of outbreaks of 
disease in the locality. 
Endemic and nonendemic areas 
Morbidity in endemic and  nonendemic areas  is  related 
to herd immunity status.  De Alwis and Sumanadasa 
(1982) showed that the percentage of animals with 
naturally acquired immunity is highest in endemic areas 
and  is totally absent in  nonendemic areas. That such 
naturally acquired immunity is the direct result of 
exposure to disease was well established by De Alwis 
(1982b) and  De Alwis et al.  (1986), who found a sharp 
rise  in antibody titres among surviving animals 
following outbreaks. 
De Alwis (1981) also found that when occasional 
sporadic outbreaks occurred in  nonendemic areas, 
morbidity was high and was scattered evenly in all age 
groups.  In contrast, when regular,  seasonal outbreaks 
occurred in endemic areas,  morbidity was low, and was 
restricted to young animals, generally in the 6-12-
month group. In such situations, no explosive 
outbreaks occurred but the disease kept smouldering 
among older calves and young adult animals. This 
susceptible group consisted of those calves born after 
the previous outbreak (hence unexposed) or,  in the 
case of vaccinated herds, those born after the last 
annual vaccination program. 
Husbandry methods 
Generally,  HS  is either nonexistent or rare  in  small, 
well-managed, stall-fed herds, in  contrast to larger, 
nomadic, free-roaming herds. De Alwis and Vipulasiri 
(1980) observed that in endemic areas  in  Sri  Lanka the 
incidence of HS was four to five times higher in  herds 
with over 50 animals than it was in  herds of under 10 
animals.  In this study,  herd size was directly related to 
husbandry practices:  herds of 50 or more animals 
invariably led  a nomadic existence, whereas herds of 
under 10 animals were generally better managed and 
always kept in confinement. 
4.6  Naturally 
Acquired Immunity 
A small proportion of animals possess natural immunity 
to HS.  This phenomenon was first described by Baldrey 
(1907) and  Holmes (1910) but was  'rediscovered' by 
Bain  (1954) among buffaloes in Thailand. Bain 
concluded that about 10% of all  buffaloes in Asia are 
naturally immune. De Alwis and  Sumanadasa (1982) 
found that the percentage of animals with naturally 
acquired immunity varied from herd to herd, and 
within a herd from time to time, resulting from natural 
exposure of cattle and  buffaloes to infection. 
De Alwis (1982b) and  De Alwis et al.  (1986) confirmed 
the cause of naturally acquired immunity by monitoring 
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HS.  The latter investigation covered three mixed herds 
of cattle and  buffaloes where vaccination had  never 
been carried out and where outbreaks of HS had 
occurred a few days before the investigation. During 
the period immediately after the outbreak, 80%, 
88.8% and 92% of the surviving animals in the 
respective herds developed antibody titres. The former 
study involved monitoring antibody status in a group 
of 26 unvaccinated buffalo calves where an  outbreak 
occurred. There was a steep rise  in antibody levels from 
two to four weeks after the outbreak. 
De Alwis and Sumanadasa (1982) investigated the 
immune status of a wider range of animals, in 
unvaccinated herds. Their sample consisted of 504 
animals in  endemic areas, 209 from moderate incidence 
areas where sporadic outbreaks occurred, and 212 
from low incidence areas,  where the disease  is an 
exceptional occurrence. Around 36% of animals in 
endemic areas had naturally acquired antibodies, 
compared with 7.2% and 0.47 %, respectively, for the 
other two categories. 
There are,  however, a few instances on  record where 
antibodies against the specific serotype have been 
detected in situations where the disease does not exist. 
In a joint project at Michigan State University, United 
States in  1977-78, M.C.L De Alwis and  G.R. Carter 
(unpublished data) found mouse protective antibodies 
among cattle with no history of exposure to HS. Similar 
observations have been made in a broader study in the 
United States (Sawada et al.  1985), Australia (Bain 
1954) and  Chad (Bain et al.  1982). In  these instances, 
immunity may have been  induced by related serotypes 
of P.  multocida, sharing common antigens. 
Once the main cause of naturally acquired immunity was 
recognised  as sublethal exposure to disease, it became 
possible to understand the different morbidity and 
mortality patterns in endemic and  nonendemic areas. 
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4.7  Carrier Status 
4.7.1  Presence of pasteurellae in 
carrier animals 
Nasopharynx 
The presence of the HS organism in  the nasopharynx of 
healthy cattle and  buffaloes is well documented (Singh 
1948; Mohan et al.  1968). Originally, it was believed 
that such animals were present at low levels in a herd 
(about 1-2  %). Wijewantha and  Karunaratne (1968) 
found that 15 % of animals brought to an abattoir were 
carriers. In a more recent study, Sheikh et al.  (1994) 
examined 500 buffaloes in  Pakistan for carrier status 
and found a 4.6% carrier rate. 
Further investigations showed that the presence of 
nasopharyngeal carrier animals was related to recent 
outbreaks of the disease. Gupta (1962) observed, 
significantly, that during an  outbreak 7.5% of clinically 
normal animals were nasopharyngeal carriers, and that 
none could  be detected 40 days later. Mustafa et al. 
(1978) found 44  % of healthy animals in a herd  of 
cattle with a current outbreak to be nasopharyngeal 
carriers.  In three other herds, unassociated with the 
disease at the time, the carrier rates were 3.8%,0% 
and  5.5% respectively.  Hiramune and  De Alwis (1982) 
found 22.7% of animals to be nasopharyngeal carriers 
in four herds where an  outbreak of HS had occurred 
one week earlier.  In  herds where the interval between 
the outbreak and examination was longer, there was a 
progressive drop in the percentage of nasopharyngeal 
carrier animals detected, reaching 1.9% in  herds 
examined six weeks after an  outbreak. 
These findings indicated that the percentage of 
nasopharyngeal carriers was related to recent exposure 
to disease. All of these researchers identified carriers by 
swabbing the nasopharynx through the external nares 
on one occasion only. Wijewantha and  Karunaratne 
(1968), on the other hand, swabbed the nasopharynx 
directly, after slaughter, and this procedure probably 
accounted for the higher detection rate of 15%. Singh 
(1948) found that his detection rate doubled with 
direct swabbing postmortem compared with swabbing 
the external nares in  the live animal. Other sites 
In another abattoir study, Wijewardana et al.  (1986c) 
also found that pasteurellae were not confined to the 
nasopharynx; these researchers were also able to make 
isolations from the associated lymph nodes of 
slaughtered animals. Saharee et al.  (1993) made similar 
observations among cattle in Malaysia. In this study, 
pharyngeal swabbing pre- and post-slaughter gave an 
isolation rate of only 0.3 %. When retropharyngeal 
lymph nodes were also cultured, a 13% isolation rate 
of pasteurellae was recorded, but only 3 % were type B. 
A three-year survey in  Indonesia used a combination of 
nasopharyngeal swab and  lymph node culture. Of over 
1500 animals sampled, 2.49% were found to be 
carriers of Pasteurella spp.  (Dartini and  Ekaputra 1996) 
but most of the isolates were type A. 
De Alwis et al.  (1986) monitored both the 
nasopharyngeal carrier status and the antibody status 
in three herds for a few months, starting soon after 
outbreaks of HS.  Upon repeated swabbing, they found 
that different animals displayed the carrier status on 
different days of swabbing, and the percentage of 
animals that were nasopharyngeal positive on at least 
one occasion ranged from 12 % to 40%. The methods 
used  in  different studies and the different results 
obtained are summarised in Table 4.1. De Alwis et al. 
(1986) observed that some animals displayed a positive 
status, then negative, and subsequently positive again, 
indicating an  intermittent appearance of the organism 
in the nasopharynx. The question therefore arose as to 
where the organism remained lodged during the 
interim period of disappearance from the nasopharynx. 
4.7.2  Experimental studies on 
carrier status and naturally 
acquired immunity 
In order to understand more clearly the status of carrier 
animals, their relationship to naturally acquired 
immunity and their significance in the epidemiology of 
the disease,  De Alwis et al.  (1990) produced carrier 
animals by controlled experimental infection or natural 
exposure.  Using 57 young buffaloes, these researchers 
were able to produce a carrier status in 32  animals. 
These carrier animals were divided into several groups 
for different investigations. One group was maintained 
for a period of 360 days; carrier status was determined 
by positive nasopharyngeal isolation from swabs 
inserted through the external nares, and antibody 
status measured by an  indirect haemagglutination 
test.  In  most animals, pasteurellae appeared in the 
nasopharynx for a short period and then disappeared. 
In others, it reappeared  intermittently after long 
periods of absence. The longest period after which 
such  reappearance occurred was 215 days after initial 
exposure. All of these carrier animals also showed 
rising antibody titres, reaching a peak lasting for 
around 150-180 days, and then declining. 
Further groups of immune carrier animals were 
slaughtered at varying intervals and attempts were 
made to isolate the organism from 14 different sites. 
The most consistent site from which isolations were 
made was the tonsil (20 out of 27 animals). The 
longest period after initial exposure when isolations 
were made from the tonsils was 229 days.  In all these 
experiments, animals were exposed to a streptomycin-
resistant organism; the resistance factor served  as a 
marker to ensure that the organism recovered was 
the one used  in the initial exposure. 
Having established under experimental conditions that 
the tonsil was the site of localisation of pasteurellae in 
carrier animals, Wijewardana et al.  (1993) examined 103 
pairs of tonsils from cattle in an abattoir in  an  endemic 
area.  Forty-nine isolations of P.  multocida were made. 
The majority (23) were capsular type A;  10 were type B. 
The other 16 could not be typed by the capsular typing 
procedure. All but one from this third group could be 
typed by Heddleston's somatic typing, but none were of 
somatic type 2 (which is associated with HS) or type 5 
(which cross-reacts with type 2). This work, in general, 
established that, under natural conditions as well as for 
experimental animals, the tonsil was a site of localisation 
of all types of pasteurellae. 
4.7.3  Latent and active carriers 
The field observations and experimental findings 
outlined above led to the conclusion that two types of 
carriers exist - latent and active.  It appears that in 
endemic areas,  where frequent outbreaks occur, most 
adult animals harbour pasteurellae in  their tonsils.  From 
time to time, active multiplication takes place in the 
tonsils and the organism spills over into the 
nasopharynx and  is  shed  in  nasal secretions. These 
latent carriers show high levels of antibody by the IHA 
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12 %, 20% and 40% in three 
herds. All isolates were type B test - levels not attainable by vaccination. Hence high 
IHA titres may be regarded as  an  indication of a latent 
carrier state, and such  an  animal may be considered a 
potential source of infection. 
It is  not currently known what provokes a latent carrier 
to become active. It may be postulated that a host of ill-
defined factors collectively referred to as  'stress' may be 
responsible. In countries where the disease occurs, 
factors such  as  excessive rains and poor weather 
conditions, overwork in the rice fields and poor nutrition 
due to lack of adequate forage in grazing lands etc. are 
generally considered as  'stress' factors and are 
associated with outbreaks of HS.  Experimentally 
produced carriers subjected to long spells of similar 
work, however, failed to shed  pasteurellae (T.G. 
Wijewardana, M.C.L. De Alwis and P . Abeynayake, 
Veterinary Research  Institute and Faculty of Veterinary 
Medicine, Peradeniya, Sri  Lanka, unpublished data 
1995). When De Alwis et al.  (1995) subjected latent 
carriers to treatment with corticosteroid preparations 
(dexamethazone and methylprednisolone acetate) with 
and without neostigmin (which stimulates secretions, 
thereby facilitating shedding), no shedding was 
observed. Thus, the factors that cause the conversion of 
latent carriers to an  active shedder state are still unclear. 
4.7.4  Localisation of the 
pasteurellae in the tonsils 
De Alwis et al.  (1990) found that treatment of latent 
carrier animals with antibiotic preparations to which the 
organism was sensitive in vitro failed to eliminate the 
carrier state. Latent carriers given a three-day course of 
oxytetracycline, chloramphenicol or sulfadimidine, and 
slaughtered one week later, yielded positive tonsillar 
isolations that were sensitive in vitro to the same 
antibiotics. Evidently, the antibiotic did not reach the 
organism in the tonsils. In order to determine the sites 
where pasteurellae were lodged within the tonsils, 
Horadagoda and Belak (1990) examined sections of 
tonsils from latent carriers using immunochemical 
methods. Using a peroxidase-anti  peroxidase technique, 
it was revealed that the bacteria were not lodged in the 
tonsillar tissue itself but in the crypts of the tonsils, thus 
accounting for the persistence despite antibiotic 
therapy (Figure 4.2). 
Figure 4.2.  Sections of the tonsils.  (a)  Immunoreactivity of 
the tonsillar crypt in an experimentally produced HS carrier 
animal (immunoperoxidase/haematoxylin stain x10). 
(b) Diffuse immunostaining of tonsillar crypt contents which 
consist of desquamated necrotic epithelial cells and debris 
Ommunoperoxidase/haematoxylin stain x25). 
(c) Intracytoplasmic immunostaining of macrophages (arrows) 
within the tonsillar crypt (immunoperoxidase/haemotoxylin 
stain x50). 
41 4.8  Presumptive 
Epidemiological Cycle 
With the available epidemiological information, it is 
now possible to work out a probable sequence of 
events in the epidemiology of HS.  Figure 4.3 outlines 
this presumptive epidemiological cycle. 
In  an endemic area,  after one outbreak of disease, a 
large number of surviving animals become latent 
carriers. They intermittently shed  the organisms, the 
frequency diminishing with time. Since the herd 
immunity is  also high, there are  no fresh clinical cases. 
The first clinical case occurs when a shedder comes 
into contact with a susceptible animal, which will 
invariably be one born after the previous outbreak, or 
one introduced into the herd from elsewhere. 
Movement of animals has frequently been associated 
with epidemics of HS, for example the 1993-94 
outbreak in  the Philippines (Molina et al.  1994). 
Movement of animals associated with the rice 
cultivation cycle  is a common occurrence in  Asia.  In  Sri 
Lanka an  instance is on record where, under a river 
valley development program, a new human settlement 
was established in  the endemic dry zone.  Due to the 
limited number of cattle and buffaloes in this area and 
the improved husbandry practices, nearly 100% 
vaccination coverage was achieved. During the 
cultivation season, due to a shortage of draught power 
in the area,  however, additional animals had to be 
brought in from elsewhere. An outbreak of HS 
occurred, but only the animals brought in  from outside 
were affected. 
Movement of animals can  precipitate disease in two 
ways.  Firstly, the animals being moved may be carriers 
. and able to infect susceptible stock. Secondly, the 
animals being moved may be susceptibles, which may 
be infected from native immune carriers.  In  either case, 
explosive outbreaks could result. Thus, the chances of 
such  contact will increase with time, as the susceptible 
population builds up. 
Once the first clinical case occurs,  more bacteria are 
shed and disseminated. Their survival in the 
environment and transmission to other animals depend 
on  such factors as the climatic conditions, closeness of 
contact and  hygiene. The magnitude of the outbreak 
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Figure 4.3. Presumptive epidemiological cycle for 
haemorrhagic septicaemia. 
that follows depends on the proportion of immune to 
nonimmune animals in the herd. Thus,  in  situations 
where occasional sporadic outbreaks occur, the build 
up of susceptible nonimmune animals can  result in a 
major outbreak. Where regular, seasonal outbreaks 
occur,  more animals are likely to be immune (through 
frequent exposure) and the outbreaks will be of a 
minor nature. The old  belief that carrier animals break 
down into clinical cases, thereby initiating an  outbreak, 
may not hold ground, since the available evidence 
shows that carrier animals are also immune  . 
Considering the large number of organisms that are 
required to give clinical disease under experimental 
conditions, it is  not clear how a carrier could transmit 
such large numbers to a susceptible animal. Some of the 
questions that still exist in the epidemiology of HS are: 
•  What are the factors that cause activation of latent 
carriers? and 
•  What causes a susceptible animal to develop clinical 
disease with a presumably low dose of bacteria in 
natural transmission from a carrier? Diagnosis 
Overview 
Clinical diagnosis 
A clinical diagnosis of haemorrhagic septicaemia (HS) 
is based on a combination of clinical signs, gross 
pathological lesions and a consideration of relevant 
epidemiological parameters and other similar diseases 
prevalent in the locality. 
Routine laboratory diagnosis 
Routine laboratory diagnosis is by culture and serology. 
Material for laboratory diagnosis usually consists of 
blood or a long bone for bone marrow culture. Pure 
cultures are obtained from contaminated material  by 
mouse inoculation and culture of the mouse blood. A 
positive diagnosis is available within 24-48 hours. 
Other diagnostic tests 
Additional serological, biochemical and molecular 
techniques are available as research and 
investigational tools. 
If reporting is  delayed and no material is available for 
culture and isolation at the time of investigation, 
antibody levels  in surviving animals can be assayed 
as an indicator of HS infection. 
5.1  Provisional Diagnosis 
When a suspected outbreak of haemorrhagic 
septicaemia (HS)  is  reported, a provisional diagnosis 
can  be made based  on  clinical signs and, if carcases 
are available, on  the gross pathological lesions seen on 
postmortem examination. An investigation of relevant 
epidemiological parameters is also helpful. It is also 
important to consider other diseases prevalent in  the 
locality that could account for the clinical signs 
observed, lesions and the number and  pattern of 
deaths observed. 
A provisional diagnosis is important since preventive 
measures to control the spread of the disease are 
required immediately, without waiting for laboratory 
confirmation. At the earliest opportunity, however, 
appropriate material should be collected, suitably packed 
and dispatched to the nearest laboratory where facilities 
are available for diagnostic tests to be performed. A 
combination of clinical signs, gross pathological lesions 
and epidemiological features, coupled with the isolation 
of the organism and  identification of serotype, will help 
in  arriving at a definitive diagnosis. 
5.2  Clinical Diagnosis 
As outlined in  Chapter 3, the disease presents a variety 
of clinical signs,  none of which, when taken 
individually, is specific for HS.  Thus, the clinical picture 
should be considered as a whole, together with the 
pathological lesions and the epidemiological findings. 
As  HS  occurs mostly in  animals reared  under poor 
husbandry conditions, no clinical signs whatever may 
be observed in the first cases of an  outbreak. Thus, the 
first reports may be of animals found dead suddenly, 
with no observed illness. Thereafter, upon closer 
observation, clinical signs will become evident. More 
advanced cases  will show submandibular oedema 
spreading to surrounding areas,  nasal discharge, 
43 salivation and laboured breathing. Those in  the early 
stages may be off their food and, if monitored twice 
daily, show a marked increase in rectal temperature. 
The most obvious postmortem lesions are 
subcutaneous oedema and  petechial haemorrhages, 
particularly on the base of the ventricle. The next most 
obvious lesions are those in the lungs, initially 
congestion, progressively moving towards 
consolidation and thickening of the interlobular septa 
giving rise to lobulation (see Section 3.4). 
The clinical signs and pathological lesions must be 
combined with available epidemiological data. The 
classical epidemics of HS found in earlier records do not 
occur any longer, particularly in endemic countries, 
unless the disease is freshly introduced into virgin areas. 
Thus, the observed morbidity and  mortality pattern has 
to be interpreted against the background of information, 
such as the species affected, vulnerable age group, 
endemicity of the location, season  and vaccination 
history. The presence of any triggering circumstances, 
such  as sudden or seasonal climate changes or 
movement of animals, also provides useful clues. 
5.3  Differential Diagnosis 
HS  has to be differentiated from other diseases that 
present a similar syndrome and that are prevalent in 
the location where the disease has been  reported. If 
the condition is  an  acute one characterised by sudden 
death, other diseases likely to cause sudden deaths, 
such  as anthrax, rinderpest and  black quarter, should 
be taken into account. Equally important are the 
noninfectious causes of sudden death such  as 
lightning, snakebites and acute poisoning. The more 
protracted syndrome dominated by respiratory signs 
has to be differentiated from other forms of 
pasteurellosis caused  by serotypes other than groups B 
and  E,  or by Pasteurella haemo/ytica. It must be borne 
in  mind that the chronic or subacute pneumonic form 
of HS always displays a terminal septicaemia, which 
may not be a consistent feature with other serotypes. 
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5.4  Samples 
5.4.1  Collection of samples 
The ideal material for isolation of the specific pathogen 
is the tissues where it is  most likely to be present in 
largest numbers and which are free,  or contain minimal 
numbers, of other extraneous organisms such as 
contaminants and postmortem invaders. Tissues of a 
fresh carcase, preferably blood, fulfil this requirement. 
If facilities are available at the location of the carcase,  a 
postmortem examination should be immediately 
carried out and blood drawn directly from the heart. 
The gross pathological lesions can  be observed at this 
time. Alternatively, blood may be obtained by puncture 
of the jugular vein. 
In  regions where the disease occurs frequently, 
reporting systems may be suboptimal. Under tropical 
conditions, decomposition of the carcase  may take 
place rapidly within a few hours and the blood may 
contain an  abundance of postmortem invaders. It is, 
however, possible to isolate pasteurellae from blood 
collected from carcases even 24 hours after death by 
biological screening using mice.  In  such  situations, it is 
advantageous to collect and dispatch a long bone, 
which can  be used for culture and biological 
examination of bone marrow. This can  be done even 
from animals exhumed a few days after burial. 
Material collected from clinically affected animals 
before death may not give consistent results.  Nasal 
secretions may yield virulent pasteurellae upon culture. 
Blood will give positive cultures only in  the terminal 
stage immediately before death. Much of the bacterial 
multiplication takes place in  the carcase after death. 
It is  always better to dispatch to a laboratory material 
from more than one animal in  an  outbreak. Care  must 
be taken to avoid collecting material from animals 
treated with antibiotics. 
5.4.2  Dispatch of diagnostic samples 
The fragile nature of pasteurellae and their poor survival 
outside the animal body has already been discussed in 
Chapter 3.  Dhanda (1959a) reported that common 
contaminants such  as Bacillus subtilis and Pseudomonas 
a  eruginosa, and also B.  anthracis, adversely affected the viability of P.  multocida. It has also been  reported that 
when kept on  cotton wool swabs and contaminated 
experimentally with small quantities of B.  suhtitis and 
staphylococci, pure cultures of the HS serotypes of 
P.  multocida, or blood of infected animals, were rapidly 
overgrown by the contaminants at room temperature. 
When stored at refrigeration temperature, or when the 
swab was kept immersed in a transport medium, 
overgrowth by contaminants was arrested (De Alwis 
1972, 1973). It was further reported that blood swabs 
collected from a carcase within six hours of death due to 
HS could be stored for four days at room temperature 
and up to one week in the refrigerator with consistent 
viable counts (within 0.5 log units). In swabs collected 
24-30 hours after death, rapid overgrowth by 
contaminants occurred and no pasteurellae could be 
isolated on the third day.  These observations have to be 
taken into account in determining methods for dispatch 
and storage of material during transport to a laboratory. 
Blood should be  packed  in  ice or placed in a suitable 
transport medium. If this is  not possible, the swab 
should  be dispatched at room temperature to the 
laboratory as  quickly as  possible.  Long bones should be 
cleaned of all  muscle tissue,  and sent to the laboratory 
with minimum delay. 
Transport media 
Several transport media are now commercially 
available. The one used  by De Alwis (1973) was a 
simple non nutrient inert medium that contained 
disodium phosphate, thioglycollic acid and  agar (0.4 %) 
to give a semisolid consistency, and methylene blue as 
an  indicator. Warner (1996) developed a transport 
enrichment medium with antibiotic and antifungal 
additives that promoted the survival of the pasteurellae 
and suppressed contaminants. Details of transport 
media are given in Appendix 1. 
5.5  Laboratory Diagnosis 
Laboratories in countries where HS is endemic receive a 
variety of specimen types and quality for diagnosis. 
Appropriate methods may therefore be needed to deal 
with these specimens. The serotypes of P.  multocida 
that cause  HS are not difficult to isolate, even  in a 
laboratory with modest facilities. A wide range of 
laboratory diagnostic tests has been developed over 
the years.  These include: 
•  culture and  biological tests for isolation of the 
causative organism; 
•  biochemical and serological tests for identification 
of the organism and serotype; 
•  non serological tests for presumptive identification 
of serotype; and 
•  molecular methods for strain differentiation 
within serotypes. 
The conventional method of laboratory diagnosis is 
therefore based  on  isolation of the organism from 
animal tissues and identification by biochemical and 
serological methods. The  nonserological tests and 
molecular techniques are  useful investigatory tools but 
are not substitutes for the conventional tests.  In 
instances where reporting is delayed and  no material is 
available for culture and isolation at the time of 
investigation, high levels of antibody or,  more 
specifically, rising antibody titres in surviving animals 
are useful indications in  arriving at a presumptive 
diagnosis (see Section 5.11). 
A routine laboratory diagnostic procedure that can  be 
adopted in  any laboratory in  the endemic countries of 
Asia and Africa having modest facilities is illustrated in 
Figure 5.1 . 
If the material is uncontaminated, colonies can  be isolated 
on a direct culture plate within 24 hours. These could be 
subjected to a rapid slide agglutination test.  Based on 
colonial appearance, direct smear examination from 
culture plate and a positive rapid slide agglutination test, 
the laboratory could issue a positive report. 
If the material is contaminated, as  is often the case, a 
pure culture can only be obtained by mouse inoculation 
and culture of mouse blood. In addition to the above 
tests, pathogenicity to mice, and a mouse blood smear 
with an  abundance of bipolar staining gram-negative 
coccobacilli, provide useful clues.  Culture of the mouse 
blood and a rapid slide agglutination test on the culture 
confirms the diagnosis. Thus, within 24-48 hours, it is 
possible to issue a positive report from a laboratory. As 
a routine, this procedure has proved to be quite 
satisfactory.  If further serotyping is considered 
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Figure 5.1. Scheme for routine laboratory diagnosis of 
haemorrhagic septicaemia. 
necessary,  both capsular and somatic typing can  be 
completed within a further three days. 
In laboratories where there is a rapid turnover of 
samples, stocks of formalinised or glutaraldehyde-fixed 
erythrocytes and  immunodiffusion media can  be held 
to facilitate and  hasten the process. 
5.6  Routine Microbiological 
Procedures 
5.6.1  Microscopic examination of 
stained blood smear 
When blood smears from the dead animal (usually 
cattle or buffalo) are stained with methylene blue or 
Leishman  stain, and  Gram stain, they show the 
presence of bipolar staining, gram-negative short 
bacilli. This test alone is  not sufficient to confirm 
diagnosis, however, as other gram-negative bacilli may 
present a similar appearance. 
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5.6.2  Isolation of pasteurellae 
Culture 
Pasteurellae grow on ordinary media such  as nutrient 
agar, or enriched media such  as tryptose agar or 
casein-sucrose-yeast agar (CSY agar), with or without 
5% sterile blood. Blood of a young calf - the natural 
host - free of antibodies is  preferred. Enrichment of 
the media and the addition of blood promotes growth. 
A small volume of sterile physiological saline is  mixed 
with the blood swab.  For bone samples, the surface of 
the bone is cleaned with alcohol sterilised by flaming 
and cut open with a sterile saw.  A small quantity of 
bone marrow is scooped out. One drop of this material 
(blood or bone marrow) is  placed  on the edge of a 
culture plate and spread with a flame-sterilised 
platinum loop, cooled by placing on  the medium. 
Streak cultures are made at right angles to each other, 
sterilising and cooling the loop at each stage. This 
procedure helps to isolate individual colonies on  the 
final streaks in cases when the inoculum is  heavily 
laden with organisms, or on  the initial spread  area 
when it is only weakly laden with organisms. 
Freshly isolated colonies on tryptose agar or CSY agar 
enriched with blood are approximately 2 mm in 
diameter after 24 hours at 37"C. Blood agar cultures 
yield colonies of approximately 1 mm and colonies on 
plain  unenriched media devoid of blood may be 
smaller. Colonies on enriched media are smooth, 
nonmucoid, greyish, glistening and translucent. 
Inoculation onto triple sugar iron (TSI) agar helps to 
differentiate pasteurellae from the common gram-
negative enteric bacteria. Pasteurella gives a slow acid 
reaction with no gas, and no detectable production of 
hydrogen sulfide in this medium. Cultures are oxidase 
and catalase positive, produce indole and  reduce 
nitrates, but fail to produce urease,  utilise citrate, grow 
on McConkey agar medium or liquify gelatin. These 
biochemical tests are of diagnostic value. 
Isolation by direct culture alone is only successful  if 
there is little or no contamination and when the 
interval from collection to culture is short, or the 
material has been  stored in transport medium or 
refrigerated. Otherwise, the plate may be overgrown 
with contaminants that will mask the pasteurellae. Biological screening (mouse inoculation) 
Since most swabs reaching diagnostic laboratories have 
a high proportion of extraneous bacteria, the best 
method to isolate the organism is  by subcutaneous 
inoculation of a mouse with about 0.1-0.2 mL of a 
saline suspension of the blood or bone marrow sample 
prepared as described above for culture. If P multocida 
types that cause  HS are  present, the mouse will die 
within 24 hours. Smears of the heart blood of the 
infected mouse will show an  abundance of bipolar 
staining coccobacilli when stained with Gram, 
Leishman or methylene blue stains, the bipolar nature 
being more evident with the latter two stains (see 
Figure 5.2a,b). The blood of the mouse can  also be 
cultured, and will yield pure cultures. 
Type B pasteurellae that cause  HS are highly virulent 
for mice, with a 50% lethal dose (LD50) of 1-10 viable 
organisms. Thus, this method is extremely useful in 
situations where the material has only a few viable 
organisms, even amidst numerous contaminants. 
Hence, the value of this biological test cannot be 
underestimated. Mouse inoculation also greatly 
facilitates the isolation of pasteurellae, even from 
nasopharyngeal swabs, tonsils, lymph nodes etc.  in 
healthy carrier animals. 
Figure 5.2.  (a) Smear of  P.  multocida serotype B:2  (Gram stain 
x400). (b) Blood smear of mouse that died after inoculation 
of infected cattle blood swab washed in saline.  Note the 
abundance of bipolar staining short bacilli (Leishman stain 
x400). 
5.7  Conventional 
Serological Tests 
Serological identification of pasteurella is based on the 
detection of the capsular and somatic antigens (see 
Chapter 2). Over the years, a variety of tests have 
been developed but the results of the different 
techniques are not strictly comparable. These methods 
are described in Appendix 2. 
The following conventional tests are currently in  use in 
diagnostic laboratories: 
•  rapid slide agglutination test (capsular); 
•  indirect haemagglutination test (capsular); and 
•  agar gel precipitation test (somatic). 
5.7.1  Rapid slide agglutination test 
for capsular typing 
This is a convenient test used routinely in diagnostic 
laboratories. It is based on the technique of Namioka and 
Murata (1961 a) for simplified capsular typing using fresh 
cultures. A drop of physiological saline is placed on a 
clean slide. A single colony is picked from a fresh culture 
plate and  is mixed with the saline to form a uniform 
suspension. A loopful of antiserotype B:2 pasteurella 
hyperimmune sera prepared as described in Appendix 2 
is thoroughly mixed with this suspension, gently warming 
the slide over a flame. A rapid, flaky agglutination 
appearing within a few seconds, with complete clearing 
of the background, indicates a positive test. 
The above test should not be confused with the slide 
agglutination test for somatic typing developed by 
Namioka and Murata (1961 b,  c),  which uses a 
suspension of HCI-treated cells as antigen. 
5.7.2  Indirect haemagglutination 
test for capsular typing 
In the indirect haemagglutination (IHA) test, the surface 
antigen of the organism is  liberated by mild heat 
treatment. The cell  residue  is  removed and the 
supernatant, which contains the antigen, is used to coat 
erythrocytes. Agglutination of the coated erythrocytes 
in  serial  10-fold dilutions of hyperimmune rabbit 
antiserum is considered positive. A positive control may 
be set up using a known reference culture to prepare 
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suspension is  used  as the negative control. The serum 
used  is the same as for the rapid slide agglutination test. 
The original test described by Carter (1955) used fresh 
human '0' erythrocytes. Subsequently, Carter and 
Rappay (1962) used formalinised human '0' erythrocytes 
whilst Sawada et al.  (1982) used glutaraldehyde-fixed 
sheep erythrocytes. Wijewardana et al.  (1986a) modified 
this test using fresh sheep erythrocytes and suspensions 
of bacterial cells standardised on the basis of turbidity. An 
antigen titration was also carried out to standardise the 
amount of antigen used for coating the erythrocytes. 
5.7.3  Agar gel precipitation 
test for somatic typing 
The agar gel precipitation test (AGPT) for somatic 
typing is carried out basically according to the method 
of Heddleston et al.  (1972) using Noble agar medium 
at a concentration of 0.9% in 8.5% sodium chloride. 
For antigen preparation, a concentrated harvest of 
pasteurellae grown on a culture plate is made in 8.5% 
saline with 0.3% formalin. Antiserum for somatic 
typing is  prepared in chicken. The test antigen is  placed 
in  a central well in the agar,  with antisera against 
various somatic types in  the peripheral wells. A positive 
result is indicated by diffusion bands of 
antibody-antigen precipitate, which develop overnight. 
5.8  Other Serological Tests 
In  addition to the above conventional tests, which are 
necessary to confirm a diagnosis, several other 
serological tests have been developed. 
5.8.1  Agar gel precipitation 
test for capsular typing 
A simple immunodiffusion test has been described for 
capsular typing (Anon. 1981; Wijewardana et al. 
1982). The gel medium consists of 1 % Noble agar in 
0.2 M  phosphate buffer containing merthiolate at a 
final concentration of 1 in  10000. As for the indirect 
haemagglutination test, rabbit hyperimmune sera 
prepared against whole cells and 56°C/30 minute 
supernatant are used as sources of antibody and 
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antigen, respectively. Reference antiserum is  usually 
placed in  the centre well and test antigens in  peripheral 
wells.  Homologous antigen prepared from a reference 
strain placed in alternate peripheral wells serves as a 
positive control, and physiological saline or control 
serum from an  unimmunised rabbit placed in one 
peripheral well serves  as a negative control. Bands 
develop overnight. 
5.8.2  Counter-immunoelectrophoresis 
This test was originally developed by Carter and 
Chengappa (1981). The principle underlying the test, 
and the reagents used, are the same as for the AGPT. 
Parallel rows of wells are made on  the medium on a 
slide. The wells on the side of the cathode are loaded 
with antigen while the wells on the side of the anode 
are loaded with antiserum. Electrophoresis is for 30 
minutes, during which time precipitation bands appear. 
Results can  be obtained much more rapidly by this 
method than by AGPT. 
5.8.3  Coagglutination test 
This test was developed by Rimier (1978). It is  used to 
differentiate between type Band E strains that cause 
HS by a coagglutination test using antibody-coated 
staphylococci. The test has no distinct advantage over 
other methods and has therefore not gained popularity 
as a routine test in diagnostic laboratories. 
5.8.4  Agglutination test for 
somatic typing 
This test was developed in the early 1960s (Namioka 
and Murata 1961 b,c) and at that time proved to be a 
useful supplement to Carter's capsular typing in the 
differentiation of strains associated with various disease 
conditions. The antigen preparation was  made by 
treating cultures harvested from yeast-protease-cysteine 
agar plates (see Appendix 1) with normal HCI saline 
(0.85% saline in normal HCI) overnight. After several 
washes, the cell  residue was suspended in  phosphate 
buffered saline (PBS).  Whole cell  rabbit hyperimmune 
serum  was used for slide agglutination tests. 
When applied to P.  multocida in general, this typing 
method is very complex as  it involves a complex system 
of absorption of sera,  in order to avoid cross-reactions (see  Chapter 2). However, since there were only two 
somatic types detected in capsular type B (6 and 11), 
and only one (6) within capsular type E,  the 
identification of the HS strains is  relatively easy,  and 
unabsorbed sera can  be used. 
To facilitate interpretation, antisera prepared against 
three reference strains (Asian  [6:B], African [6:E]  and 
Australian [11 :B]  also known as strain 989]) are used  in 
agglutination tests with the three homologous antigens 
and the test antigen as  shown in Table 5.1. 
5.8.5  Enzyme-linked 
immunosorbent assay 
An enzyme-linked immunosorbent assay (ELISA)  for 
identification of P.  multocida that cause  HS was 
developed by Dawkins et al.  (1990) in  Australia (HS-
antigen ELISA;  see Appendix 3). These researchers 
examined 124 strains, consisting of 58 reference strains 
from collections in  various laboratories and 66 field 
isolates, and reported a specificity of 99% and a 
sensitivity of 86%. This technique has proved useful for 
screening a large number of cultures from a collection, 
rather than occasional diagnosis of HS from specimens 
reaching a laboratory from time to time. In  its present 
form, it has a serious limitation in  that it fails to 
differentiate between the Asian (B:2) and African (E:2) 
types. This is not surprising as the antigen used  in  this 
test was the boiled antigen similar to that used  in 
Heddleston's somatic typing, where the somatic 
antigen 2 was common to both Asian and African 
types.  From an  epidemiological standpoint and for the 
purpose of initiating control measures in  an  outbreak, 
it is  important to know the serotype. 
5.9  Nonserological tests 
Several  non-immunological tests have been developed 
for the rapid identification of strains. These include the 
acriflavine flocculation test described by Carter and 
Subronto (1973) for identification of type D strains, 
the hyaluronidase decapsulation test for type A strains 
(Carter and Rundell 1975) and the hyaluronidase 
production test for the rapid identification of type B 
strains (Carter and Chengappa 1981). 
5.9.1  Hyaluronidase production test 
The production of the enzyme hyaluronidase is a 
characteristic of many species of gram-positive 
bacteria such  as  staphylococci, streptococci and 
clostridia. Among the gram-negative bacteria, type B 
strains of P.  multocida have been found to produce 
appreciable amounts of hyaluronidase. Two methods 
have been  used to demonstrate the production of this 
enzyme. In the first method, a hyaluronic acid 
producing culture of Streptococcus equi is  streaked 
across a freshly prepared blood agar plate. 
Table 5.1.  Somatic typing of pasteurella strains using HCI-treated antigen. 
Serum 
Asian  (6:B) 
African (6:E) 
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at right angles. Several streaks can  be made across,  in a 
single plate. The plates are then incubated at 37°C for 
18 hours. Hyaluronidase production is  indicated by a 
reduction in  size of the streptococcal growth adjacent 
to the pasteurella streak.  Better results are obtained by 
using dextrose starch agar medium and a humidified 
incubator, where the production of hyaluronic acid  is 
enhanced. P multocida type A,  which produces large 
mucoid, capsulated colonies containing hyaluronic acid, 
may be  used  instead of S.  equi. 
In  the second method, test cultures are spotted onto a 
medium containing sodium hyaluronidate and  bovine 
albumin fraction V.  The test pasteurella is grown in 
brain-heart infusion broth for 18 hours at 37°(, The 
plates are then inoculated with the pasteurella broth 
culture, incubated at 37°C for 18 hours and flooded 
with acetic acid. The nondegraded substrate 
precipitates with the albumin, leaving a clear zone 
around the pasteurella growth that produced 
hyaluronidase. 
Of 74 test cultures of P.  multocida used  by Carter and 
Chengappa (1980), only 13 type B strains were found 
to be positive, whilst type A,  D and  E strains were 
negative. On subsequent investigation, it was found 
that within type B strains, the property of 
hyaluronidase production is  restricted to serogroup B:2, 
which is the classical Asian serotype. Other type B 
strains such  as  B:3,4 were negative. De Alwis et al. 
(1996) reported a type B:2  mutant that was of low 
virulence for mice, and failed to produce HS,  but was 
hyaluronidase positive. 
5.10  Molecular Techniques 
With recent advances in  molecular biology, a number 
of new techniques have been developed to analyse the 
genome (DNA) of organisms.  Some of these techniques 
have been  used  in the diagnosis of HS. These not only 
differentiate the serotypes that cause  HS but also help 
in  the differentiation of strains within serotypes. They 
are therefore of diagnostic as well as of epidemiological 
significance. These methods are described in 
Appendixes 4 and 5. 
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5.10.1  Polymerase chain  reaction 
Polymerase chain  reaction (PCR) methods amplify 
minute quantities of DNA present in samples and allow 
accurate detection of specific genetic sequences, 
including bacteria.  PCR tests have been developed for 
the diagnosis of HS and  used  by many workers 
(Thomas 1996; Natalia 1996; Brickell 1996; Townsend 
et al.  1998; see Appendix 4). 
An  appropriately designed PCR test has the distinct 
advantages of being able to be performed directly on 
clinical  material even with low numbers of bacteria and 
of giving rapid results. Natalia (1996) tested 100 
tonsillar swabs of cattle taken from abattoirs in 
Indonesia using a PCR test; the results were consistent 
with those obtained using a standard bacterial culture 
method. The specificity and sensitivity of the test were 
shown to be valuable for detecting P.  multocida type 
B:2  from field specimens. 
In  a PCR test, primer sequences are designed to enable 
identification of the pathogen concerned at any level 
of specificity (i.e. strain, serotype, species etc.),  thus 
bringing some flexibility into the test.  In  a given test, 
only the specific agent for which the test is designed 
will be detected. For example, if a test is designed to 
specifically identify serotype B:2,  any other serotype 
such  as  E:2  or B:3,4 that may be present in specimens 
in  similar circumstances will not be detected. In this 
regard, a conventional mouse inoculation test coupled 
with isolation of the agent and serotyping will allow 
the detection of any other serotype, as  well as any 
other pathogen such  as anthrax, which often occurs 
in similar situations to HS. 
Townsend et al.  (1996) identified clones using genomic 
subtractive hybridisation of closely related  P.  multocida 
isolates. These were useful in differentiating type B 
strains that cause  HS from type E and other type B 
strains that cause similar septicaemic disease.  Further 
analysis of these clones resulted in the development of 
a type-specific PCR test for the identification of HS-
causing type B serotypes of P.  multocida, namely B:2, 
8:5 or B:2,5 (Townsend et al.  1998). 
Townsend et al.  (1997a) analysed  HS-causing isolates 
of P multocida by a PCR-based fingerprinting method 
known as  repetitive extragenic palindromic (REP)  PCR. Multiple genomic DNA fragments are amplified by 
outwardly facing primers based  upon the REP 
consensus sequence, generating complex profiles 
useful in strain differentiation. The analysis of HS-
causing P.  multocida strains provided evidence of a 
disease-associated  REP  profile with a high degree of 
homogeneity observed among the strains, regardless of 
whether the capsular serotype was B or E.  These 
profiles were clearly distinct from serologically similar 
strains that do not cause  HS,  but exhibited a degree of 
relatedness to strains that cause clinically similar 
septicaemic disease such  as  B:1,  B:2,  B:3,  B:4.  These 
findings have paved the way for a disease-specific test 
rather than a serotype-specific test. 
5.10.2  Ribotyping and field 
alternation gel electrophoresis 
Ribotyping and field alternation gel electrophoresis 
(FAGE)  have also  been  used to analyse the DNA of 
strains of P.  multocida that cause  HS, after digestion 
with restriction enzymes (Adamson et al.  1993; 
Townsend et al.  1997b; see Appendix 5). 
Analysis of the DNA restriction patterns using these 
methods has proved useful in differentiating bacterial 
strains that have been denoted as  identical by all 
previous typing methods. Restriction profiles 
demonstrated by Asian  strains showed a remarkable 
degree of homogeneity. Asian  isolates displayed similar 
ribotype and FAGE patterns irrespective of the 
restriction enzyme used, thus indicating that they are 
epidemiologically related  both genetically and 
phenotypically. FAGE displayed a greater degree of 
discrimination between strains, compared with 
ribotyping. It was particularly useful in distinguishing 
the North American type B:2 strains that produced HS 
from the Asian strains. 
Both ribotyping and  FAGE analysis also helped to 
differentiate between the classical Asian  B:2  strains that 
cause  HS and the reportedly avirulent strain designated 
Izathagar 25, isolated from cases of paraplegia among 
cattle in  India (Dhanda and  Nilakanthan 1961). This 
strain  has not been serotyped by the 
Carter-Heddleston method but has been found to 
belong to Roberts type I,  and  has been  biochemically 
differentiated from other strains by its ability to ferment 
xylose (Dhanda and  Sen  1972). 
5.10.3  Restriction 
endonuclease analysis 
Restriction endonuclease analysis (REA) of a wide 
range of cultures of P.  multocida associated with HS 
has been carried out (Wilson et al.  1992; Rimier 
(1997)(see Apendix 5). The DNA was digested with 
Hhal and  Hpall endonuclease, and examined by 
agarose gel electrophoresis. Gels were stained with 
ethidium bromide, and the band patterns (DNA 
fingerprint profiles) were viewed and photographed in 
ultraviolet light. Reverse  negative photographs of gels 
were made and  scanned  to create an  image profile. 
Images of fingerprint profiles were analysed  by 
computer program. 
Forty-two different DNA fingerprint profiles were 
recognised among 190 serotype B:2  strains using Hhal 
endonuclease. Twelve DNA fingerprint profiles were 
found among 35 serotype B:3,4 strains with the same 
enzyme.  Further distinction could be made among B:2 
or B:3,4 strains with Hpall endonuclease.  For example, 
treatment with Hpall resulted  in  seven different DNA 
fingerprint profiles within 56 serotype B:2  strains that 
produced a profile designated Hhal 0018. Thus, a 
strain could be assigned a descriptive identification 
epithet (DIE) code such  as  B:2 IHhal 0018 1 Hpall 
0016 based  on  the REA results.  Strains were analysed 
on  the basis of associated species and country. Among 
64 serotype B:2  strains from Sri  Lanka, 24 fingerprint 
profiles were defined using Hhal endonuclease. 
Further, among 17 strains designated  B:21 Hhal 0018, 
originating from animals such  as cattle, buffalo, swine 
and  elephant, six Hpall profiles were identified. Similar 
profiles were found among isolates from swine and 
buffaloes in  India. 
5.11  Antibody Detection 
in  Host Animals 
As  mentioned elsewhere,  HS occurs mostly in  situations 
with poor husbandry conditions.  In  such circumstances, 
disease-reporting systems are also poorly developed. 
Deaths usually occur quickly and situations are likely to 
arise in  which, by the time veterinary personnel arrive 
at the scene,  no clinically affected animals or carcases 
are available for examination. 
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following exposure to natural infection, surviving 
animals develop high antibody levels as  measured by 
the IHA test, using the 56°C/30 minute supernatant as 
antigen to coat erythrocytes (De Alwis 1982b, De Alwis 
et al.  1986). De Alwis (1982b) was able to specifically 
demonstrate a steep rise in antibody level within two to 
four weeks of such  exposure. Such  high levels of 
antibody have not been attained by administration of 
conventional vaccines.  Hence, the presence of such 
levels of IHA antibody following recent deaths in a herd 
provides reasonable circumstantial evidence that deaths 
were  due to HS. 
The test used to detect such  an  antibody response is 
important. The HS-antibody ELISA (Johnson et al. 
1989; see Appendix 3) may not detect such  antibody, 
since the test uses boiled supernatant as antigen. This 
was borne out in experiments with a live vaccine when, 
following vaccination, IHA antibodies continued to rise, 
as  in  natural exposure, but the ELISA titres did not 
(M.C.L.  De Alwis, unpublished data). 
A single radial haemolysis test for measuring HS 
antibodies has been described (Rahman et al.  1987; 
Rahman and Ashfaque 1991). This test was carried out 
using a sonicated antigen. In  a comparison of this test 
with the conventional IHA, a high degree of correlation 
(r=0.792) was observed. There is no information on the 
use of this test for detecting naturally acquired 
immunity resulting from natural exposure. 
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5.12  Choice of Diagnostic Tests 
The choice of diagnostic tests must take into account 
the nature of the material available, the facilities 
available in the laboratory and the proximity of the 
laboratory to the outbreak of disease. Any modest 
diagnostic laboratory charged with the responsibility of 
HS diagnosis should have a basic facility for microscopic 
examination and  bacterial culture. It should also have a 
supply of hyperimmune rabbit antisera and, ideally, a 
laboratory animal facility with access to a mouse colony. 
The most reliable procedure is the mouse inoculation 
and mouse blood culture followed by rapid slide 
agglutination. Serotyping by the IHA test and AGPT 
(Heddleston) may be subsequently carried out in  the 
same laboratory, or the culture may be passed on to the 
next higher grade of laboratory where such a capability 
exists. In situations where serotypes other than B:2  or 
E:2  are present (such as  B:1,  B:4, B:3,4), AGPT  is the 
definitive test. The procedure, starting with the mouse 
inoculation, detects even small  numbers of organisms, 
even  in  the presence of contaminants. 
Where a PCR facility and technical know-how is 
available, stale material containing small  numbers of 
organisms can  still  be used.  However, PCR will pick up 
only the target organism for which the test is designed, 
and will fail to detect any related serotypes, or other 
bacteria, such  as Bacillus anthracis, which are likely to 
cause similar sudden death syndromes. 
Rapid  serological tests such  as AGPT using the 
56°C/30 minute supernatant as antigen and counter-
immunoelectrophoresis detect the capsular serogroup, 
but not the specific somatic type. The hyaluronidase test 
is also specific for P multocida B:2  strains that cause  HS, 
and serves as  an additional complementary test. 
Other molecular tests, besides PCR, such  as ribotyping, 
REA and FAGE,  are useful for identifying strains within 
serotypes. They are therefore useful as markers in 
epidemiological studies and as research and investigatory 
tools rather than as routine diagnostic tests. Treatment and Control 
Overview 
Haemorrhagic septicaemia (HS) is classified as a List B 
disease by the Office International des Epizooties. 
Control and treatment of the disease are therefore an 
important issue in countries where the disease is 
endemic. 
Treatment 
Treatment with antibiotics is of limited value unless 
carried out in the very early stages. Most field cases are 
not detected in the early stages, making treatment 
ineffective. In an organised farm incontact animals can 
be checked regularly and animals showing an increased 
temperature can be separated and treated with 
antibiotics. 
Prevention and control 
Vaccination is the most effective method of control, in 
conjunction with other measures. Three broad categories 
of activities are recommended for prevention: 
prophylactic measures in endemic countries; measures 
needed in the event of an outbreak; and measures needed 
to prevent the spread of disease from endemic to 
nonendemic areas. 
Eradication 
Eradication of haemorrhagic septicaemia is  difficult to 
achieve because of the existence of latent carriers. 
6.1  International Classification 
As described in  Section 1.4.1, the Office International 
des Epizooties (OlE), or World Organisation for Animal 
Health, has classified haemorrhagic septicaemia (HS)  as 
a List B disease (along with most other bacterial and 
parasitic diseases that are considered to be of 
socioeconomic and/or public health importance within 
countries, and also of significance to the international 
trade in  animals and animal products). List A diseases, 
on  the other hand, are mainly viral diseases, and 
include those that spread  rapidly and have the scope to 
spread beyond national borders. The classification 
presumably influences the priority status given to the 
disease by governments in  endemic countries and the 
allocation of resources for treatment and control. 
6.2  Treatment 
As  HS  is a primary bacterial disease with no other 
biological agents involved, treatment may appear 
simple using the wide range of antibiotics currently 
available.  In  reality,  however, treatment is constrained 
by a host of practical considerations. It has been found 
in  practice that animals can  only be cured if they are 
treated in  the very early stages of the disease. 
However, as the disease occurs mainly in  situations 
with primitive husbandry practices most field cases 
escape detection in  the early stages, thus rendering 
treatment ineffective. 
In  organised farms,  however, a practical method of 
achieving early detection and  successfully treating 
animals is  to check the rectal temperatures of all 
incontact animals regularly once an  outbreak has  been 
detected. Any animals showing an  increased 
temperature can  be separated and treated with a 
course of an  appropriate antibiotic. 
Although not documented, there is  considerable 
information from reports of field outbreaks indicating 
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accelerates death. This may be because administration 
of antibiotics to an  animal with septicaemia precipitates 
an  endotoxin shock due to release of free endotoxin 
from the killed  bacteria. 
6.2.1  Antibiotic therapy 
The oldest therapy recommended was intravenous 
treatment with sulfonamides. Intravenous infusion of 
sulfadimidine sodium 33.33% at a dosage of 1 mL per 
5 pounds bodyweight (about 2.3  kg)  has been 
practised. However, the large volume of drug to be 
injected, the practical difficulties of intravenous therapy 
in  the type of animal involved and the consequences of 
leakage of the drug into the surrounding tissues all 
weigh heavily against this treatment regimen (De Alwis 
1984). De Alwis (1984) observed that intramuscular 
treatment with streptomycin or oxytetracycline was 
very effective. 
Resistance to antibiotics in  HS strains of P.  multocida 
has not been a major problem. When 10 strains 
obtained from Malaysia, Indonesia, Thailand, 
Myanmar, India and  Sri  Lanka were tested against 10 
commonly used  antibiotics (penicillin, ampicillin, 
streptomycin, tetracycline, chloramphenicol, 
erythromycin, neomycin, sulfadiazine and a 
sulfonamide-trimethoprim combination), no resistance 
was recorded apart from partial resistance of the Thai 
strains to streptomycin (De Alwis 1984). 
Bandopadhyay et al.  (1991) tested 16 isolates obtained 
from different outbreaks in  the Gujarat State (India) 
against 19 antibiotics. They found that 14 isolates 
(87.5%) were resistant to compound sulfonamides. 
Resistance was also observed to vancomycin (75%), 
tetracycline (50%), colistin (37.5%), streptomycin and 
novobiocin (25%), and  nitrofurantoin and  carbenicillin 
(6.25%). All isolates were sensitive to peniCillin, 
ampicillin, chloramphenicol, erythromycin, gentamicin, 
caphalothin, polymyxin Band tilmicosin. 
In an outbreak of disease in  pigs in  India caused  by the 
HS serotype B:2,  isolates were found to be  sensitive to 
erythromycin, gentamicin, nalidixic acid and  neomycin 
(Verma 1988). In  Pakistan, from the results of a 
questionnaire survey, it has  been concluded that 
preparations containing amoxicillin, sulfapyrazole, 
gentamicin and chloramphenicol produced positive 
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clinical results (Sheikh et al.  1996). Abeynayake et al. 
(1992) tested 27 Sri  Lankan  isolates against 17 
antimicrobial agents. These were mainly strains 
derived from field outbreaks from cattle and  buffaloes 
during the period 1985-90. Also included were a few 
strains isolated from clinically normal carrier animals, 
isolates from species other than cattle and buffaloes, 
and  national reference strains. All of these were of 
serogroup B:2. All  strains tested were sensitive to 
penicillin, ampicillin, enrofloxacin, chloramphenicol 
and  nitrofurantoin. A majority of isolates were also 
sensitive to neomycin (26/27), gentamicin (26127), 
oxytetracycline (25/26), streptomycin (24125) and 
sulfonamide-trimethoprim (25127). Variable degrees 
of resistance were shown to some antibiotics, the 
number of sensitive strains being oxacillin (17/27), 
spiramycin (16127), clindamycin (17127) and 
sulfamethoxazole (12127). 
Thus,  of the antibacterial compounds that are 
recommended for use  in  cattle and  buffaloes, and that 
can  be conveniently and economically administered, 
penicillin, ampicillin and oxytetracycline appear to be 
the most useful. The sensitivity patterns, however, are 
likely to vary from one country to another depending 
on the prevailing drug usage practices; a knowledge of 
the sensitivity patterns of local strains will be  use'ful  in 
deciding the drug of choice. It is interesting to note the 
observation of Bain  et al.  (1982) that while penicillin 
was effective against the organisms in vitro, it was 
ineffective in vivo, a point that must be noted in the 
choice of an  antibiotic. 
6.2.2  Serum therapy 
Serum therapy is only of theoretical interest. Kheng and 
Phay (1963) used 60-100 mL of hyperimmune serum 
for experimental administration to two-year-old (400 Ib 
[about 180 kg]) buffaloes at varying periods from six 
hours before to 18 hours after infection. No significant 
therapeutic effect was recorded. 6.3  Prevention and Control 
There are three categories of measures for prevention 
and  control of HS: 
•  measures to be adopted in endemic countries 
on a prophylactic basis; 
•  measures to be taken in the event of an outbreak; and 
•  measures necessary for prevention of spread  across 
regional or national borders. 
6.3.1  Prophylactic measures in 
endemic countries 
Taking into consideration available information on the 
nature of the disease, the organism, its survival outside 
the animal, resistance to external agents and  relevant 
epidemiological parameters, the preventive measures 
shown below should  be taken within a country or 
region  where HS  is endemic. 
•  Vaccinate on a routine prophylactic basis. 
Vaccination is  best done two to three months before 
the high-risk season  (in  areas where seasonality 
occurs) so  as to ensure peak immunity during the 
period of maximum risk. 
•  Establish a good reporting system. This will enable 
information on suspected outbreaks to reach  animal 
health authorities as quickly as  possible.  In  most 
endemic countries HS  is  listed as a notifiable disease. 
•  Create awareness of the disease among farmers. 
Educate farmers to recognise signs of the disease. 
•  Prevent mixing of animals from endemic and 
nonendemic areas.  In endemic areas, a significant 
proportion of animals are latent carriers and are 
potential sources of infection. In  nonendemic areas, 
animals are not regularly exposed to infection, lack 
naturally acquired immunity, are not usually 
vaccinated, and are  highly susceptible. An  outbreak 
originating from an  activated carrier in such  an 
instance can  be explosive. If contact between such 
animals is unavoidable, it is of utmost importance 
that susceptible animals from nonendemic areas are 
vaccinated at least two weeks before contact with 
animals from an  endemic area. 
6.3.2  Preventive measures during 
an outbreak 
In the event of an  outbreak of disease occurring, there 
are equally important measures that should be taken to 
control further spread. 
•  Continue vaccination programs. Vaccination is 
recommended even  in the face of an  outbreak. In 
such  situations broth bacterins or the alum-
precipitated (or aluminium hydroxide gel) vaccine is 
preferred. Broth bacterin and the oil adjuvant 
vaccine may be administered at different sites, 
simultaneously. 
•  Isolate and treat animals showing clinical signs 
with a parenteral broad-spectrum antibiotic 
(relatively easy in organised farms or herds that are 
paddocked at night or for part of the day). 
•  Check the rectal temperature of all immediate 
incontact animals in the herd. This should be done 
at least once every morning; those animals showing 
increased temperatures should be treated as above. 
•  Search daily for sick animals or carcases of dead 
animals (free-roaming, nomadic herds). 
•  Confine herds as  much as possible, and prevent 
movement of animals in and out of diseased 
premises or villages. 
•  Take immediate action to carry out postmortem 
examinations (iocal veterinarians). Make a tentative 
diagnosis. 
•  Dispatch specimens to the nearest diagnostic 
laboratory. Specimens should be stored and 
transported under appropriate conditions (see 
Chapter 5). 
•  Dispose of carcases of dead animals properly. Deep 
burial or effective incineration is recommended. 
Often, after animals die, carcases are disowned by 
farmers.  Stray dogs and other scavenging animals can 
disseminate infection by carrying away portions of 
infected carcases,  and carcases dumped into streams 
and waterways are important sources of infection. 
•  Properly dispose of unconsumed fodder, bedding 
etc. from infected premises. Deep burial or drying 
and  burning should be carried out within the 
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should be prevented from being washed away from 
the premises.  Drains carrying such  material should 
be  led  into a deep protected pit within the premises, 
or subjected to disinfectant treatment. 
•  Closely monitor or stop rain-associated activities. 
Activities such  as  ploughing and preparation of fields 
for rice cultivation cause considerable movement of 
draught cattle and  buffaloes.  HS often breaks out 
during wet seasons. 
6.3.3  Prevention of 
spread across  borders 
Where animals are moved from an  endemic country or 
region to a nonendemic country or region, such as 
during imports, certain practical procedures can  be 
observed to eliminate or at least minimise the transfer 
of the disease. 
•  Ensure that the animals originate from a region 
where no outbreaks of HS  have occurred for a 
minimum period of one year.  How extensive this 
disease-free 'region' should be will depend on the 
system of management practised in the region.  If 
animals are confined to farm premises, the region 
may be  as  narrow as a radius of half a kilometre. On 
the other hand, where the animals are on a free-
range system, the radius of the disease-free zone 
may have to be several  kilometres. 
•  Bleed a random sample of animals. This should 
include the herd or farm of origin and/or other 
incontact animals. 
•  Test for the presence of antibody by the IHA test. 
The presence of high indirect haemagglutination 
(IHA) antibody titres is an  indication of recent 
exposure to disease and therefore the presence of 
disease-causing agent in the locality. 
•  Hold animals under observation for two to three 
weeks before transport. During this time repeated 
attempts should  be made to check nasopharyngeal 
swabs for pasteurellae by mouse inoculation and 
culture.  Blood collected at the beginning and end of 
such  a period should be checked for antibody by the 
IHA test. Animals harbouring type B pasteurellae 
and/or showing IHA titres should be eliminated. The 
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detection of any carriers or animals with antibody 
titres would justify an  extended period of 
pretransport observation for other incontact animals 
in the group. 
•  Quarantine animals after transport to the new 
location. The animals can  be held for a similar period 
of time to that used  before transport. During this 
time, the same procedures should be carried out. 
•  Vaccinate animals from disease-free locations in 
endemic countries. A dose of oil adjuvant vaccine 
may be given at the end  of the quarantine period, 
followed by a booster three months later.  It is 
equally important to vaccinate all  animals in the 
country of import that are likely to come into 
contact with animals introduced from endemic 
countries or regions. 
Vaccination is the most important control procedure 
adopted in all countries where the disease  is endemic. 
Details of the vaccines in  use and vaccination 
procedures are given in Chapters 7,  8 and 9. 
6.4  Eradication 
No country has ever attempted to eradicate HS.  This 
reflects the belief that the existence of carriers makes 
eradication too hard. This has been strengthened by 
recent findings indicating that a larger proportion of 
animals are carriers than was originally thought and 
that for most of the time the disease remains latent. 
The existence of carriers among feral  ruminants may be 
a further factor that will make eradication difficult. 
The only known attempt at eradication was made by 
the Government of Indonesia on a pilot scale on  the 
island of Lombok with a cattle population of 300 000. 
The program started in 1978 with intensive vaccination 
campaigns that were targeted to achieve the highest 
possible coverage in all  susceptible species.  The 
coverage actually achieved over a three-year period 
was 89% in cattle, 94% in  buffaloes, 82% in goats, 
93 %  in sheep and  80% in  pigs. The program was 
evaluated in  1981, after three annual vaccinations 
using the oil adjuvant vaccine.  During this period, 53 
cases of HS were reported. Culture of pharyngeal 
mucous membrane samples from 220 animals 
slaughtered in an  abattoir yielded positive isolations from five a.nimals (2.2%). Mass vaccination was 
continued, and a second evaluation was  made in  1985. 
A total of 450 abattoir samples from cattle, buffaloes, 
goats and pigs were negative. Also,  103 specimens 
from animals suspected of HS were negative. This 
island was declared free of the disease in  1985. 
However, subsequent evaluations based on culture, 
serology and field reports indicate that HS  is  still 
present in  Lombok (Darmadi 1991; Syamsudin 1993). 
These observations provide useful indicators of the 
complexities involved in  attempting a total eradication 
program for HS even on a small island; the implications 
are  much more complex in countries with land borders 




Vaccine production consists of four important steps: 
selection and maintenance of seed culture, production 
of bulk dense culture, inactivation of dense culture and 
formulation of vaccine. Simplified methods of vaccine 
production as well as sophisticated technologies are 
available. 
Types of vaccine 
The types of vaccine used against HS are bacterins, 
alum preCipitated vaCCine, aluminium hydroxide gel 
vaccine, and oil adjuvant vaccine. 
Quality testing 
All  HS vaccines have to be tested for purity, stability 
and sterility. Potency tests are usually carried out in 
mice. The production technique must be validated in 
an experiment using natural host animals. 
7.1  Vaccine Production 
Haemorrhagic septicaemia (HS)  is  preventable using 
vaccines containing the causative bacterial agent. 
However, pasteurella is a poor immunogen and a large 
amount of antigen (usually whole bacteria) therefore 
has to be injected. This procedure occasionally leads to 
endotoxic shock. One way of overcoming this problem 
is to use a suitable adjuvant. Adjuvants potentiate the 
action of the immunogen, and provide a depot effect, 
delaying absorption by a slow release  mechanism that 
simulates the administration of multiple doses. 
HS vaccine production involves the following stages: 
•  selection and maintenance of a seed  culture; 
•  preparation of a bulk dense culture; 
•  inactivation of the dense culture; and 
•  formulation of the vaccine. 
7.1.1  Selection of a seed culture 
It is generally agreed that vaccines produced from fresh 
field isolates are more effective than those produced 
from seed cultures propagated in vitro in  laboratories 
over long periods. Most countries have therefore used 
local isolates as seed  culture. Bain (1979b) carried out 
active protection tests in  mice using Pasteurella 
multocida propagated in bovine cells and as laboratory 
subcultures. Bacteria grown in vivo gave cross-protection 
between Asian strains (B:2), African strains (E:2) and the 
Australian strain 989 (B:3,4), whereas laboratory 
subcultures gave only homologous protection. 
There has been some speculation as to whether strains 
exist in  nature that have special immunogenic merit. 
The Burmese 'Katha' strain and the Indian P52  strain 
have been  used even in countries other than that of 
their origin because they were believed to have special 
immunogenic properties. In  Malaysia, vaccines were 
59 produced from five different strains, derived from five 
regions within the country, presumably as a safeguard 
in  case different strains had different immunogenic 
properties, although there is  no evidence for this. 
De Alwis (1984) carried out a comparative study of 
strains originating from Malaysia, Indonesia, Thailand, 
Myanmar, India and Sri  Lanka.  He grew strains under 
the same conditions and then immunised mice with 
suspensions of bacteria standardised on a dry weight 
basis to examine cross-protection. The results showed 
that the density of growth, and therefore the dry 
weight yield of whole bacteria, varied between strains 
and that no consistent immunogenic differences were 
demonstrable when the mice were challenged with a 
local isolate. On the basis of dry weight yield, the 
Malaysian strain tested (C 82) conSistently gave the 
highest yields. 
The variation in  dry matter yields when different seed 
strains are grown under the same conditions was also 
shown in  the study of Arawwawela et al.  (1981) in  Sri 
Lanka.  It is likely that strains that are well capsulated 
and therefore contain a full complement of antigens 
give higher dry matter yields, and may therefore be 
better immunogenic strains for vaccine production. 
Considering the above information, it appears that it is 
best to select as the vaccine seed an  isolate of known 
serotype designation  which has been tested and proven 
to be  immunogenic and which gives high dry weight 
yields.  Once a relationship between dry weight and 
turbidity of growth is  established, turbidimeter readings 
can  be  used as an  index of dry weight (see Appendix 7). 
7.1.2  Storage and maintenance 
of seed cu Itu res 
Once the seed culture has been selected, it is good 
practice to passage it in a natural host (a calf) at least 
once a year.  Before calf passage, the LD50 for mice can 
be determined to ensure its virulence.  It is  best to collect 
infected blood from either the heart or the main blood 
vessels two to three hours after death; by this time there 
will have been a reasonable multiplication of the 
pasteurellae without postmortem invaders. In practice, 
this procedure is difficult because the time of death of the 
infected animal is unpredictable and may occur at night. 
An alternative practical method is to collect blood from 
the jugular vein of the dead calf, culture on a suitable 
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medium, pick one or two well capsulated colonies and 
inoculate them onto defibrinated ox blood or ox blood 
collected aseptically into a sterilised vessel containing 
sodium citrate or ethylenediamine tetraacetic acid  (EDTA) 
as anticoagulant. The ox blood should not contain HS 
antibodies. The inoculated blood is incubated for six to 
eight hours (or even overnight). A smear is examined for 
purity and for the presence of pasteurellae and the blood 
is dispensed in 1-mL aliquots into small bottles that are 
screw-capped and stored in a deep freezer below -20°C 
or in liquid nitrogen. Alternatively, the blood may be 
divided into O.2-O.5-mL aliquots, Iyophilised and stored 
at 3-8°C in a refrigerator. Most laboratories stock a year's 
supply and the process  is  repeated each year.  For each 
batch of vaccine, a new seed vial, or one to two 
subcultures in a blood-containing medium, should be 
used. 
7.1.3  Bulk culture media 
Various media have been developed in different countries 
to grow dense cultures. Dense suspensions of bacteria 
can  be obtained by growing the cultures in a solid agar 
medium in  Roux flasks and harvesting the bacteria in 
physiological saline. This is a laborious process and before 
harvesting and pooling each flask has to be examined, at 
least visually, for contaminants. The method has therefore 
not been popular, although it has been  used  in  India and 
Iraq (FAa 1979). In  India only 2.8% of the total vaccine 
production uses the agar-wash method. 
Liquid media are the most commonly used, because 
they are  less time consuming to process.  Liquid media 
consist of a protein as  a source of amino acids (digest 
of casein,  beef extract etc.), a fermentable sugar,  and 
growth promoters such  as  yeast extract or autodigest 
of pancreas etc., in a phosphate buffered medium. 
Examples of liquid media are given in  Appendix 7. 
In Sri  Lanka, Arawwawela et al.  (1981) have produced 
a simple and economic medium for dense culture 
production. They found that the protein content of the 
medium could be  reduced to one-tenth of the quantity 
used before without significantly affecting growth; that 
yeast extract was highly effective in  increasing the 
yields; and that the presence of buffer and the addition 
of sucrose (or refined cane sugar) increased yields. The 
study led to production of a medium that cost about 
one-third as  much as the conventional medium 
previously used. 7.1.4  Culture methods 
Vaccine production requires bulk production of dense 
cultures. Either liquid or solid media can  be used for 
this purpose, but seeding and harvesting from solid 
media are neither practical nor economical in  large-
scale production. Consequently, the following sections 
focus on liquid culture. Different workers have used 
different methods to suit the scale of operation within 
the available facilities,  but it is  important to maintain an 
optimum temperature and pH, and a steady supply of 
air through an  aeration process. The  main aeration 
methods used are vortex aeration and sparger aeration. 
Vortex aeration 
This method uses a vortex tank. A compressor 
(usually around 0.5 hp) delivers a stream of air at 
10-15 pounds pressure through a filter candle or any 
modern type of commercial in line filter. This stream of 
sterilised air is  passed  through the vortex tank, which 
contains only around 50% of its volume of liquid 
medium with the necessary nutrient factors for optimal 
growth and which is sufficiently buffered to minimise 
pH  changes.  Rotation of a propeller connected to a 
motor at the bottom of the tank produces a vortex 
current in the liquid; the air passes through the vessel, 
but not through the liquid medium. 
The tanks are sterilised with the medium and the air 
sterilisation assembly in  an  autoclave at 120°C for 
about 45 minutes. They are seeded  by injection 
through a rubber diaphragm on the side of the upper 
portion of the tank. It is  best to seed the cultures after 
aeration has started, so that the positive pressure 
within the tank prevents air from being sucked  in  and 
contaminating the culture. The entire tank is  placed in a 
37°C incubator room. 
Contamination can  occur if the tank is understerilised 
or if air leaks through the seals at the point of entry of 
the propeller shaft. The former is easily overcome by 
adequate sterilisation; the latter is more difficult to 
overcome, because the air in the 3JOC  room is  normally 
highly charged with bacteria and even a small volume 
of air leaking in  can  provide a significant dose of 
contaminants when the seed  culture is introduced. 
Such contamination can  be minimised by building up 
a positive pressure within the tank before seeding. 
Sparger aeration 
In sparger aeration systems, a current of sterile (filtered) 
air is dispersed through the liquid medium using a filter 
candle, a block of pumice stone or a fish tank aerator.  It 
is the experience of the author that the finer the 
dispersion of the air, the better the growth. In such 
systems, a propeller arrangement may be used to churn 
the liquid, but it is  better to avoid this: a vigorous 
sparger aeration itself will churn the medium sufficiently. 
One of the problems with sparger aeration is the 
development of froth, which tends to clog the air 
outlets. Various antifoam agents are available but there 
is  little information on the effect of such agents on the 
denSity and quality of growth. Alcohols, oils and 
silicones may be toxic or inhibitory to growth. Silicones 
and esters of fatty acids are effective and  nontoxic, but 
limited experiments by Bain  (unpublished) indicated that 
sparger cultures treated with silicone or linseed oil were 
less immunogenic than cultures prepared using other 
methods. More information in this regard  is required. 
Two common bulk culture methods use sparger 
aeration. One uses a simple culture system with a large 
vessel and the other makes use of a commercial 
'fermentor' as the culture vessel and requires more 
specialised procedures and  trained personnel. 
Simple culture system. A simple and effective sparger 
aeration system  has been developed in  Sri  Lanka. A 
40-litre vessel  containing the medium is  placed  in a 
water bath at 37°C, thereby eliminating the need to 
use an  incubator room. Sparger aeration is controlled 
and excessive froth is collected in  a froth trap, while 
outflowing air is  bubbled through a formalin trap. A 
detailed description of this equipment and its use, 
which is  within reach  of even the most modest 
vaccine-producing laboratory, is described in 
Appendix 7.  The equipment is simple enough for use 
in a laboratory with very modest facilities. It has, for 
example, been installed and used  successfully in a 
vaccine laboratory in  Cambodia, where it is  housed in 
a shipping container 40 feet long with a width and 
height of 8 feet (about 12 x 2.5 x 2.5 metres). 
Bacterial yields of at least 1.5 mg/mL dry weight can 
be obtained in this system, and the yield compares 
favourably with that obtained in  a sophisticated 
fermentor. 
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industrial fermentation equipment to produce bulk 
cultures. A fermentor provides a bulk culture vessel  in 
which a constant temperature, pH and oxygen tension 
can  be maintained throughout the growth period with 
churning of the medium and aeration. It is  a closed 
system,  where the medium is sterilised and cooled to 
37°C in  situ and where seeding can  be done and 
samples withdrawn for testing at any stage without 
opening the vessel. 
Commercially available fermentors range in  working 
capacity from 50 to 500 litres and allow control of 
temperature, oxygen pressure etc. The manufacturer 
can  build in any special features. A detailed description 
of the use of a fermentor for vaccine production is 
given in Appendix 7. 
Any laboratory purchasing a fermentor should first 
determine precisely the specific requirements and 
scale of operation. It is vital that spare parts, servicing 
and  maintenance facilities are available as well as the 
general infrastructure facilities needed to operate the 
fermentor. These factors should be taken into account 
when preparing specifications for a fermentor. It is 
also important to train the technicians before a 
fermentor is purchased. 
7.1.5  Continuous and batch cultures 
Bulk cultures may be produced by batch culture or 
continuous culture using the simple sparger aeration 
system or a fermentor. For batch culture, fresh  medium 
and fresh  seed  is  used for every batch. For continuous 
cultures, a predetermined volume of harvest is 
removed, and an equal volume of fresh  medium 
introduced aseptically once the maximum turbidity is 
reached.  Generally, around 25% of the total volume 
can  be harvested every hour and the process can  go on 
for several days unless contamination sets in.  In a 
sense,  continuous culture is a form of repeated 
subculture from the original seed, which is grown in 
blood. It is the experience of the author that when the 
process  is  continued for more than two to three days, 
the density of the harvest begins to diminish, 
presumably through loss of capsular material. Batch 
cultures are therefore preferred. 
62 
Contamination occurs with most systems; one method 
of avoiding it is to use a relatively large inoculum and a 
short incubation. Batch cultures inoculated at 50 mL 
per litre of medium reach  a maximum turbidity in 
15-18 hours, at which time growth can  be terminated 
and the entire batch harvested. This enables the 
pasteurellae to grow rapidly and overcome any 
contaminants that may be present in small  numbers. 
7.1.6  Inactivation of dense cultures 
and production of vaccines 
Cultures produced in the way described above are 
inactivated by the addition of 0.5% formalin (36-40% 
formaldehyde solution). Once a dense suspension of 
inactivated bacteria is obtained, it is used to prepare 
one of the four types of vaccine used against HS  (see 
Section 7.2). 
7.2  Types of Vaccine 
There are four different types of vaccine used against 
HS:  broth bacterins; alum precipitated vaccine; 
aluminium hydroxide gel vaccine; and oil adjuvant 
vaccines. 
7.2.1  Bacterins 
Bacterins are the simplest form of vaccine and consist 
of a suspension of whole cells.  The common bacterins 
consist of inactivated broth cultures and are referred to 
as  broth bacterins. Rarely,  agar wash  bacterins are 
produced by harvesting the growth from agar plates or 
from Roux flasks. 
If dense, formalinised suspensions are injected, shock 
reactions occur in  a small  percentage of animals, which 
is  presumably due to free endotoxin present in the 
preparation. The formalinised bacterial suspension 
(bacterin) should therefore be diluted so as to contain 
not more than 0.5 mg bacteria (dry weight) per mL 
and a 3-mL dose may be administered. Another 
disadvantage is that the antibody response to plain 
bacterin is poor and only provides rapid immunity for 
about six weeks.  Repeated  booster doses therefore 
need to be given. 7.2.2  Alum precipitated vaccine 
Alum precipitated vaccine is the most widely used 
vaccine  in  Asia and Africa.  It consists of a bacterin to 
which potash alum has been  added to give a final 
concentration of 1  %. If derived from aerated culture, 
the density of the bacterin should be adjusted to 
approximately 0.75 mg dry weight per mL,  so that a 
3-mL dose will contain a minimum of 2.0 mg bacteria. 
The disadvantages of this type of vaccine are that it 
only provides reliable immunity for three to four 
months and shock reactions can  also occur.  It is 
important to thoroughly mix the contents of the bottle 
before use  because precipitation with alum causes the 
cells to settle at the bottom. If this precaution is  not 
taken, animals receiving vaccine from the bottom of 
the bottle will receive a large dose of bacteria, and  the 
chances of shock will be increased. 
7.2.3  Aluminium 
hydroxide gel vaccine 
Aluminium hydroxide gel vaccine shares common 
properties with the alum precipitated vaccine. Aerated 
cultures are blended with aluminium hydroxide gel at a 
final concentration of 3 %.  Standardisation is  required 
to ensure that a 3-mL dose contains approximately 
2 mg of dry bacterial substance. Although six  months 
immunity is sometimes claimed (and twice yearly 
vaccination is therefore practised), reliable immunity 
following a single dose at primary vaccination may be 
similar to the protection obtained with APV (about four 
months). This  is the main type of vaccine used  in 
Thailand. 
7.2.4  Oil adjuvant vaccine 
The  use of oil as an  adjuvant (substances that increase 
the antibody-producing effect of antigens) in vaccines 
dates back to 1916 when what was described as a 
lipovaccine was produced against Salmonella 
typhimurium by emulsifying a suspension of organisms 
in  liquid paraffin, using lanoline as a stabilising agent 
(Le Moignac and Pinoy 1916). The aim was to reduce 
the toxicity of the vaccine, but there was also delayed 
absorption and enhanced immune response.  Nearly 
two decades later, in  1935, the adjuvant properties of a 
wide range of oils and  lanoline were investigated. 
Subsequently, Daubney (1937) made an  oil adjuvant 
vaccine against pleuropneumonia in cattle in  Kenya 
and, at Weybridge in  England, Gilbert (1943) produced 
an  oil adjuvant brucellosis vaccine.  In  1937, Freund 
demonstrated that the addition of paraffin oil to 
tubercle bacilli enhanced both lesion formation and 
sensitisation to tuberculin in  experimental animals.  In 
1948, he and  his co-workers studied the enhancement 
of immune responses to vaccines in  various emulsions, 
without the addition of mycobacteria, and this 
emulsion is what is  now known as the 'Freund's 
incomplete adjuvant' (Freund et al.  1948). 
When oil adjuvant vaccines  are injected, a vaccine 
depot forms at the site of inoculation. This depot serves 
as a prolonged source of antigen. There is  little 
production of antibody around the depot, the main 
sites of production being the local  lymphatic chain and 
ultimately the reticulo-endothelial system.  In  the 
United States, Talmage and  Dixon (1953) injected 
protein in oil emulsion and  showed that absorption 
took place exponentially from the site of injection with 
a half-life of about 14 days.  The antibody response to 
the protein antigen in  this form remained constant for 
over 300 days. This contrasted with the antibody 
response to the same antigen in aqueous solution or 
alum precipitation, which declined after 10 days. 
An emulsion was originally defined as  'a system 
containing two liquid phases one of which is  dispersed 
as globules in the other'. The liquid that is broken into 
globules is called the dispersed phase and the liquid 
surrounding the globule is called the dispersing medium. 
The two liquids, which must be  immiscible or nearly so, 
are frequently referred to as  the internal and external 
phases respectively.  In the oil adjuvant vaccine, the two 
phases are the dense bacterin (aqueous phase) and the 
oil. To  provide stability to the emulsion, a third entity 
(an  emulsifying agent) is also required. The choice of 
emulsifying agent used  is  determined by the type of 
emulsion required, i.e. water in  oil or oil in  water. 
Oil adjuvant vaccine for HS 
An oil adjuvant vaccine for HS was first developed in 
the 1950s (Bain and Jones 1955). It consists of a water 
in oil emulsion, where the aqueous phase consists of a 
dense broth culture and the oil  phase a light mineral oil. 
Various mineral oils have been  used and  some 
commercial products that have been  used with success 
are Ondina 17 (Shell) and Marcol52 (Esso).  The most 
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purified anhydrous lanoline.  It is semisolid in 
consistency at tropical room temperatures (25-30°C), 
and contributes significantly to the viscosity of the 
vaccine.  Another agent widely used  in vaccines is 
mannite mono-oleate, a commercial preparation of 
which is available under the brand name Arlacel NM 
An  improved grade Arlacel A is preferred because it is 
less irritable to tissues.  This product is a clear liquid at 
tropical temperatures and  produces thinner emulsions. 
In  preparing oil adjuvant vaccines, equal or nearly equal 
volumes of the bacterial suspension (aqueous phase) 
and oil  need to be  used. Thus, the bacterial content 
(i.e. antigen content) of the bacterin is  halved in the 
emulsified vaccine.  If a conveniently administered 3-mL 
dose  is to be used, the minimum requirement of 2 mg 
dry bacteria should be present in  1.5 mL of bacterin. A 
bacterial density of 1.5 mg/mL is therefore a reasonable 
target for dense culture production using aerated 
cultures.  In order to increase the antigen content per 
unit volume of vaccine,  it is logical to increase the 
proportion of the aqueous phase,  but this results  in a 
marked increase in viscosity of the emulsion. 
The percentage of the emulsifying agent required to 
form a stable emulsion to some extent depends on the 
type of oil  used. With Marcol 52, 4 % Arlacel A forms a 
stable emulsion. A concentration of 4-6% anhydrous 
lanoline forms stable emulsions with most light mineral 
oils.  Original formulations contained 8-12% lanoline. 
In order to reduce the viscosity De Alwis (unpublished 
data) produced emulsions containing equal volumes of 
bacterin and oil, with the lanoline content ranging from 
2 % to 12 %. It was fou nd that a concentration of 4 % 
was the minimum requirement to form a stable 
emulsion. For the preparation of the emulsion, a turbo-
emulsifier is generally used. The oil with the melted 
lanoline is  sterilised in a sealed vessel. The propeller of 
the emulsifier is inserted into the vessel and, while this 
mixture is thoroughly churned, the bacterin is added 
gradually over a few minutes. The resulting emulsion 
should be pure white in colour, and  stick evenly to the 
walls of a glass vessel. 
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7.3  Quality Testing 
7.3.1  Quality control 
during manufacture 
Tests for in-process control consist of visual 
examination of the seed  culture upon plating, testing 
selected colonies for agglutinability and testing the 
seed  flasks and the final harvest for purity and 
agglutinability. The harvest is tested for sterility after 
the addition of formalin and standing for six hours at 
room temperature. In  the case of oil adjuvant vaccines, 
tests should  be carried out for stability of emulsion and 
the emulsification formula must be found to be 
satisfactory. The best test for stability is to store the 
vaccine emulsion at the body temperature of the 
species in  which it is to be  used for 14 days, though 
this does not need to be done with every batch of 
vaccine.  It is  all  right to have a thin layer of oil on  the 
surface,  provided the two phases do not separate so 
that the aqueous phase settles at the bottom, with a 
white cloudy mass on  the top. 
7.3.2  Potency tests 
Active mouse protection tests (AMPTs) should be 
carried out using the method of Ose and Muenster 
(1968). This test is practical even for testing of every 
batch of vaccine (Nagarajan et al.  1972; Gupta and 
Sareen  1976; Chandrasekaran and Yeap  1978; 
Vipulasiri et al.  1982). A well-prepared vaccine should 
give 4-6 log units protection in  mice. 
Other potency tests include the passive mouse 
protection test (PMPT) using sera of vaccinated cattle 
to protect mice before challenge (Bain et al.  1982; 
Gomis et al.  1989). Gomis and  co-workers 
experimented with vaccines with a bacterial content 
ranging from 0.75 to 4.5 mg dry weight per cattle dose 
(3  mL). They found that the active mouse protection 
value did not diminish even at the lowest bacterial 
concentration (0.75 mg/dose) whilst the passive  mouse 
protection value of cattle sera declined rapidly when 
doses of less than 1.5 mg were used. 
In order to establish a standard, the minimum 
protective value in AMPTs must be determined. In the 
original work of Ose and Muenster (1968), the pasteurella strains used were not those that cause  HS. 
Further, the protection level of 2 log units was fixed 
quite arbitrarily and was not based on any established 
relationship between mouse protection and cattle 
protection. Moreover, for HS  vaccines there is  as yet no 
established quantified relationship between active 
protection in  mice and  protection in cattle/buffaloes. 
Gomis et al.  (1989) tried to establish such  a 
relationship, but found that active mouse protection in 
mice did not diminish even  at the lowest concentration 
of bacteria tested. They were,  however, successful  in 
establishing a relationship between bacterial content of 
vaccine and cattle protection. When the bacterial 
content of a dose of vaccine fell  below 1.5 mg, passive 
mouse protection of serum from vaccinated cattle 
began to drop. Most well-prepared oil adjuvant 
vaccines give protection levels  ranging from 4 to 6 log 
units in  the AMPT (Chandrasekaran and  Yeap  1978; 
Vipulasiri et al.  1982; Chandrasekaran et al.  1987; 
Gomis et al.  1989). However, the actual protection 
level varies with the quality of the seed  culture and 
other factors. For example, Gomis et al.  (1989) also 
noted that low protection levels  have been recorded  in 
vaccines even though the bacterial content was 
adequate at 2.25 mg per dose. 
As a routine potency testing procedure, active 
immunisation and challenge tests in  rabbits have been 
used  in Malaysia (Thomas and Saroja 1972) and 
extensively in  India for alum precipitated (Jaiswal et al. 
1983) as  well as for oil emulsion vaccines (Mittal and 
Jaiswal  1976; Mittal et al.  1979; Yadev and  Ahooja 
1983). However, this active protection and challenge 
test has not been standardised and  is  not widely used. 
For the present, apart from the purity and sterility tests 
(see Appendix 7), for validation as a vaccine, the oil 
adjuvant vaccine  is  required to confer at least 104  units 
protection in  mice and contain a dry bacterial weight of 
at least 2.0 mg per cattle dose of vaccine, allowing a 
margin above the minimum level of 1.5 mg determined 
experimentally (Gomis et al.  1989). 
7.4  Shelf Life 
A well-prepared emulsion, if appropriately stored, 
should retain its pure white colour and adhere 
uniformly to the glass vessel;  only a thin layer of oil will 
separate on  the surface.  Physical  signs of deterioration 
include discolouration into an  off-white colour, oil 
consistency and failure to stick evenly to a glass 
surface, and separation of a substantially thick layer of 
oil on the surface.  Unstable emulsions will eventually 
'crack', with the aqueous phase settling at the bottom 
and a white cloudy mass floating on  the surface. Tests 
for stability and  potency have indicated that when 
stored at 4-8°C in a refrigerator, loss of potency is 
minimal for six months. Thereafter, there is  a rapid drop 
in potency (Vipulasiri et al.  1982; Chandrasekaran et al. 
1987). Gomis et al.  (1989), experimenting with 
vaccines containing varying percentages of the 
emulsifying agent lanoline, found that stability 
improved with increase in  lanoline content. Active 
mouse protection potency also showed a similar trend 
up to six months but, whilst higher lanoline content 
(8%) improved stability for up to one year,  potency 
appeared to drop after six months. Both  stability and 
potency were influenced by storage temperature, 
4-8°C being better than room temperature (17-33°C). 
In general, vaccines can  be kept for about six months. 
It was found, however, that vaccine formulae with 
higher amounts of lanoline had a higher viscosity, which 
made them difficult to inject. Gomis et al.  (1989) found 
that vaccines containing equal volumes of bacterin and 
oil with 4%, 6% and 8% lanoline had viscosities of 110, 
350 and 600 centipoise at 25°C. Thus,  thin emulsion 
vaccines produced with low lanoline contents must be 
stored at 4-8°C in a refrigerator, and  used within six 
months. Storage at room temperature for even two 
weeks caused  an approximately 20% drop in  potency in 
the low lanoline emulsions, whereas in  vaccines 
containing 8% lanoline, the corresponding drop was 
less than 3% (Gomis et al.  1989). 
There is  no information on  the influence of storage 
temperature and time for vaccines containing 
emulsifying agents other than lanoline, or for the alum 
precipitated or aluminium hydroxide gel vaccines. 
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Overview 
Rationale 
The rationale for routine vaccination programs is 
evident from active surveillance studies which show 
that in endemic areas significant numbers of cattle and 
buffalos die from haemorrhagic septicaemia. 
Vaccination program 
A strategic vaccination program must be based on a 
sound knowledge of the epidemiology of HS and the 
quality of vaccines used and good vaccination coverage 
are essential criteria for success. 
Recommended vaccine and schedule 
The recommended vaccine is  a well-prepared oil 
adjuvant vaccine. The vaccination schedule should 
include vaccination of pregnant dams and four- to six-
month-old calves followed by booster doses at one year 
and annually thereafter. 
Evaluation of vaccination programs 
Vaccination programs can be evaluated by 
investigations into adverse reactions, reduction in 
occurrence following vaccination and measurement of 
the antibody response following vaccination. 
Simultaneous vaccination with other diseases 
Simultaneous vaccination and the use of combined 
vaccines of haemorrhagic septicaemia with foot-and-
mouth disease, rinderpest or black quarter have been 
found to be effective. 
8.1  Rationale 
In endemic areas, there are no longer massive 
epidemics of haemorrhagic septicaemia (HS).  Losses 
occur mainly in  a specific age group (young adult 
animals) and are restricted to a small  number each year. 
Such  insidious losses are often not notified or positively 
diagnosed, yet the cumulative losses over a period of 
time can  be considerable.  In  nonendemic areas within 
endemic countries, on  the other hand, occasional 
massive outbreaks occur.  Neither of these scenarios 
appears to justify routine prophylactic vaccination. 
The real  situation, in  terms of economic losses, only 
becomes apparent when a detailed study is  made.  In 
one such  study it was found that in  the endemic areas 
of Sri  Lanka 15.2 % of buffaloes and 8.1 % of cattle 
died of HS  (De Alwis and Vipulasiri 1980). Similarly, 
another study of indigenous buffaloes in  Sri  Lanka 
(Kumaratileke and  Buvanendran 1979) showed that 
approximately one in every five buffaloes born die 
before reaching adulthood and that two out of every 
three such  deaths is due to HS. 
These findings provide justification for a prophylactic 
program. Projecting the results to 12 endemic districts 
in  Sri  Lanka gives 180000 cattle and  buffaloes lost 
each  year.  If the carcase value is 500 Sri  Lankan rupees 
per animal, this amounts to an annual loss of 90 million 
rupees (equivalent to US$6 million). In the early 1980s, 
the total cost of administering a dose of vaccine to an 
animal in  mass vaccination campaigns was estimated at 
1.5 Sri  Lankan  rupees.  Thus the annual cost of 
vaccinating 1.7 million cattle and  buffaloes in these 12 
districts would be around 2.5 million rupees 
(US$166,000) (De Alwis 1983,1986). Hence, the 
benefits from such vaccination are very evident, even if 
losses were reduced  by only 50%. 
With continued vaccination using a good quality 
vaccine and a high coverage (70% or more), outbreaks 
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outbreaks, veterinary administrations in  many countries 
are often asked  whether there is a need to continue 
vaccination. The answer is  not easy.  Where there is  no 
vaccination, the natural epidemiological cycle works, 
with some young, previously unexposed, animals dying 
each  year,  while others build up immunity. In  this 
situation, the disease smoulders without major flashes. 
With continued regular vaccination, no outbreaks occur 
and the natural cycle will cease to operate. However, 
animals will become more and  more dependent on the 
vaccine for immunity. If vaccination  is then 
discontinued for a few years, a susceptible stock will 
build up and  if any focus of infection is  activated (say 
through an  activated carrier or a new introduction), an 
explosive outbreak can  occur. Veterinary authorities in 
endemic countries therefore continue routine, 
prophylactic vaccination, whilst a few countries practise 
ring vaccination when outbreaks occur. 
8.2  Planning a 
Vaccination Program 
In  order to achieve a high degree of success, a vaccination 
program  needs to satisfy the following criteria. 
8.2.1  Vaccine quality 
and administration 
The quality of vaccine is of utmost importance. A 
highly potent vaccine with reasonable shelf life and 
duration of immunity should be available.  It should be 
a sufficiently free-flowing liquid for easy injectability. 
Oil adjuvant vaccine based on the newer formulae 
satisfies these requirements to a large extent. 
Proper storage facilities should be available. Vaccines 
should be stored in a refrigerator at 4-8°C. Before use, 
bottles of vaccine should be placed at room 
temperature overnight (because it is difficult to inject 
vaccine removed from the refrigerator just before use). 
Unused bottles of vaccine should be returned to the 
refrigerator at the end of each day's vaccination and  in 
any event not later than two to three days. 
Proper syringes and  needles should  be  used for 
administering the oil adjuvant vaccine.  Nylon syringes 
of 5-mL capacity fitted with centre metal nozzles are 
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useful.  Lock-type needles should be  used so that they 
will remain with the syringe and not the animal. They 
should be  of 14 or 15 gauge and  1-1.5 inches (about 
2.5-3.5 cm)  in  length. The suitability of the syringes 
and needles is  an  important determinant of the number 
of vaccinations possible in a day, which in turn 
determines the cost of a single vaccination. 
8.2.2  Vaccination coverage 
Good vaccination coverage is very important. It is 
generally believed that if a coverage of 70% or higher 
is achieved, the chances of an  outbreak are minimised. 
In  most endemic countries, the disease occurs in 
situations where husbandry practices are poor.  In  such 
circumstances there will be a certain proportion of 
animals that are inaccessible to the animal health 
services.  Steps must therefore be taken to improve the 
infrastructure so  as to improve accessibility, and every 
effort must be made to attain a near 100% coverage 
among accessible animals.  In  a questionnaire-based 
field study in  Sri  Lanka (De Alwis 1983,1986), 
information received from vaccinators revealed that 
lack of farmer cooperation was the biggest constraint 
to the program. Farmer education and the actual 
demonstration of success of vaccination in the field will 
help to win their cooperation. 
It must also  be remembered that farmers in  most 
developing countries where the disease  is endemic are 
not primarily livestock farmers.  Livestock are a 
supplementary entity that support their main industry 
such  as cultivation of rice or other crops. They provide 
draught power, dung (which serves  as  manure) and 
some  milk and  meat. The timing of vaccination 
programs must therefore take into consideration the 
crop-related cycle of activities, so that the farmers are 
free to present the animals for vaccination. 
Adequate personnel and  mobility should  be available 
so that an  entire vaccination program in  a given region 
can  be completed within a short period of two to three 
months. Where free-roaming animals are paddocked 
for the night, the best time to vaccinate is  early 
morning, before the animals are sent out of the 
paddocks. A movable cattle crush, which can  be 
dismantled and assembled anywhere,  is  a useful asset. 8.3  Vaccination Schedules 
Different countries have developed different 
vaccination schedules, depending on  the type of 
vaccine used,  ease of access to animals and other 
practical considerations. 
Until 1994, the aluminium hydroxide gel vaccine was 
the only vaccine used  in Thailand, with a twice-yearly 
vaccination program. About 7 million doses of vaccine 
were produced annually for the cattle and  buffalo 
population of approximately 10 million and coverage 
was around 30%. Since  1994 the aluminium hydroxide 
gel vaccine has  been  replaced  by the oil adjuvant 
vaccine, with a coverage of around 45% (Atti 1996). 
India produces around 70 million doses of vaccine 
annually. Of this only a small percentage is of the oil 
adjuvant type, and that is  used only for superior stock 
in organised farms. Elsewhere, once-yearly vaccination 
is  practised, with mass-produced alum precipitated 
vaccine administered before the rainy season.  In  Nepal, 
the principal immunising agent is also the alum 
precipitated vaccine. Around half a million doses are 
produced annually and are used for ring vaccination in 
outbreaks, and  not on a prophylactic basis. 
Laos produces both oil adjuvant and aluminium 
hydroxide vaccine, but coverage is  less than 20%. 
Myanmar routinely produces six to seven  million doses 
of alum vaccine for its cattle and  buffalo population of 
approximately 11.5 million. Malaysia uses broth 
bacterin in the face of outbreaks, followed by the oil 
adjuvant vaccine two to three weeks later. The latter 
vaccine is the one used for annual vaccination on a 
prophylactic basis. 
In  Indonesia, the oil adjuvant vaccine is the predominant 
vaccine used. Approximately 10 million doses are 
produced annually for the susceptible stock of 13 million. 
In  Sri  Lanka, currently, the only prophylactic agent used 
is the oil adjuvant vaccine;  mass vaccination programs 
are carried out over a three-month period from June to 
August to provide peak immunity during the following 
wet season. This procedure has resulted in the shift of 
peak incidence of the disease from October-November 
to a lesser peak in January-February, reflecting the 
effects on  calves that were too young for vaccination in 
the June-August period. A small quantity of alum 
vaccine is always held in stock in Sri  Lanka for use during 
outbreaks. Cambodia, as yet, has only a modest-scale 
vaccine laboratory; it produces around one million doses 
of vaccine of which two-thirds is of the oil adjuvant type 
and the balance is alum vaccine (FAO 1979; ACiAR 
1993 - Country Reports). 
8.4  Recommended 
Vaccine and Schedule 
To date, the recommended prophylactic agent has been 
a well-prepared oil adjuvant vaccine, with a minimal 
bacterial dry weight of 2 mg.  It should provide a 
minimum of 4 log units protection in  mice.  Experimental 
evaluation of the duration of immunity conferred by 
such  a vaccine has yielded slightly variable results: 
•  Bain  (1956, 1959) reported 8 to 12 months 
immunity with the oil adjuvant vaccine; 
•  animals immunised using the oil adjuvant vaccine in 
India were protected when challenged nine months 
and 20 days later (Dhanda et al.  1958); 
•  Geneidy et al.  (1967) found that in  Egypt the 
vaccine conferred one year of immunity; 
•  almost one year of immunity was reported in 
Malaysia (Thomas et al.  1969); 
•  in  India, immunity lasting two years and four 
months was claimed for an  'oil adjuvant yeast 
extract agar wash vaccine' (Dhanda and Sen  1972); 
•  an experimentally produced vaccine in 
Thailand conferred one year of immunity 
(Neramitmansook 1993). 
Sri  Lanka and  Indonesia have found that their oil 
adjuvant vaccines provide six to nine months protection 
(FAO 1979; De Alwis et al.  1978). De Alwis et al. 
(1978) have made an  extensive study of the immunity 
conferred by the alum and oil adjuvant vaccines under 
different situations in endemic as well as  nonendemic 
areas.  Besides lack of standardisation, this study 
highlighted numerous factors that might influence the 
observed duration of immunity. When the oil adjuvant 
vaccine was used, animals in endemic locations were 
solidly protected from challenge at 12 months. Animals 
in  nonendemic areas, which had  been completely free 
of the disease for at least 10 years previously, gave 
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only partial protection at nine months and  no 
protection at 12 months. 
It is therefore reasonable to conclude that the extended 
immunity among animals in  endemic areas  is  the result 
of subsequent exposures that serve as  boosters. This 
was clearly shown in  one of the experiments of De 
Alwis et al.  (1978) when immunity levels in 
experimentally vaccinated animals were boosted when 
an  outbreak occurred among other animals in close 
proximity to the experimental animals. 
De Alwis et al.  (1978) also found that when calves 
ranging from two to five months were vaccinated, the 
younger calves  responded poorly to vaccination, 
whereas there was a markedly higher response among 
animals over 3.5 months of age.  It is  presumed that 
animals below this age possess maternal immunity that 
interferes with the development of active immunity, 
and the calves may also be immunologically 
incompetent. It has also  been observed that calves 
under six months of age have a very low susceptibility 
to HS  (De Alwis et al.  1976). Based  on all these 
findings it was concluded that when calves of four to 
six months of age were given primary vaccination with 
oil adjuvant vaccine and  maintained under conditions 
free from further exposure, they were protected from 
challenge for six to nine months. 
The currently recommended vaccination schedule using 
oil adjuvant vaccine is therefore as follows: 
•  vaccination of pregnant dams at six to seven  months 
of pregnancy, to ensure peak antibody levels at the 
time of parturition and  provide maximal maternal 
immunity; 
•  primary vaccination of calves at four to six 
months of age; 
•  in farm animals, a booster dose six  months later and 
annual vaccination from then on; and 
•  in free-range animals that cannot be selected and 
restrained for vaccination, annual vaccination of all 
animals over four months of age,  preferably two to 
three months before the outbreak season  (where 
such  seasonality exists); where possible, all  calves 
under one year of age should be vaccinated six 
months later (i.e.  between two annual mass 
vaccinations) . 
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Such  a schedule, if practised rigidly with a coverage 
of over 70%, will help to eliminate losses to a 
considerable degree. 
8.5  Evaluation of 
Vaccination Programs 
When a vaccination program is implemented in a 
defined area over a period of time, the important 
criteria for measuring its success are: 
•  the absence of any adverse reactions in 
vaccinated herds; 
•  the extent of reduction in occurrence of the disease; 
•  levels of antibody following vaccination. 
These criteria are discussed further below. 
8.5.1  Adverse reactions 
Post-vaccination shock 
Post-vaccination shock reactions have been  reported in 
a small  proportion of animals,  particularly with dense 
broth bacterins or the alum precipitated or aluminium 
hydroxide gel vaccines. The frequency of such  reactions 
ranges from 0.1 % to as  high as  10%. The occurrence of 
reactions is irregular and therefore cannot be 
reproduced predictably. Shock  reactions are virtually 
absent with the oil adjuvant vaccine, but the 
inadvertent injection of cracked emulsions has produced 
reactions (Bain et al.  1982). Shock reactions may occur 
with some batches of vaccine but not with others.  In 
Thailand, it was once reported that of a batch of 206 
animals given the aluminium hydroxide gel vaccine, 16 
developed shock reactions (De Alwis 1989). 
Animals may show symptoms within a few minutes of 
vaccination, or sometimes after several  hours delay.  In 
the acute fulminating type of reaction, animals show 
laboured breathing (dyspnoea), sweating, 
incoordination, prostration, occaSionally violence, severe 
colicky symptoms, blood stained frothy discharges from 
the mouth and  nostrils, and sometimes anal discharges, 
followed by death. Less severe cases may merely show 
dullness, increased respiration, mild dyspnoea, frothing 
and diarrhoea. On postmortem examination, fatal cases 
show pulmonary oedema, congestion of the intestines, endocardial haemorrhages and  pericardial and  pleural 
effusions. The entire syndrome resembles one of 
anaphylactic shock, and is comparable with the picture 
observed in endotoxic shock. 
There are many factors that may account for post-
vaccination shock reactions. The age of the culture may 
be important; when very young cultures are used  in 
vaccine production, reactions appear to be more 
frequent. The post-precipitation procedure may also be 
important for the alum preCipitated vaccine because if 
the supernatant is  removed after the bacterial cells are 
precipitated with alum and the cells are washed and 
resuspended  in  formalinised saline, the occurrence of 
shock reactions is virtually eliminated. There are no 
controlled trials to establish these observations but it 
seems likely that some surface antigens that are 
liberated into the medium and found in the 
supernatant may be causing the reaction. Other 
extraneous protein material remaining in the growth 
medium may a.lso  be responsible.  In  most conventional 
media, which contain approximately 2% of protein 
material, there is very little decrease in  protein during 
growth, as evidenced by protein estimations on the 
medium before growth and the supernatant after 
growth (M.C.L. De Alwis, unpublished data). Thus, a 
considerable amount of free protein remains with the 
vaccine,  unless the supernatant is  replaced by 
suspending the cells in fresh formalinised saline. 
Injectable antihistamines and adrenaline have been  used 
for the treatment of postvaccinial shock with varying 
degrees of success. 
Local reactions 
In  some animals, following vaccination, lumps appear 
at the site of inoculation. This occurs very rarely and 
irregularly. A small proportion of the lumps are 
abscesses caused  by infection entering through the 
pierced skin.  In situations where abscesses occur 
frequently, it may be necessary to sterilise the skin 
surface of animals at vaccination (this is  not usually 
necessary unless there are visible deposits of mud or 
dung). More commonly, the lumps that appear are 
hard and  fibrous, and arise when the vaccine which 
should  be injected into deep intramuscular tissue leaks 
out into subcutaneous tissues. 
In some animals, the administration of the alum 
precipitated vaccine results in a local reaction that 
gradually leads to induration resulting in  a persistent 
hard lump (Nagarajan et al.  1975). These authors 
compared the normal alum vaccine at a pH  ranging 
from 5.0 to 5.4 with a neutralised vaccine.  In  rabbits, 
neutralisation of the vaccine prevented local reactions. 
In cattle and  buffaloes, it reduced the reaction  but did 
not eliminate it altogether. 
Abortions 
There appears to be a belief among livestock farmers 
that vaccination during pregnancy could result in 
abortions. With regard to HS vaccination, there is little 
evidence to prove or refute this belief. M .C.L.  De Alwis 
(unpublished data) vaccinated buffaloes in advanced 
pregnancy with doses of up to 10 mL of the oil adjuvant 
vaccine. Twenty buffaloes receiving the highest dose, 
which is  more than three times the recommended dose, 
did not abort.  In fact, they did not produce any obvious 
adverse reactions, though detailed measurements of 
physiological parameters were not made. 
Physiological reactions 
Limited information is available on the effect of 
vaccination against HS on physiological parameters. 
Pandey et al.  (1987) used  what is described as an 
'anaculture' of HS produced by the Institute of 
Biological Products in Mhow, Madhya Pradesh, 
India on 300 animals consisting of pure and cross-bred 
Tharpaker cattle and  Murrah buffaloes. They observed 
a 1.2-1.5% rise  in the rectal temperature at 24 hours 
after vaccination, dropping to normal levels at 
48 hours except in  buffaloes, where it persisted a little 
longer. The percentage drop in  milk yield was 4.8 to 
8.3 and the feed  intake dropped by 6.2 % at 24 hours 
after vaccination. 
Shah  (1998) investigated the effects of administering a 
single dose (2  mL) and a double dose of oil adjuvant 
vaccine on five healthy buffalo calves six to eight 
months of age.  He found approximately a 2°C rise  in 
body temperature six hours after vaccination, which 
had  returned to normal levels at 24 hours. The 
respiratory rate and feed  intake remained unaffected. 
Two calves showed a mild transient depression at six 
hours after vaccination. 
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occurrence after vaccination 
All countries where HS  is  endemic agree that using 
vaccination as  a control measure has reduced the 
occurrence of the disease.  Considering the number of 
'reported deaths', which might be a rough guide to the 
trend, India recorded a drop in deaths from between 
30000 and 40 000 per year in  the 1950s to under 
10000 per year in  the 1970s; this was attributed to 
vaccination. Laos reported a reduction of deaths by 
around 50% from 1981 to the end of the decade. Sri 
Lanka recorded a steady reduction from 1170 reported 
deaths in  1981  to 269 in  1990 (FAO 1979, 1991; 
Country Reports). 
In  order to accurately assess the efficacy of vaccination 
on disease occurrence, organised studies have to be 
carried out. The results of two such  surveys from Sri 
Lanka serve as  reliable indicators (De Alwis and 
Vipulasiri 1980; Wijewardana et al.  1995). 
The first study covered the th ree years from 1978 to 
1980. The recommended vaccination program was 
prophylactic vaccinations for all cattle and buffalo herds 
throughout the year.  However, this was not achieved in 
all  cases and the actual vaccination status of the 
animals fell into three categories: 
•  category A - 36.5% of buffalo herds and 34% of 
cattle herds received  prophylactic vaccinations 
throughout the year,  using an alum precipitated 
vaccine that was  known to give only three to four 
months of protection; 
•  category B - 24.4  % of buffalo herds and  15 % of 
cattle herds were vaccinated only when outbreaks 
were reported in  neighbouring herds; 
•  category C - in the rest of the herds there was no 
vaccination, either prophylactic or during outbreaks. 
Two parameters were estimated and compared for the 
three categories of herds:  percentage of herds affected 
with the disease; and  mortality in affected herds. 
In  category A, the percentage of herds affected, in 
both species (cattle and buffaloes), was lower than 
those affected in category C,  and this difference was 
statistically significant. On the other hand, there was 
no significant difference in  mortality between 
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categories A and C.  In  contrast, for buffaloes in 
category B,  the mortality was significantly less. 
A number of interesting interpretations arise from these 
observations, which can  be related to the quality of the 
program itself. Prophylactic vaccination resulted in a 
significant reduction in the percentage of herds 
affected, but not in the mortality in  affected herds. 
Thus, this type of vaccination may have helped to 
prevent the first case from occurring, but did not stop 
the spread of disease within the herd after it had  been 
introduced. The first case of disease occurs as a result 
of a carrier shedding a few organisms, or a few viable 
organisms being introduced by some means from 
outside the herd. Vaccination therefore appeared to 
provide some immunity against this lower level of 
infection (as with the first case)  but did not protect 
against the heavy burden of infection that occurred 
when the disease broke out within the herd. 
A second interesting observation is the significant 
reduction in  mortality in  category B,  where the 
buffaloes were vaccinated when disease had  broken 
out in  neighbouring herds. This  is a reflection of the 
short duration of immunity, which was at its peak at 
the time of outbreak in  category B,  but not in category 
A,  since buffaloes were prophylactically vaccinated 
throughout the year with no regard to season, or 
relationship to outbreaks. 
During the 1980s, based  on  lessons learnt from this 
study, the Sri  Lankan vaccination strategy was 
changed. A good-quality oil adjuvant vaccine was 
substituted for the alum vaccine.  In  place of 
vaccination throughout the year,  a seasonal  intensive 
vaccination program was introduced in  the endemic 
areas,  during a three-month period immediately before 
the rainy season.  After a 10-year period of 
implementation of such a prophylactic vaccination 
program, a new survey was carried out, using the same 
methods as those used  in  the previous study for data 
collection and analysis.  In  the study area,  the 
prophylactic vaccination coverage was 72.5%. The 
disease status in  the entire area of study before and 
after the improved control program was implemented 
was compared, using data from the 1980 and  1995 
studies. The percentage of herds affected dropped 
from 48.4% to 14.7% in  buffaloes and from 38.5% 
to 17.5% in cattle. The mean mortality in  outbreaks 
dropped from 24.2 % to 3.4  % in  buffalo herds and from 17.8% to 4.0% for cattle. The value of a well-
formulated vaccination program based  on a sound 
knowledge of the epidemiology of the disease in  a 
country was very evident from these findings. 
8.6  Measuring Immunity 
Following Vaccination 
8.6.1  Antibody-mediated immunity 
A variety of tests have been  used  in different countries 
to measure immunity in vaccinated animals. These 
include the passive  mouse protection test (PMPT), 
indirect haemagglutination (IHA) test and antibody 
enzyme-linked immunosorbent assay (ELISA).  The tests 
have been  used to study the duration of immunity in 
vaccinated animals in  controlled experiments, as  well as 
for evaluating herd immunity under natural field 
conditions. In  some instances, attempts have  been 
made to correlate the results of these tests to the 
outcome of direct challenge. 
Passive mouse protection test 
The PMPT involves inoculation of mice with sera of 
vaccinated cattle and challenging them with a defined 
dose of live,  virulent organisms. The tests of different 
workers vary as  regards number of mice used, volume 
of serum etc. The tests are controlled by protecting 
control groups of mice with sera of unvaccinated cattle 
from the same location and also using prevaccination 
serum from the same animals. Bain  et al.  (1982) used 
0.5 mL of serum for protection and 100 LD50 of 
virulent organisms for challenge. Survival of even one 
mouse of a group of five was  regarded as an  index of 
protection, provided all of an  equal number of controls 
died. De Alwis et al.  (1978) used three mice per cattle 
serum sample tested, with an  equal number of 
controls. Gomis et al.  1988/1989 protected groups of 
10 mice with 0.5 mL of pooled sera per mouse and 
expressed protection as the percentage surviving (out 
of 10). Johnson et al.  (1993) and  Natalia et al.  (1993) 
used five mice per serum sample with two mice as 
controls and used 0.2 mL of serum in serial  dilutions for 
protection. Their results were expressed as a protective 
index (PI), where PI=log2  serum dilution + proportion 
of mice surviving. Using the Burmese 'I<atha' strain and 
a buffalo B strain to immunise cattle, Johnson et al. 
found 93 % and 72 % protection, respectively, for 
homologous challenge, even when the sera were 
diluted 1  :32.  In a series of cross-protection tests using 
different serotypes of Pasteurella multocida these 
workers found the PMPT to be highly specific. Diluting 
the sera helped to make the test more discriminatory, 
eliminating any low degree of cross-protection. Natalia 
et al.  (1993) found 95% of their vaccinated animals to 
be PMPT positive using as their cut-off point 20% 
protection, which was the smallest measurable 
protection level,  with one of the five mice surviving. 
Their test sera were derived from cattle immunised with 
an  oil adjuvant vaccine.  It may be  recalled that 
originally the PMPT was  used for serotyping of strains 
of P.  multocida (Roberts 1947). In this test, undiluted 
hyperimmune rabbit serum was used.  By this 
classification, what is  now known as the Asian type 
(B:2), the African type (E:2) and the Australian non-HS 
type (B:3,4, then known as  11 :B) were grouped 
together as  Roberts type 1. If serum dilutions had  been 
used, it may have been  possible to differentiate 
between these types. 
Whilst many workers stili  rely on PMPT for the 
demonstration of immunity to vaccination, 
Chandrasekaran et al.  (1991, 1993a, 1994b) reported 
that in buffaloes there was no correlation between results 
of direct challenge and  PMPT. The basis for this absence 
of a correlation is still obscure. These workers postulated 
that one possible explanation may be the absence of 
specific receptors on the mouse phagocytic cells for the 
predominant buffalo isotope(s). This theory is supported 
by the observation that sera from immune mice not only 
passively protected nonimmune mice but also exhibited a 
low dose-response relationship. More recently De Alwis 
et al.  (1998), experimenting with a live aerosol vaccine, 
using a low virulent type B:2  mutant, found that, at 11 
months postvaccination, 40% of the animals showed 
passive mouse protection; only 20% survived direct 
challenge one month later. The B:3,4 deer strain live 
intranasal vaccine developed in Myanmar on the other 
hand provided protection to 82.5% passively immunised 
mice when 40 weeks postvaccination serum was used. All 
of the cattle survived challenge at 52 weeks. 
Thus, the reliability of PMPT as an  absolute indicator of 
protective immunity in all instances (natural exposure 
and vaccination using live and  inactivated preparations) 
needs to be investigated further. 
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The I  HA test, which was originally devised for 
serological typing of P.  multocida (see Section 5.7.2 
and Appendix 2),  has also been  used to detect 
immunity in  vaccinated animals.  In  animals which have 
been exposed to natural infection, it has been  observed 
that there is a strong IHA response, antibodies 
detectable by this test appearing within 10-14 days of 
exposure and  rising to a peak in three to four weeks 
(De Alwis 1982b; De Alwis et al.  1990). In  vaccinated 
animals, however, the IHA antibody response is  poor. 
De Alwis et al. (1978) found that when protection to 
challenge was 100% (n=6), the percentage of PMPT 
positives was 60% (n=1 0), whereas only 27% of 
vaccinates showed IHA antibody (n=26) six  months 
after administration of an oil adjuvant vaccine and 
reared  under conditions free from natural exposure. 
Chandrasekaran et al.  (1993a) found that of 12 
buffaloes that resisted direct challenge, only three 
showed measurable IHA titres. It appears that, whilst 
the IHA test is effective in detecting antibodies 
produced in  response to natural exposure, its sensitivity 
in detecting response to inactivated vaccines, with or 
without adjuvants, is  poor (Chandrasekaran et al. 
1993a,b, 1994a,b). It is also noteworthy that in  the 
experiments of De Alwis et al.  (1998), when all of a 
group of 10 young buffaloes were showing IHA titres 
ranging from 1 in  10 to 1 in  160 (mean 1 in  100) at 
11  months after vaccination, only two animals survived 
challenge one month later.  In these studies, a live 
aerosol vaccine produced from a low virulent type 8:2 
mutant was  used  as an immunising agent. When a 
similar aerosol vaccine incorporating the deer strain 
(serotype 8:3,4) was  used  in Myanmar, 80% of animals 
(n=46) showed IHA titres to type 8:2  at 30 weeks 
postvaccination, and  none showed IHA antibodies at 
40 and 52 weeks. The titres were also  higher 
(approximately 1 in 3000) up to five weeks, dropping 
to a mean of 1 in 30 at 14 weeks. All the animals (n=8) 
survived challenge at 52  weeks. 
The fact that 8:3,4 vaccinated cattle developed 
antibodies detected by 8:2 coated erythrocytes 
provided evidence that the response detected was to 
the outer cell  components (loosely termed 'capsular'). 
Thus, the IHA response to 8:2, in animals given a 8:2 
mutant vaccine and a 8:3,4 vaccine, are conflicting. 
With the former,  IHA titres perSisted  but animals failed 
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to resist challenge. With the latter, IHA titres 
disappeared early,  but animals resisted  challenge. 
Absence of correlation between IHA titres and survival 
to challenge was also reported by Singh et al.  (1994). 
The overall information on the IHA response appears to 
indicate that it is a humoral response directed against 
the outer cell  components, which is  more pronounced 
when the animal is  exposed to live organisms, and 
perhaps in  vivo multiplication, than when inactivated 
antigens are used.  Its reliability as  an index of 
protection in  all  instances needs to be  reassessed. 
Enzyme-linked immunosorbent assay 
ELISA,  which has been developed and applied to HS 
over the past decade or so,  is  now available as a 
screening test for detecting humoral response to 
vaccination. Once the test is standardised and 
established in  a laboratory, it appears to be more suited 
than most other tests for screening large numbers of 
serum  samples.  Many workers (Johnson et al.  1988, 
1989; Johnson et al.  1993; Chandrasekaran et al. 
1993a,b; Natalia et al.  1993) have successfully used the 
test to measure the response to vaccination (see 
Appendix 3). 
The test devised by Johnson and  his co-workers (HS-
antibody ELISA)  used a boiled antigen of a P.  multocida 
type 8 strain similar to that used  by Heddleston et al. 
(1972) in their somatic serotyping technique. Such a 
preparation would contain crude lipopolysaccharide 
extracts. They were able to demonstrate high titres in 
animals immunised with an  oil adjuvant vaccine 
prepared from the homologous strain. Chandrasekaran 
et al.  (1993a,b), comparing several serological tests and 
direct challenge in  buffaloes, found that whilst PMPT 
and IHA results did not correlate with protection to 
direct challenge in  buffaloes, there was a marked 
correlation between the ELISA titres and survival 
following challenge.  Natalia et al.  (1993), on the other 
hand, using the same  HS-antibody ELISA technique to 
evaluate immunity in  cattle following immunisation 
with an  oil adjuvant vaccine prepared from the same 
strain, found that there was a significant correlation 
between HS-antibody ELISA results and  PMPT (r=0.76; 
P<0.01). No studies on direct challenge were carried 
out by these workers. Neramitmansook et al.  (1990) an  HS-antibody ELISA 
test to measure the immune response in vaccinated 
cattle and  buffaloes and found that the ELISA titres 
correlated well with the results of direct challenge. 
Neramitmansook et al.  (1993) examined a large number 
of cattle and  buffalo serum samples by HS-antibody 
ELISA and  PMPT.  Here too, a close correlation was 
observed. They concluded that the ELISA was a more 
suitable test for assessment of immunity, compared with 
the more laborious and expensive PMPT. 
When evaluating the antibody response to vaccination, 
particularly involving large numbers of animals, most 
workers consider ELISA to be the most appropriate test. 
However, it must be noted that the specificity of ELISA 
in detecting either antigens or antibodies depends on 
the nature of the antigen preparation. If the supernatant 
of boiled cells  is used  (often referred to as  boiled 
antigen), it will fail to differentiate between types B:2 
and  E:2  since the boiled antigen contains the somatic 
component 2 (Heddleston et al.  1972). This  is 
particularly important in  countries where both strain 
serotypes exist. 
8.6.2  Cell-mediated immunity 
It is  generally believed that immunity to HS  is 
predominantly humoral. The contributory role of cell-
mediated immunity (CMI), however, cannot be 
discounted. This  is  an  area which has hardly been 
investigated. Verma and Jaiswal (1997) investigated 
the response to direct challenge, the humoral response 
and cell-mediated immune response in calves 
immunised with a multiemulsion vaccine. They used 
the leucocyte migration inhibition test (LMIT) as  an 
indicator of CMI (Timms 1974). The  LMIT was carried 
out according to the procedure described by 
Chaturevedi and Sharma (1981). It was found that 
there was  less than 20% migration inhibition during all 
pre- and post-challenge periods. The mean  per cent 
migration inhibition declined during 24-72 hours 
followed by an  increasing trend at 6 and  10 days. 
Thus, there was definite evidence of an  involvement 
of a CMI mechanism in  HS. 
It is significant to note that both humoral and cellular 
immune mechanisms are involved in  P.  multocida 
infection in chicken and turkeys (Dua and Maheswaran 
1978). Maheswaran and Theis (1979) reported that 
lymphocytes from cattle immunised with various strains 
of P.  multocida showed significantly higher stimulation 
indices when incubated with homologous antigen, 
suggesting the involvement of CMI. Thus, the extent 
to which CMI is  involved in the protection merits 
further investigation. 
8.7  Vaccination Failures 
Instances of vaccination failures, i.e.  outbreaks of 
disease despite vaccination, are not uncommon. The 
cause of these failures does not necessarily reflect on 
the quality of the vaccine.  If stringent quality control 
tests have been carried out and  proper methods of 
storage and  handling under tropical conditions have 
been observed, the 'vaccine quality' factor can  be 
eliminated. Other factors that may cause vaccination 
failures are described below. 
•  Vaccination coverage. A particular owner may 
achieve a high coverage (though not 100%) among 
his animals. However, if these animals mingle with 
large numbers of unvaccinated animals in  common 
pastures, they are at risk,  particularly the few 
unvaccinated animals in  his herd. 
•  Age at vaccination. Calves vaccinated too young 
may succumb to disease up to the age of five to six 
months. This  is  due to the presence of maternal 
immunity (Sheikh et al.  1994), which presumably 
interferes with the development of an  active immune 
response to the vaccine.  De Alwis et al.  (1978) found 
that when calves  in the age range of two to five 
months were vaccinated, the number of calves under 
3.5 months that developed detectable antibody titres 
was low in comparison with 72 % of calves over 
3.5 months that responded. 
•  General condition of animals at the time of 
vaccination. Weak, undernourished calves may not 
respond optimally to vaccination. Specific nutritional 
factors such  as deficiencies of vitamin E and 
selenium are associated with poor immunity and 
susceptibility to disease. 
•  Other diseases.  Although there is  no confirmed 
evidence, it is suspected that trypanosomiasis and 
theillerosis diminish the immune response to 
vaccination (Phan  et al.  1996). 
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among vaccinators to ascribe the entire blame to the 
vaccine.  It is therefore desirable for all vaccine 
manufacturing laboratories to retain samples from each 
batch  under optimal conditions; these can  be tested 
and the potency rechecked after the relevant period of 
storage in  case any dispute occurs. 
8.8  Simultaneous and 
Combined Vaccination 
The need to administer the vaccine against HS 
simultaneously with other vaccines arises  in  situations 
where the disease coexists with other communicable 
diseases such  as foot-and-mouth disease (FMD), 
blackleg, anthrax and  rinderpest. In tropical countries 
where these diseases exist, it is  not possible to round 
up the animals and  restrain them several times during 
the year for vaccination. Therefore the ability to 
administer more than one vaccine simultaneously is an 
advantage. Simultaneous vaccination against HS and 
FMD is  practised in Malaysia, Thailand and Sri  Lanka. 
Whilst the practice of simultaneous vaccination has 
become popular in  many countries, production and use 
of combined vaccines appear to be  restricted  largely to 
experimental work. It appears that the technologies 
required for their production need to be perfected, 
particularly for large-scale production. Further, the 
combinations required  in  different countries vary 
depending on the priority status given to each  disease 
in  the respective countries. 
8.8.1  HS and FMD vaccination 
The serological response to simultaneous vaccination 
was studied by Joseph and  Hedger (1984) in Malaysia. 
A total of 104 cattle consisting of calves and adults were 
divided into three groups. Two groups were given the 
HS and the FMD vaccines individually, and the third 
group was given the two vaccines at two different sites 
simultaneously. Response to FMD vaccine was estimated 
by a virus neutralisation test, and that to HS  by the 
PMPT and the IHA test.  No difference in response was 
observed between the groups. The  HS vaccine was of 
the oil adjuvant type, incorporating a Carter type B 
strain. The FMD vaccine was a monovalent 0  type, 
inactivated aluminium hydroxide gel adsorbed vaccine. 
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In Thailand, inactivated aluminium hydroxide gel 
vaccines against both diseases are administered to 
cattie, twice yearly.  Such practices may be prevalent 
in other countries as well. 
A combined vaccine against HS and FMD was 
experimentally developed and tested in  rabbits (Afzal 
and Muneer 1990). This water in  oil emulsion vaccine 
gave protection to rabbits against both diseases 
comparable with the protection afforded by the two 
vaccines administered separately to rabbits.  Since these 
two diseases coexist in  many Asian countries, the 
technology for commercial production of such  a 
vaccine will have a vast potential provided that the 
different serotypes of the FMD virus prevalent in 
different countries can  be incorporated. 
8.8.2  HS and rinderpest vaccination 
Simultaneous vaccination against HS and rinderpest has 
been tested in cattle in  Egypt, on a limited scale using 
small groups of four animals. The vaccines used  were a 
live rinderpest vaccine at 200 TClD50 (median tissue 
culture infective dose) and an  inactivated HS vaccine 
(2  mU. Virus neutralisation and  IHA tests were carried 
out to measure serological response to HS and 
rinderpest, respectively. There was no difference, 
whether the vaccines were administered singly or 
simultaneously (Osman et al.  1990). 
8.8.3  HS and blackleg/black quarter 
Combined vaccines against HS  and  other diseases have 
also been  used  in  many countries. The most common 
such vaccine is the one combined with blackleg, used 
mainly in  India (Sinha and  Prasad  1973; Srivasthawa 
et al.  1976). Sinha and Prasad tested the immune 
response to different combinations of various types of 
HS and  black quarter vaccines. These were plain broth 
bacterin, alum precipitated broth bacterin, alum 
precipitated agar wash vaccine and oil adjuvant agar 
wash vaccines for HS together with the black quarter 
broth bacterin either plain or with the respective 
adjuvants. Immunity was assessed  at three to four 
weeks by the PMPT and IHA tests for HS and  by direct 
challenge for both diseases.  Best results were obtained 
with the agar wash alum precipitated combined 
vaccine. This is  presumably due to the fact that the 
agar wash vaccine may have contained a higher concentration of organisms.  Duration of immunity was 
not studied. If tested a few months later, the oil 
adjuvant vaccine may have been found to be superior. 
Srivasthawa et al.  (1976) carried out a similar study, 
where several combinations of the two vaccines were 
tested.  In their experiments, whilst the IHA and  PMPT 
were carried out at different intervals, the challenge 
test was done on  day 79 and day 215 after 
vaccination. The best performance was with vaccine 
that contained a suspension of P.  multocida type B 
equivalent to Brown's opacity tube 16 (5 parts), 
aluminium chloride precipitated black quarter vaccine 
(10 parts), liquid paraffin (10 parts), and lanoline 
(1  part), mixed in  a Waring blender to give a stable 
emulsion. Reference is also made to the use of a 
combined HS and  black quarter vaccine in  Iran  (FAO 
1979; Country Report) 
8.9  Vaccination Costs 
In  most countries vaccination is the main disease 
control method. Thus, to determine the economics of 
disease control, the cost of vaccination must be 
weighed against the expected reduction in  losses. 
Many countries have calculated the cost of vaccine 
production but the method of calculating the cost 
varies between countries. Information on the cost of 
delivering the vaccine is  scarce.  In  most countries, HS 
vaccines are produced by government institutions and 
administered to animals under national disease control 
programs, free of charge to the animal owner. The 
costs of vaccine production reported by various 
countries are shown in Table 8.1. 
In Thailand it was estimated in  1989-89 that a change 
from the alhydrogel vaccine (two doses per year) to a 
single dose of an  oil adjuvant vaccine using lanoline 
increased the total vaccine cost per animal by 
approximately 75%. These estimates did not take into 
account the overheads. 
The formulation of vaccines significantly affects the 
cost.  For instance, substituting Arlacel A for anhydrous 
lanoline as the emulsifying agent increases the cost of 
this component 10-fold. Since the emulsifying agent is 
the most expensive item in  the formulation, this 
amounts to a nearly 100% increase in the cost per 
3 mL dose of vaccine, not counting the overheads.  Few 
countries produce HS vaccine for the market. In  the 
Philippines, vaccine produced by the government 
laboratories is marketed at US$0.11  per dose whereas 
a private vaccine company markets vaccine at 
US$0.52 per dose (ACIAR 1993). 
In  Sri  Lanka, HS vaccine is  produced centrally and 
distributed to the provincial veterinary administrations 
for use  in  accordance with a national disease control 
program formulated by the centre,  in  collaboration 
with the provinces. The vaccination program is also 
monitored from the centre. The cost of delivery of the 
vaccine varies from one province to another. An 
important determinant of this cost is the number of 
vaccinations a single vaccinator can  do in a day, and 
this depends primarily on  the herd size.  For large herds, 
more animals can  be covered  per day than for small 
scattered herds, which involve more travel. The delivery 
cost has been estimated to range between US$0.08 to 
0.1  per animal. Considering the value of animals saved, 
this expenditure on vaccination  is undoubtedly a 
worthwhile investment. In Thailand it has been 
estimated that the cost of immunising a single animal 
against HS  (including delivery cost) is 70 Thai baht 
(approximately US$2.40), including the vaccine cost 
and the cost of delivery. 
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a Approximate figures only: exact figures  depend on  factors such  as  costs of materials, power, water and wages;  depreciation of 
equiment, land and  buildings;  and  value of the local  currency. 
Source:  ACIAR 1993 
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Overview 
Vaccine characteristics 
The ideal vaccine must be economical to produce, 
stable under tropical conditions and easy to inject. As 
well, the production technology in endemic countries 
must be sustainable. Such a vaccine should not produce 
adverse reactions and should result in  a high level and 
prolonged duration of immunity. 
Vaccine research 
Research into new vaccines has been directed towards 
the use of other adjuvants, production of oil adjuvant 
vaccines of low viscosity, development of vaccines 
incorporating purified extracts, identification of 
immunogenic components and the development of live 
vaccines. Research carried out so far has indicated that 
no single component is  totally responsible for immunity. 
9.1  The Ideal Vaccine 
Most countries where haemorrhagic septicaemia (HS)  is 
endemic produce some type of vaccine and carry out 
vaccination programs. A considerable amount of 
research  has focused on a search for a better vaccine.  It 
is widely recognised that an ideal vaccine should have 
the following characteristics: 
•  easy and economical to produce, with sustainable 
production technology in  the endemic countries; 
•  stable for use  in  the tropics; 
•  easy to handle in the field with a consistency that 
makes it easy to administer; 
•  no adverse reactions; 
•  high level of immunity with a minimum delay after 
vaccination and lasting for at least a year. 
None of the vaccines developed so far satisfy all of 
these requirements. Attempts to find an  ideal vaccine 
have met with varying degrees of success,  but none 
has replaced the existing vaccines for routine 
prophylactic use. 
9.2  Improved Vaccines 
Attempts to produce better HS vaccines can  be 
classified into several groups: 
•  use of other adjuvants; 
•  production of oil adjuvant vaccines of low viscosity; 
•  production of vaccines based  on  purified extracts of 
the organism and on the identification of the 
protective antigens; and 
•  use of live vaccines. 
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In Africa, Bhatty (1973) produced a type 6:E vaccine 
using 2 % sodium alginate as  adjuvant. Comparative 
trials showed that this and the oil adjuvant vaccine both 
provided one year of immunity as  indicated by survival 
on  challenge.  In  Iran, a saponin-lysed vaccine was 
introduced in  the 1930s but was subsequently replaced 
by a saponin-formalised vaccine (FAO 1979). None of 
these vaccines have gained widespread acceptance. 
9.2.2  Improved oil adjuvant vaccines 
There have been several attempts to improve oil 
adjuvant vaccines by using new formulations to reduce 
viscosity to improve injectability, concentrating the 
antigen to permit small doses to be given, and  by using 
double emulsification to produce a thinner, more easily 
injectable vaccine. 
Reduced viscosity 
The proportion of lanoline in  the vaccine affects 
viscosity and injectability. The earliest oil adjuvant 
vaccines used  around 8% to 10% lanoline. 
Experiments in  Sri  Lanka indicated that stable 
emulsions could be prepared using equal volumes of a 
light mineral oil  and bacterin, with 4% lanoline, 
thereby reducing the viscosity. Viscosity has also been 
reduced  by incorporating Arlacei A as the emulsifying 
agent, together with Tween 80. A thin, stable emulsion 
was formed using 40 parts of broth bacterin, 55 parts 
of mineral oil (Marcol 52), 4 parts of Arlacel A and 
1 part of Tween  80 by weight (Neramitmansook 1993). 
Other emulsion formulae have used  newer, highly 
purified mineral oils and  emulsifying agents. The 
enhanced humoral antibody stimulating effect of 
vitamin E reported by other workers (Tengerdy 1980; 
Tengerdy et al.  1983) has even led to attempts to 
replace the mineral oil with a-d-tocopherol acetate 
(vitamin E) (Muneer and Afzal 1989; Muneer et al. 
1993). These  workers prepared three stable 
formulations of oil  adjuvant vaccines of low viscosity: 
•  formula 1 - 30 parts of Marcol 52, 10 parts of 
Montanide 888 and 30 parts of bacterin; 
•  formula  2 - 63  parts of Marcol 52, seven parts of 
Arlacel A and 30 parts of bacterin containing 5 % 
Tween 80; 
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•  formula 3 - 63  parts of a-d-tocopherol acetate, 8 
parts of Montanide 888 and 30 parts of bacterin. 
All three preparations elicited a good antibody 
response, which was detected with an  enzyme-linked 
immunosorbent assay  (ELISA) test.  Significantly high 
antibody levels were maintained with all three vaccines 
up to 270 days after vaccination, as compared with 
control animals and those given an  alum precipitated 
bacterin. 
Formula 1 gave the best response, with 2 and 3 
following in that order. Small groups of buffalo calves 
given all of the three vaccines resisted challenge 
12 months after vaccination. However, there was no 
enhanced response with formula 3,  which contained 
vitamin E.  Shah  et al.  (1997) used a mineral oil  (Marcol 
52) as adjuvant, with Span 85 and Tween  85 as 
emulsifying agents (Bokhout et al.  1981). In  an  ELISA 
test using ultrasonicated total membrane preparation 
as antigen, the principal antibody response to the 
vaccine was of the IgG class  with only mild IgM 
responses.  The  response increased gradually up to day 
75, then dropped slightly, and remained constant up to 
one year.  Young buffalo calves one to two years of 
age,  immunised using this vaccine and challenged at 
250 days, were completely protected and did not 
develop any disease symptoms following challenge 
with 109  viable organisms.  It was observed, however, 
that control animals when challenged developed 
characteristic symptoms but recovered within three 
days. This vaccine is  reported to have low viscosity and 
to be stable for three years at room temperature. The 
criteria and  methods for determination of stability and 
retention of potency on  storage are  not described. 
Concentration of  antigen 
Chandrasekaran et al.  (1996) produced a low-volume 
oil adjuvant vaccine. They were able to incorporate a 
larger quantity of bacterial substance per unit volume 
by concentrating the antigen. Ten  per cent alum was 
added to the dense bacterin to give a final 
concentration of 1.5 %, and the bacterin was left at 
room temperature for 24 hours. ,I\fter the bacterial cells 
had settled at the bottom, two-thirds of the 
supernatant was siphoned off, leaving a concentrated 
bacterin. This bacterin was then emulsified with mineral 
oil (Ondina 15) and  lanoline. By this means it was 
possible to reduce the dose to 2 mL. Double emulsion 
A significant advancement in the oil adjuvant vaccine 
production technology is the development of the 
double emulsion (also  referred to by some workers  as 
multiemulsion) vaccine.  Herbert (1965) redispersed 
globules of water in oil emulsion through a second 
external phase using another emulsifier, Tween 80, to 
stabilise the product. Mittal et al.  (1977) applied this 
technique to the oil adjuvant HS vaccine,  prepared 
from dense bacterin and  paraffin oil using lanoline as 
the emulSifying agent. The standard oil adjuvant 
vaccine was re-emulsified using an  equal volume of 
2 % Tween 80 in 0.3 % formalinised saline. The 
resulting product was a free-flowing white liquid with a 
milk-like consistency which was stable and  more easily 
injectable than the oil adjuvant vaccine.  Its main 
disadvantage, however, was that the vaccine was 
diluted 1:1  in the process of the second emulSification, 
and therefore, in order to ensure that the required 
amount of dry bacterial mass was administered in every 
dose, the dose volume had to be doubled. In the initial 
experiments, the multiple emulsion vaccine gave good 
levels of protection in  mice, rabbits and calves  but the 
duration of immunity in calves was somewhat lower 
than with the conventional oil adjuvant vaccine (Mittal 
et al.  1977, 1979). Subsequently, Yadev and  Ahooja 
(1983) prepared multiple emulsion vaccines  using 
conventional vaccine and Tween 80/saline solution in 
the ratio of 3:3,3:2, and 3:1  respectively. They found 
that vaccines prepared using the 3:1 ratio gave results 
comparable with those of the conventional 011  adjuvant 
vaccine.  Chandrasekaran et al.  (1991, 1993b), found a 
double emulsion vaccine prepared in accordance with 
the original 1:1  formulation to be  as  protective as the 
conventional vaccine up to one year in  buffaloes. 
In order to prepare a multiemulsion vaccine using a 1:1 
ratio of conventional vaccine to Tween 80/saline, so  as 
to get the favourable consistency without reducing the 
bacterial content it will  be possible to prepare the initial 
emulsion using a bacterin whose volume is  reduced by 
50%, using the alum precipitation technique to 
concentrate the antigen.  Such  a vaccine would have 
the required dry mass of bacteria, the favourable 
consistency and  low volume for easy injectability and a 
satisfactory level  of efficacy. 
Apparently, a large-scale vaccine production 
technology using the multiemulsion  principle has not 
yet been developed, and  hence this vaccine still 
remains at an experimental stage. 
9.2.3  Vaccines incorporating 
purified extracts 
Studies on  the various cell components of Pasteurella 
multocida serotypes that cause  HS have indicated that 
the cell capsule is associated with serogroup specificity, 
virulence and immunogenicity (see  Section 2.2.6). This 
led to the belief that capsular extracts may be superior 
to whole cells as antigen in vaccines. The earliest 
attempt to produce vaccines containing crude capsular 
extracts was that of Dhanda (1959b). It was believed 
that the protein components of the capsule were 
immunogenic and were responsible for protection. 
Penn and Nagy (1974) recognised two major antigenic 
components, the capsular antigen and endotoxin in 
saline extracts and  phenol-water extracts of 
P.  multocida types Band E.  The crude capsular extract 
was purified  by solvent fractionation and precipitated 
with cetyl pyridinium chloride. Vaccines were prepared 
by filter sterilisation and the addition of 25% (vol/vol) 
sterile aluminium hydroxide gel. Rabbits immunised 
with this vaccine failed to produce adequate passive 
protective antibodies, and  none of the rabbits survived 
subcutaneous challenge with viable organisms. Calves 
immunised with this vaccine,  however, developed 
passive mouse protective antibodies (Penn and  Nagy 
1974, 1976). Subsequent experiments by these 
workers showed that cattle immunised with capsular 
extract vaccine of type E (the endotoxin-free, 
aluminium hydroxide adjuvant) survived  challenge; the 
results of the indirect haemagglutination (IHA) 
response and the passive  mouse protection test (PMPT) 
response corresponded with the challenge results. The 
IHA test was carried out using erythrocytes coated with 
solvent-purified capsular antigens of type E (Nagy and 
Penn  1976). 
More recently, attempts were made to separate in  pure 
form polysaccharides, proteins and lipopolysaccharides 
of serotype B:2 in order to determine the most 
immunogenic components. Muniandy et al.  (1993), 
found that capsular polysaccharide in a highly purified 
state was non immunogenic. Muniandy and Mukkur 
(1993) found that while lipopolysaccharide (LPS) 
extracts prepared  by the Westphal  method were 
protective in mice,  the protectivity was abolished  by 
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Thus,  it was concluded that the protectivity of these 
preparations was actually due to the contaminating 
outer membrance proteins (OMPs). 
Several  attempts have also been  made to identify and 
isolate the immunogenic proteins. Ramdani and Adler 
(1993) isolated three protein antigens of molecular 
weights 29,36 and 42 kDa. Attempts to protect mice 
with these protein antigens have succeeded  in 
achieving only 25-67% protection. Of these, the 
42  kDa protein is  believed to be  in the cell  membrane. 
Pati et al.  (1996) prepared OMP extracts from 
P multocida strain P52  (the Indian vaccine strain of 
serotype B:2).  Using sodium dodecyl sulfate 
polyacrylamide gel  electrophoresis (SDS-PAGE),  10 
major polypeptide bands of molecular weight ranging 
from 88 to 25 kDa were detected. Immunoblots 
indicated that the 44, 37 and 30 kDa fractions were 
the major immunogens. Buffalo calves in two groups 
were vaccinated using a commercial whole cell  oil 
adjuvant vaccine and  an  oil adjuvant vaccine prepared 
from the OMP extract. Antibody responses were tested 
by IHA and ELISA techniques and the protection by 
PMPT in mice and by direct challenge.  Higher titres 
were observed  in the ELISA,  as compared with the IHA 
test, the highest titres being recorded around 21  days 
after vaccination. In  both groups, the highest passive 
mouse  protection was during the period day 21  to day 
26 after vaccination.  Upon  direct challenge, all of five 
OMP vaccinated buffaloes and two of three buffaloes 
given the commercial vaccine survived. 
Srivastava (1996) prepared a whole cell  protein extract 
by ammonium sulfate gel precipitation of sonicated 
extracts of strain  P52.  The sonicated extract showed 12 
protein bands upon analysis by SDS-PAGE and these 
ranged from 120 to 30 kDa.  The ammonium sulfate 
precipitated extract, on the other hand, yielded a 
protein-rich material comprising at least 14 polypeptide 
bands,  ranging from 91 to 30 kDa. This latter product 
was tested  as a vaccine for immunogenicity in  rabbits 
and  mice, compared  with whole cells,  with both 
vaccines incorporating an  adjuvant. In  rabbits,  both 
vaccines gave 100% protection against challenge with 
the P52  strain at the dosage tested.  In  mice, the whole 
cell vaccine gave 85.4 % protection, whilst the extract 
vaccine gave only 68.5% protection. All of these 
findings demonstrate the role of the protein fractions of 
the cells in providing some degree of protection. 
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It is also believed that certain OMPs are produced by 
serotype B:2  strains in vivo but not in  ordinary media in 
vitro. These OMPs may be associated with the solid 
immunity found in convalescent or naturally immune 
animals.  In vivo, the bacterial pathogens have restricted 
access to iron in their environment, primarily due to the 
presence of haemoglobin, transferrin and lactoferrin. 
Several bacterial pathogens have been shown to have 
surface receptors that recognise and  bind these iron 
sequestering proteins and mediate iron acquisition from 
them. Although much work has  been  done on these 
high molecular mass OMPs produced in vivo, and  in 
iron-restricted media in  vitro, by type A strains of 
P multocida associated with avian pasteurellosis and 
bovine pneumonia, the results have been  inconclusive 
(Snipes et al.  1988; Lu et al.  1988, 1991; Abdullahi et al. 
1990; Choi-Kim et al.  1991; Ogunnariwo et al.  1991). 
Studies with type B:2  strains of P multocida showed 
that bacteria grown in  iron-restricted media gave better 
protection than those grown in  iron-replete medium 
(Kennett et al.  1993). This superior protection was 
attributed to a high molecular weight protein fraction 
(see Section 2.2.6). A study of protein profiles by SDS-
PAGE and  immunoblotting, carried out using serum 
from buffaloes naturally immune as a result of 
experimental exposure to a virulent 8:2  strain, 
recognised a high molecular weight protein fraction 
(116 kDa), whereas sera from buffaloes immunised 
with the inactivated oil adjuvant vaccine failed to do so 
(T.G.  Wijewardana, Veterinary Research  Institute, 
Peradeniya; personal communication). Veken et al. 
(1994, 1996) found that convalescent phase sera from 
buffaloes reacted against some iron-restricted and 
other proteins, indicating that these proteins were 
produced in vivo. A specific 82  kDa high molecular 
mass bovine transferrin binding iron-regulated outer 
membrane protein was produced by serotype 8:2, but 
not by serotype 8:3.4. 
It has also been  found that both polysaccharide and 
LPS exhibit anti phagocytic activity in vivo, a factor 
which may be important in the pathogenesis of HS. 
The  role of endotoxin, which is  predominantly LPS,  in 
the pathogenesis of the disease  is  also well established. 
Thus, these components may also playa vital role in 
immunogenicity (see Section 2.2.6). From the research  on  vaccines  based  on  identification 
of immunogenic components of the cell,  it can  be 
concluded that no single component is totally 
responsible for immunity. All fractions,  LPS and  proteins 
and polysaccharides evidently contribute towards 
immunity. The complete set of immunogens is  present 
in  whole bacterial cells grown in  vivo or cultivated in 
vitro in  a medium that provides all essential in vivo 
conditions for the full expression of relevant 
immunogenic components. It appears that there are 
many common components in  the different types of 
P.  multocida that also playa role in  protection. 
Rimier (1996) found passive immune cross-protection 
in  mice,  using rabbit antisera against different serotypes 
of P.  multocida. Eleven  isolates from different host 
species,  including those causing HS,  bovine pneumonia 
and fowl cholera, were tested. A serotype A:5 strain 
and  a fowl cholera strain produced cross-protection 
against other strains, irrespective of the disease caused. 
The protection was attributed to antigen bands of 
20-120 kDa. 
It is also interesting to note the findings of Singh et al. 
(1994), who immunised three groups of buffaloes, using 
the P52 strain, a duck strain  (1 :A) and a pig pneumonia 
isolate in  an alhydrogel vaccine standardised to contain 
4 mg of bacterial protein per dose. Vaccinated buffaloes 
were challenged 180 days later with the P52 strain. 
Animals immunised with P52  (i.e.  homologous 
challenge) showed only 75% protection; those 
immunised with the duck strain gave the highest 
antibody titres as  measured by a tube agglutination test 
and the IHA test, but gave only 25% protection. Those 
immunised with the pig pneumonia strain gave high 
antibody titres and also 100% protection. Unfortunately, 
the serotype of the culture was  not reported. 
9.2.4  Live vaccines 
It is  generally accepted that natural exposure to live 
organisms (such  as in actual infection) produces greater 
immunity than immunisation through inactivated 
vaccines. This has been  specifically shown in  HS,  where 
the naturally acquired immunity in  exposed animals 
that results from arrested infection has been found to 
be superior to vaccinial immunity. If we can  find an 
organism that has all  the properties of the field strains, 
including all the antigen components, but has lost its 
virulence, it will constitute the basis for an  ideal live 
vaccine. As facilities for Iyophilisation are now available 
in  most countries, the use of a live, Iyophilised vaccine 
under tropical field conditions is  now feasible.  Such a 
vaccine strain should have the following characteristics: 
•  it must have all, or at least all the protective, 
antigens present in the field strains; 
•  it must grow readily in ordinary culture media; 
•  it should be avirulent to cattle and  buffaloes, or may 
be a low virulence strain (the lethal dose must be 
conSiderably higher than the immunising dose); 
•  it should be stable,  particularly in  its property of 
avirulence, and there should be  no reversion to 
virulence; 
•  it should be able to multiply sufficiently in vivo 
following vaccination, producing a full complement 
of the important immunogens, thereby stimulating 
an  immune response; and 
•  it should withstand Iyophilisation and its stability 
following reconstitution should be  high. 
Strains satisfying these criteria may occur in  nature, or 
may be produced in  a laboratory by exposure to 
mutagenic agents. 
Experimental live vaccines 
A procedure for inducing mutations in  bacteria using 
N-methyl-N nitro-N-nitrosoguanidine has been 
described (Adelberg et al.  1965; Oeschger and  Berlyn 
1974). Chengappa and Carter (1979) improved on this 
technique and produced streptomycin-dependent 
(StrD)  mutants of P.  multocida and  P.  haemolytica. Wei 
and Carter (1978), using this technique, produced StrD 
mutants of type B strains of P.  multocida associated 
with HS. These mutants were successfully used to 
immunise mice and rabbits against challenge with 
homologous strains.  De Alwis et al.  (1980) produced  a 
large number of StrD mutants from Sri  Lankan strains of 
P.  multocida type B:2  associated with HS. One of these 
mutants was used to immunise cattle and  buffaloes in 
Sri  Lanka. Though an antibody response  was observed, 
large numbers of organisms had to be inoculated to 
produce a response as measured by the PMPT.  It was 
postulated that this may be due to the absence of in 
vivo multiplication of the organism in the absence of 
streptomycin (De Alwis and Carter 1980). 
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independent revertants from StrD mutants. On 
reversion many of these assumed the normal virulence 
of the field strains. A few strains,  however, were of low 
virulence. One of these (designated R39) was selected 
as a possible vaccine candidate. It had almost all the 
required characteristics for a live vaccine seed. 
Biochemically and serologically, it was indistinguishable 
from the field strains.  It even produced hyaluronidase, 
a property shared only by type B:2  strains of 
P.  multocida that cause  HS. Restriction endonuclease 
analysis of this culture indicated a unique DNA 
fingerprint profile different from all  other Sri  Lankan 
B:2  strains (R.B.  Rimier, Midwest Area National Animal 
Disease Center,  US  Department of Agriculture, Ames, 
Iowa, personal communication), thus providing 
evidence that the loss of virulence is a change at a 
genetic level. 
In  SDS-PAGE and immunoblotting with serotype B:2 
cultures grown in  vivo in  iron-restricted media, the 
specific band that represented an  aMP of 116 kDa was 
recognised by sera of naturally immune animals and of 
R39-vaccinated animals,  but not by sera of cattle given 
the oil adjuvant vaccine (T.G. Wijewardana, Veterinary 
Research Institute, Peradeniya,  Sri  Lanka,  personal 
communication). This mutant showed low virulence for 
mice and rabbits,  the median lethal doses  (LD50s) 
being 107-8 and  104-5 CFU  respectively as compared 
with 1-10 organisms of field  strains. When injected by 
the intramuscular route or sprayed intranasally, 107 
CFU was sufficient to evoke a good IHA antibody 
response,  whilst doses as  high as  1010 CFU  produced 
no adverse reactions. The  IHA titres persisted for up to 
a year,  at which time they were challenged with a 
subcutaneous injection of a field isolate of serotype 
B:2.  There was a similar IHA response in  unvaccinated 
control animals reared in  close contact with vaccinated 
animals, suggesting lateral transmission.  However, 
upon subcutaneous challenge with virulent strains, only 
20% of vaccinated animals were protected (De Alwis 
et al.  1998). 
The use of this  live vaccine was an  attempt to simulate 
the phenomenon of naturally acquired  immunity 
resulting from natural exposure to disease.  The fact 
that animals showing a high IHA titre failed to resist 
subcutaneous challenge raises some doubt about the 
validity of this method of challenge as an  indicator of 
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ability to resist natural infection. On the other hand,  it 
is  also possible that in  natural exposure, or exposure to 
live vaccines, the rising IHA titre is only an  indicator of 
a humoral immune response and the actual protective 
antibody may not be picked up by this test. This work 
with StrD mutants and streptomycin-independent 
revertants of low virulence has thrown considerable 
light on the mechanisms involved and  opened up areas 
for future investigations, but has not directly led to the 
development of a practical vaccine. 
Exposure to the chemical mutagenic agent N-methyl 
N-nitrosoguanadine has led to the production of 
temperature-sensitive mutants of P.  multocida 
(Schimmel 1993). After two intratracheal 
immunisations, it has been  possible to prevent death in 
calves following challenge, but pneumonic lesions 
could not be prevented with fewer than four 
immunisations. It is  not likely that a practical live 
vaccine can  be developed using this mutant in its 
present form. 
Deer strain  live vaccine 
Myint et al.  (1987) used a strain of P.  multocida from 
deer as a live vaccine for cattle and  buffaloes. The 
strain (serotype B:3,4) was  isolated by Jones and 
Hussaini (1982) from fallow deer in England after an 
outbreak of septicaemic disease. The strain was 
pathogenic to mice (LD50 less than 10 organisms),  but 
doses ranging from 105 to 107 viable organisms were 
found to be safe for cattle. Subcutaneous injections of 
107 viable organisms lead to an  antibody response 
detectable  by a mouse  protection test within eight days 
following vaccination, and vaccinated animals 
withstood direct challenge with serotype B:2  nine 
months later.  It was  concluded that the protective 
fractions were in  the capsular B complex and that a 
different somatic antigen served as  a marker to 
differentiate the vaccine strain from the field strain. 
Further work (Myint and  Carter 1989,1990) indicated 
that when the vaccine strain was administered by the 
subcutaneous route, it caused  deaths in  a small 
proportion of young animals, particularly buffaloes. 
When six buffaloes three to five months of age were 
injected  subcutaneously with 1.4x1 07  viable organisms, 
three developed severe  local reactions and died 72 
hours later. Serotype B:3,4 was recovered from the 
dead animals. It was concluded that the live  B:3,4 vaccine was safe for use  as a booster vaccination in 
adult animals that had been given a primary 
immunisation with an  inactivated vaccine. 
Subsequently, the vaccine was administered intranasally 
as  an  aerosol spray (Carter et al.  1991). Several 
thousand cattle and  buffaloes over six months of age in 
several village tracts in  Myanmar were vaccinated by 
the subcutaneous or intranasal route. No adverse 
reactions were recorded. No outbreaks of HS were 
recorded in  the subsequent year in the vaccinated 
villages, whereas outbreaks did occur in  neighbouring 
villages where the live B:3,4 vaccine was not used. 
Initial attempts to demonstrate immunity by direct 
challenge of vaccinated animals picked up from the field 
were disappointing. Six weeks after B:3,4 intranasally 
vaccinated animals were challenged using serotype B:2 
by the subcutaneous route, only six out of 17 animals 
survived.  In a subsequent controlled trial, however, the 
ability of intranasal B:3,4 vaccinated cattle to withstand 
B:2 challenge by the subcutaneous route was 
demonstrated. In this trial, 52 zebu cattle in  a 
non endemic area in Myanmar were vaccinated 
intranasally (Myint 1996). Indirect haemagglutination 
tests using B:2-coated human erythrocytes showed titres 
in 73% of animals at 10 days and 82.7% of animals at 
five weeks after vaccination. The  IHA titres were high, 
and comparable with levels achieved when exposed 
naturally to type B:2.  No animals showed IHA titres at 40 
weeks after vaccination, but 82.5% of the animals gave 
positive reactions in the PMPT. At 12 months after 
vaccination, 12 animals were challenged with the B:2 
strain by subcutaneous injection; all survived, though all 
four unvaccinated controls died. 
The deer strain (B:3,4) was subjected to a host of tests, 
in order to assess  its safety and  efficacy (M.C  L.  De 
Alwis, unpublished data; M.CL. De Alwis and A. 
Myint, unpublished data). Two groups of four 
buffaloes, four to six months of age, were given 106 
and  107  viable organisms by the subcutaneous route. 
Three animals in each group died and type B:3,4 was 
recovered.  However, the syndrome was more 
protracted than that produced by strain  B:2  in  buffaloes 
under similar circumstances. In five of the six animals 
that died, death occurred in three to five days.  One 
animal died on  the 10th day.  Serotype B:2  under similar 
circumstances would normally have killed in  less than 
24 hours. Thirty-nine buffaloes given 100 times the 
recommended dose of 107 viable organisms by the 
intranasal route showed no adverse reactions. Of these, 
11  were previously unvaccinated animals and their ages 
ranged from 6 to 12 months. 
Since the strain  B:3,4 was  isolated from a small 
ruminant (deer), it may have been  pathogenic to goats, 
which are the common small  ruminant in the Asian 
region.  Four goats were given 109-1010 CFU by the 
subcutaneous route and two were given 4.8 X1011 CFU 
by the intranasal route; they showed no adverse 
reactions. 
Of all  live experimental vaccines developed so far,  this 
deer strain has the best potential for development into 
a practical vaccine for routine use.  It has been  used 
extensively in Myanmar: in  1995-96, about two-thirds 
of all  animals immunised against HS  received the B:3,4 
deer strain live Iyophilised vaccine, reconstituted and 
administered as a nasal spray. However, some 
conditions should be strictly observed. Firstly, any 
country using this vaccine should  have a good disease 
reporting system, and a readily available diagnostic 
facility that can  isolate and  differentiate between 
serotypes B:2  and B:3,4. These  precautions are 
important because the vaccine strain  is  a potential 
pathogen, though so far proven to be safe under 
experimental conditions. Secondly, the vaccine should 
only be given to animals over six  months of age, and 
only by the intranasal route. 
Standards for live vaccines 
If live vaccines are to be developed and  recommended 
for routine use  in the future, certain standards must be 
applied. The form of presentation, dilution factor, 
dosage, and  so on, should be stipulated, but there 
should be a margin for handling errors in  the field in 
addition to the margin of safety.  For example, if 
107 CFU  is the required minimum immunising dose, a 
single dose should contain at least 108 CFU, allowing 
for one log unit drop in  viable count after 
reconstitution. It is also important that 10 times or, 
preferably, 100 times (109 or 1010 CFU) the prescribed 
dose administered by the recommended route should 
be absolutely safe. 
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veterinary practitioner or paraveterinary personnel such 
as vaccinators and can  be successfully applied by 
farmers or owners of livestock.  In such  instances,  it is of 
utmost importance that the instructions for use are 
printed in a language understood by the farmers of the 
country; the diluent for reconstitution and the spraying 
device should be supplied with the vaccine. 
9.3  Protection 
between Serotypes 
It was shown by Bain  (1979b) that there was cross-
protection between Asian  and African strains when 
bacteria grown in  vivo were used to immunise mice, 
and that this cross-protection disappeared, whilst 
homologous protection remained, with successive 
subculture. The ability of a type B:3,4 strain originating 
from deer to protect against type B:2  infection in cattle 
and buffaloes was amply demonstrated by Myint et al. 
(1987) and Myint and Carter (1989,1990). More 
recent work by Shah  (1998) indicated that, although 
cross-protection existed  between the Asian,  (B:2) and 
African (E:2) strains,  B:2  vaccines gave no protection 
whatever against challenge with type B:3,4.  It must be 
noted that Myint et al.  (1987) used a B:3,4 strain as a 
live vaccine, whilst Shah  (1998) used  B:2 and  E:2 
inactivated adjuvant vaccines.  It is  interesting to 
speculate as to whether the cross-protective in  vivo 
antigens referred to by Bain  (1979b) would provide the 
explanation for the cross-protection observed with the 
live vaccine. 
Also of considerable interest are the observations of 
Singh et al.  (1994) who found that a pig pneumonia 
strain gave 100% protection in  buffaloes against 
challenge with a B:2  strain (Indian P52) and also 
evoked high antibody titres, whereas the homologous 
P52 strain gave only 75% protection. They also 
reported that a duck strain of serotype 1:A gave 25% 
protection, and gave a higher antibody titre against the 
P52 strain, than did the homologous strain. 
Unfortunately, the serotype of the pig pneumonia 
strain  has not been  recorded. 
All of these observations merit follow-up investigation, 
perhaps with a view to identifying a single strain or 
antigen grouping that will give protection against a 
wide range of challenge strains. 
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9.4  Future Prospects 
for Vaccine Development 
Two broad areas appear to have emerged for future 
vaccine  research.  Newer adjuvants that have been 
developed for low-viscosity emulsions, including the 
production of double emulsions, appear to be 
promising. It is  unlikely that a single antigenic 
component, linked with a specifically identified gene,  is 
responsible for total protection. It is therefore unlikely 
that a DNA recombinant vaccine will appear within the 
foreseeable future. Development of better media for 
bulk culture production also appears to be a promising 
area. The objective would be to provide culture 
conditions that would cause the fullest expression of 
antigenic components, coupled with a new adjuvant. It 
is  important that new emulsions should  be tested not 
only for low viscosity and  stability of emulsion, but also 
for retention of potency under different conditions of 
storage. In any event, vaccines based  on purified 
extracts will not lend themselves to large-scale 
production in the countries where the disease exists. 
A more feasible proposition is a whole cell-based 
adjuvant vaccine grown in  an  appropriate growth 
medium that will permit full expression of all antigen 
components, coupled with a suitable new adjuvant. 
The second area that warrants investigation is that of 
live vaccine development. Studies on virulence factors 
and their genomic basis may help to produce suitable 
avirulent, antigenic mutants by genetic manipulation. 
Such  an  organism, that can  be administered by any 
route, will serve  as  an ideal vaccine candidate. Further Investigation 
Overview 
Further information on some aspects of haemorrhagic 
septicaemia (HS) would be helpful in the control of the 
disease. Gaps in the current understanding of the 
disease include: 
•  pathogenesis of the disease (it is not known where 
the organism lodges when it enters the body or 
where it multiplies during incubation and the early 
clinical phase); 
•  some aspects of epidemiology (the specific 
mechanisms that convert a latent carrier to an active 
state are unkown); and 
•  immunology, especially related to vaccine 
development. 
There are still many grey areas in our knowledge of 
haemorrhagic septicaemia (HS). Significant gaps exist 
in the understanding of pathogenesis of the disease and 
some aspects of the epidemiology and immunology. A 
better understanding of these areas will lead to more 
effective control of the disease. 
10.1  Pathogenesis 
It is fairly well established that entry of the infecting 
organisms is by inhalation or ingestion (see Chapter 3). 
However, it is  uncertain where the organism lodges 
itself immediately upon entry and where it multiplies 
during the incubation period and the early clinical 
phase.  It is  known that septicaemia is terminal (M.C.L. 
De Alwis, unpublished data; Horadagoda et al.  1991) 
and this phase roughly coincides with the rapid  rise in 
endotoxin levels in the blood (N.U.  Horadagoda et aI., 
personal communication, 1998; see  page 32). It may 
be surmised that the initial multiplication takes place in 
tissues associated with the respiratory tract, but more 
investigations are needed in this regard. 
The initial multiplication may be facilitated by the 
vacuolating cytotoxic activity (Shah et al.  1996); the 
polysaccharide and lipopolysaccharide (LPS) 
components of the cell, which are known to be 
anti phagocytic (Muniandy et al.  1993), may be 
responsible for this activity. LPS also accounts for most 
features of the clinical syndrome (Rebers et al.  1967; 
Rhoades et al.  1967; Horadagoda et aI.,  personal 
communication, 1998). It is  not known whether there 
are any other virulence factors, whether these are 
merely phenotypic characters, or whether they possess 
a genetic base. 
10.2  Epidemiology 
There is ample evidence to support the existence of a 
large number of latent carriers in animal populations in 
endemic areas, and to indicate that occasionally, and 
intermittently, a few become active carriers and shed 
infective pasteurellae. The specific mechanisms that 
convert a latent carrier to an  active state are still 
unknown (see Section 4.7.3). 
87 Organisms shed  by active carriers are believed to be 
the source of infection in the initiation of outbreaks. 
In experimental transmission by natural routes of 
infection, De Alwis et al.  (1990) found that large 
numbers of viable organisms were required to produce 
infection. Such  numbers are unlikely to be transmitted 
from a shedder to an  incontact susceptible animal.  For 
an  outbreak to begin there may therefore be 
mechanisms that increase the virulence of shed 
organisms or,  conversely, diminish the defence 
mechanisms of the susceptible incontact animals. Such 
mechanisms merit further investigation in order to 
obtain a more complete understanding of pathogenesis 
and epidemiology. 
The nature of the naturally immune-cum-carrier state 
which occurs in survivors from natural outbreaks, a 
state that is believed to arise from what is described as 
'arrested infections', also needs to be defined, as do 
the effects of vaccination on the immune and carrier 
status. More evidence is  also needed on  how such 
animals respond  to challenge by different routes. 
10.3  Vaccines and Immunology 
Vaccine research  was discussed  in detail in  Chapter 9. 
Formulae that will give oil emulsions thin enough for 
easy injection have now been  developed, particularly 
for adjuvant vaccines. Vaccines prepared in accordance 
with these new formulations need to be validated for 
potency (as  measured by a defined test), stability and 
shelf life at different storage temperatures. Similar work 
is  necessary with double emulsion vaccines.  In the 
latter case, the technology for large-scale production 
needs to be developed. 
The development of a non-oily adjuvant may also  be 
useful as such a vaccine may be more user friendly 
than the oil emulsions. 
The search for the 'most potent immunogen' has been 
on for the last decade or so.  Although various cell 
components that contribute towards protection have 
been identified, no single component appears to be 
responsible for total protection. There has been  much 
hope that a transferrin-binding protein from the outer 
membrane of cells could be produced in vivo and in 
iron-depleted media in vitro. Such a protein would also 
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need to be a major immunogen (Kennett et al.  1993; 
Veken et al.  1994). More work is  necessary to 
determine whether such a protein is  expressed  by a 
wide range of strains responsible for the disease and 
the extent to which it would contribute to protection. 
Recognising that immunity following natural exposure 
to disease  is the best,  it would be worth studying the 
components expressed by the organism when 
multiplying in vivo. It may then be possible to develop 
a medium and culture conditions for bulk in vitro 
cultivation of the organism, with the full complement 
of in vivo antigens. Whatever the adjuvant, a vaccine 
based  on such a culture could be expected to provide 
better protection than current vaccines. 
A live vaccine based  on an  avirulent strain containing 
all the protective antigens of the virulent organism 
would also be a valuable asset.  Such a vaccine would 
need to be presented in  a Iyophilised form and should 
ideally lend itself to use either by injection or by 
aerosol spray. This  is  because, in some circumstances, 
it is considered easier to administer an  aerosol spray 
through the nostrils, although other field workers 
prefer to administer an  intramuscular injection from 
the rear in  semi-wild cattle and buffaloes. Where a live 
vaccine is  used, it should be possible to differentiate 
between the field strain and the vaccine strain 
relatively easily. 
Some conflicting findings from past investigations need 
further study. Myint and others have amply 
demonstrated that serotype B:3,4 deer strain as a live 
vaccine evokes both an antibody response and 
protection to challenge with serotype B:2  (Myint et al. 
1987; Myint and  Carter 1989,1990). Shah  (1998), on 
the other hand, found that vaccines produced against 
B:2  and  E:2  gave cross-protection in  mice to challenge 
with both serotypes, but that there was no protection 
at all to challenge with B:3,4 serotype. Also of interest 
are the findings of Singh et al.  (1994) on  cross-
protection between strains. They found that a pig 
pneumonia strain (serotype not stated) both evoked a 
higher antibody response and gave better protection to 
challenge in  buffaloes against a B:2  strain P52  than did 
the homologous P52  strain. Further, a duck strain 
(serotype 1  :A) gave higher antibody levels (but only 
25% protection) when challenged with strain  P52. 
These observations merit further investigation. It may also be possible to find, or develop by genetic 
manipulation, a strain that will provide a wide range of 
protection across species and disease barriers. 
Little is  known of the role of cell-mediated immunity 
(CMI) in  haemorrhagic septicaema (HS);  more is 
known about Pasteurella multocida infections in 
chicken and turkeys (Dua and Mahaswaran 1978). The 
work of Maheswaran and Theis (1979), and that of 
Verma and Jaiswal (1997), on  the role of CMI deserves 
to be followed up. 
The method of assessment of protective immunity also 
deserves further investigation. The natural routes of 
infection are ingestion and  inhalation, yet in  most direct 
challenge experiments, the subcutaneous route of 
infection is  used.  It is  not known to what extent local 
antibodies in the mucous membranes contribute 
towards immunity to natural infection. In vaccine 
evaluation experiments, however, the subcutaneous 
route of challenge is widely used, since by this route the 
disease can  be consistently and  predictably reproduced. 
To overcome the cumbersome procedures of using 
animals to assess  immunity, it is of utmost importance 
that a reliable laboratory test that measures protective 
immunity be developed. Of the tests currently used -
indirect haemagglutination, passive mouse protection 
and enzyme-linked immunoabsorbent assay (ELISA) -
ELISA has been acclaimed by many recent workers as 
being most closely related to results of direct challenge. 
Yet ELISA  has its limitations, and what it detects can  be 
influenced by the antigen used.  Some workers have 
used a sonicated extract as antigen but most use the 
boiled antigen of Heddleston (1972); as  might be 
expected, the test then fails to differentiate between a 
response to the Asian and African serotypes on account 
of the common somatic antigen. 
It is widely believed that, following an  outbreak, 
surviving animals possess a high degree of protective 
immunity. It is  also  known that high IHA titres not 
obtainable with killed vaccines develop within a few 
days of natural exposure, and  persist for about six 
months. Yet experiments with a live 8:2  mutant vaccine 
(De Alwis et al.  1998) indicated that a similar persistent 
IHA response evoked by the mutant was not an 
indication of protection because the animals that were 
showing IHA titres failed to withstand challenge. 
Passive mouse protection tests do not appear to be a 
reliable indicator of immunity in  buffaloes 
(Chandrasekaran et al.  1991, 1994b). Thus, there is a 
need to develop a serological test or a laboratory 
animal model that is capable of reliably measuring 
immunity to natural infection. 
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Dispatch of suspected material 
Modified Stuart's transport medium 
Sodium glycerophosphate  10.0 g 
Sodium thioglycollate  0.5 g 
Cysteine hydrochloride  0.5 g 
Calcium chloride  0.1  g 
Methylene blue  0.001  g 
Agar  5.0 g 
Distilled water  1 litre 
pH  7.4 ± 0.2 
The above ingredients (or 16 g of the commercial 
dehydrated medium) are dissolved in  1 litre of distilled 
water. The mixture is then dispensed into 7.0-mL 
screw-capped bottles and sterilised at 121°C for 15 
minutes. 
Amie's transport medium 
Charcoal (pharmaceutical) 
Sodium hydrogen phosphate 














0.1  g 
0.1  g 
4.0 g 
1 litre 
7.4 ±  0.2 
The above ingredients (or 20 g of the commercial 
dehydrated medium) are dissolved, bottled and 
sterilised as above. 
Transport medium formulated 
by De Alwis (1973) 
This is a simplified, non-nutrient inert medium which 
preserves the bacteriological status of the material at 
the time of collection. It is  particularly suitable for 
contaminated material, because it prevents overgrowth 
by contaminants. 
Disodium hydrogen phosphate 
(Na2 HP04. 12 H20) 
Thioglycollic acid 
Methylene blue (1 % aqueous solution) 







pH  7.4 ±0.2 
The medium is  boiled in a water bath, dispensed into 
7 -mL screw-capped bottles, and sterilised as above. 
The prepared medium is colourless and semisolid in 
conSistency.  Bottles that turn blue should be discarded. 
Pasteurellae have been isolated by direct culture seven 
days after blood was placed in  this medium (the blood 
came from an  animal that died of haemorrhagic 
septicaemia, and was collected 32 hours after death 
under tropical conditions) (De Alwis 1973). This was 
the longest period tested. 
Transport enrichment medium (TEM) 
The TEM developed by Warner (1996) inhibits the 
growth of bacterial contaminants such  as Escherichia 
coli,  pseudomonas, proteus and gram-positive 
organisms, as well as fungal contaminants. This 
improves the chances of isolating Pasteurella 
multocida from diseased animals. 
The medium consists of a sloppy brain-heart infusion 
(BHI) agar with added antibiotics. The sloppy agar is 
made by adding 0.3% agar to BHI  broth. The antibiotics 
should be made as concentrated stock solutions, and 
the filter sterilised (0.45-j..Im microorganism filter) and 
stored at -20°C when not in  use. 
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BHI  broth base  37.0 g 
Distilled water  1 litre 
Mix well, autoclave to sterilise, cool to approximately 
56°C and add the following antibiotics per litre of BHI 
solution: 
1 mL of amikacin  from 10 mg/mL  (10  jJg/mL) 
stock solution 
1 mL of gentamicin  from 10 mg/m  L  (10 jJg/mL) 
stock sol ution 
1 mL of  from 0.4 mg/mL 
potassium tellurite  stock solution  (0.4  jJg/mL) 
1 mL of bacitracin  from 6 mg/mL  (6  jJg/mL) 
stock solution 
1 mL of  from 4 mg/mL  (4  jJg/mL) 
amphotericin B  stock solution in 
acetone 
(  ) = final concentration 
Dispense in  1  O-mL aliquots (in  glass McCartney bottles 
or alternative). Store at 4°C. 
The bottles may be inoculated with any of the 
following samples: 
Swab - push swab down into agar and  break off into 
the bottle; 
Tissue  - small amounts of tissue should be pushed 
below the agar surface (should be  less than 10% of the 
volume of the media); 
Fluid - add fluid to the TEM bottle and shake to mix 
into the sloppy agar. 
To culture from the TEM bottle, place a swab down 
into the agar and then use it to make the primary area 
on a blood agar plate. Streak to obtain isolated 
colonies.  Incubate at 37°C for 24-48 hours. 
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Storage of cultures 
Semisolid medium 
Beef extract  10.0 g 
Peptone  10.0 g 
Sodium chloride  5.0 g 
Agar  7.5 g 
Distilled water  1 litre 
pH  7.4 ± 0.2 
Sterilise at 121°( for 15 minutes and dispense into 
screw-capped 7-mL bottles, in 5-mL volumes. The 
medium is  inoculated as a stab, incubated for 
6-8 hours and stored at room temperature. 
Lyophilisation of media 
Harvest 18-20-hour confluent growth in 5% skimmed 
milk or a medium consisting of tryptone (2.5 g), 
sucrose (5.0 g), glutamate (1.0 g) and distilled water 
(100 mL). The bacterial suspension  is dispensed in 
O.5-mL aliquots in vials or ampoules and  Iyophilised. 
Pasteurella growth media 
Liquid media 
Tryptose broth 
Tryptose  20.0 g 
Sodium chloride  5.0 g 
Dextrose  1.0 g 
Distilled water  1 litre 
pH  7.4 ± 0.2 Casein-sucrose-yeast (CSY) broth 
(Wi;ewardana et al.  1986a) 
Acid hydrolysate of casein 
Sucrose 
Yeast extract 
Sodium chloride, anhydrous 
Dipotassium hydrogen 










All media are sterilised at 121 o( for 15 minutes. 
Solid media 
Blood agar 
(nutrient agar with 5% ox or sheep blood*) 
Beef extract  5.0 g 
Peptone  5.0 g 
Sodium chloride  5.0 g 
Agar  15.0 g 
Distilled water  1 litre 
* If possible,  use the blood of a young calf,  reared  in  isolation 
and free of antibodies; alternatively, use sheep blood collected 
from animals similarly reared. 
Enriched tryptose agar (with 5 % ox blood) 
Tryptose  20.0 g 
Tryptone  2.5 g 
Sucrose  1.0 g 
Sodium chloride  5.0 g 
Yeast extract  3.0 g 
Agar  15.0 g 
Distilled water  1 litre 
pH  7.4 ± 0.2 
Sterilise at 121°( for 15 minutes, cool to 45°( and add 
ox blood. The yeast extract and sucrose may be filter 
sterilised and added. 
CSY agar (Wi;ewardana et al.  1986a) 
Acid hydrolysate of casein 
Sucrose 
Yeast extract 
Sodium chloride, anhydrous 
Dipotassium hydrogen 











7.4 ± 0.2 
A greater benefit is derived if the first three ingredients 
are filter sterilised and added later to the heat-sterilised 
medium. 
CSY-blood agar 












(YPC) agar (Namioka and Murata 1961a) 
Yeast extract 
Protease peptone N03 
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A.  Capsular typing 
Indirect haemagglutination (IHA) test 
Preparation of  hyperimmune rabbit antiserum 
A 6-8 hour broth culture of the reference strain  is 
seeded onto casein-sucrose-yeast (CSY) agar and 
incubated at 37°C for 18-20 hours. Growth on each 
plate is examined visually for purity and for 
agglutinability. The growth is  harvested by washing the 
plates using 2-3 mL per plate of 0.3 % formalinised, 
buffered saline. The suspension  is then centrifuged at 
8000 rpm for 15 minutes, and the supernatant is 
discarded. The sediment is  resuspended  in the same 
solution and the turbidity is adjusted to Wellcome 
opacity tube 7,  which roughly corresponds to 109 
organisms/mL. 
Two to three mature rabbits from a colony unexposed 
to pasteurella organisms are used for antiserum 
production. Each rabbit is inoculated by the intravenous 
route with 0.5 mL, 0.75 mL, 1.0 mL 1.25 mL and 
1.5 mL volumes at 3-4 day intervals. Seven to 10 days 
after the last inoculation, 0.5 mL of a live, 6-hour broth 
culture of the reference strain  is injected intravenously. 
Rabbits are bled from the ear vein 10 days later. The 
serum  is then separated and stored at -1 O°e. 
Preparation of  antigen 
A formalinised saline suspension of cells  is prepared as 
for rabbit inoculation (see above). The suspension  is 
centrifuged at 8000 rpm for 15 minutes at 4°e. The 
supernatant is discarded and the turbidity is adjusted to 
Wellcome opacity tube 6.  The cell  suspension  is then 
heated for 56°C/60°C for 30 minutes in a water bath, 
shaking intermittently. The heated suspension  is 
centrifuged at 8000 rpm for 15 minutes, at 4°C, and 
the clear supernatant is collected and stored at -20°e. 
Preparation of erythrocytes 
The blood is centrifuged at 2000 rpm for 5 minutes. 
The supernatant is discarded and the packed cells are 
washed three times in  five to six volumes of 
physiological saline. The following erythrocyte 
preparations have been  used  by different workers: 
•  fresh  human '0' cells (Carter 1955) 
•  formalinised human '0' cells 
(Carter and Rappay 1962) 
•  glutaraldehyde fixed sheep erythrocytes 
(Sawada et al.  1982) 
•  fresh sheep cells (Wijewardana et al.  1986a) 
Titration of capsular antigen 
This is carried out only when the test is  used for 
detection of antibodies, using erythrocytes coated with 
a reference antigen preparation. A preliminary series of 
IHA tests is carried out using erythrocytes sensitised 
with twofold dilutions of antigen, using one volume of 
packed cells to 15 volumes of dilutions of antigen. The 
dilution beyond which the end point starts dropping is 
noted. The antigen dilution is fixed at two twofold 
dilutions above this point (i.e. if the last antigen 
dilution beyond which the titre dropped was 1 in  64, 
then, in the test proper, antigen diluted 1 in  16 is  used). 
In the case of serotyping, where the objective is to 
identify the capsular type of the culture under test 
using a reference antiserum, undiluted antigen may be 
used without titration. 
Coating of erythrocytes (sensitisation) 
One volume of packed erythrocytes is  mixed with 15 
volumes of the antigen appropriately diluted (or 
undiluted as the case may be), and placed in a 3JOC 
water bath for 30 minutes, shaking frequently. The cell 
suspension  is then centrifuged at 2000 rpm for 
5 minutes, supernatant discarded and the sensitised 
cells washed three times in  physiological saline by 
centrifugation and  resuspended in saline to obtain 
a 1 % suspension. 
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The serum  is first inactivated at 56°C for 30 minutes. To 
one volume of packed unsensitised erythrocytes is 
added three volumes of inactivated antiserum. The 
mixture is incubated for 2 hours in a 37°C water bath 
with intermittent shaking, centrifuged, and the 
antiserum removed with a pipette and  used for the test. 
Test procedure 
The test can  be performed on round-bottom microtitre 
plates.  Physiological saline (160 IJL)  and inactivated, 
absorbed serum (40 IJL)  are added to the first well of a 
horizontal row, and 100 IJL of physiological saline to all 
others. Tenfold serum dilutions are made by mixing and 
transferring 100 IJL of the mixture up to the 
penultimate well from which 100 IJL  is discarded after 
mixing. The last well in the horizontal row is left with 
only saline, to serve  as a serum control. An equal 
volume (i.e 100 IJL) of the antigen (i.e. 
sensitised/coated erythrocyte suspension) is then added 
to each  well. To a duplicate row of similarly diluted sera, 
100 IJL  per well of a 1  % suspension of unsensitised 
erythrocytes is added to serve as an  antigen control. 
The plates are shaken and placed at room temperature 
for 2 hours. Agglutinated erythrocytes are coarsely 
distributed round the wells, whereas unagglutinated 
cells settle down to a small  button at the bottom of the 
well, indicating a negative result. 
Simplified capsular typing (rapid slide 
agglutination test) 
The antiserum used  is the same as that used  in the IHA 
test. A single colony from a fresh culture plate is  mixed 
with a drop of physiological saline on a clean  slide, and 
one drop of antiserum is added. After mixing with a 
platinum loop, the slide is gently warmed by waving 
over a flame. A positive reaction  is  indicated by a 
coarse,  floccular agglutination occurring within 30 
seconds with complete clearing of the background. Old 
cultures, and cultures that have lost part of the capsular 
material by 'dissociation' will give a finer, more granular 
agglutination, which will take a longer time to develop. 
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Agar gel precipitation test (AGPT) for capsular 
typing (Anon. 1981; Wijewardana et al.  1982). 
The antigen and  hyperimmune rabbit serum used  in 
this test are the same products used  in the IHA test. 
The  plates are prepared using a medium of 1.0% Noble 
agar or equivalent product in 0.2 M  phosphate buffer. 
Merthiolate is added to give a final concentration of 
1 in  10000. The medium can  be set in 10-cm petri 
dishes or,  more economically, on glass slides.  A number 
of groups of wells can  be cut with a centre well 
surrounded by six peripheral wells. 
The test is carried out by placing reference serum in 
the centre well, test antigens in  five peripheral wells, 
and a reference antigen (which serves as a positive 
control) in the sixth well. The plates/slides should be 
placed in a warm humidified chamber overnight and 
observed for precipitin bands between the centre and 
the peripheral wells. 
(ounterimmunoelectrophoresis «(IE) 
This  is  basically an  agar gel  precipitation test modified 
for rapid results. The method described  is that of Carter 
and Chengappa (1981), with suitable modifications. 
The antigens and antisera are the same as those used 
in the AGPT.  The medium for CIE  plates is as follows: 
Agarose 
Barbitone sodium 
Diethyl barbituric acid 
Distilled water 
Merthiolate (1  in  1000 solution) 
The composition of the veronal acetate buffer 
(barbitone buffer) is as follows: 
Barbitone sodium 
Sodium acetate (anhydrous) 
Hydrochloric acid 0.1  M 












The electrophoresis plates are prepared by coating glass 
slides (57 mm x 70 mm) with 12 mL of medium. Seven 
wells, each of 4 mm, and 7 mm apart, are cut in a row. 
A parallel set of wells is cut 6 mm (centre to centre) 
away from the other set of wells. The wells on the side of the cathode are loaded with 
20-fJL volumes of antigen while an equal volume of 
antiserum is loaded on to the wells on  the side of the 
anode. Two pairs of wells are kept as controls, one 
containing the positive reference antiserum against a 
physiological saline in the antigen well and the other 
containing a negative rabbit antiserum against positive 
reference antigen. The electrophoresis tank is filled with 
the barbitone buffer at pH  8.8. The antigen and 
antiserum are electrophoresed at 150 V (25 V  fcm) for 
30 minutes. Plates are examined for precipitin bands 
between antigen and antiserum wells. 
B.  Somatic typing 
Agar gel precipitation test (Heddleston 
et al.  1972) 
Reference cultures 
The  16 reference strains representing the 16 somatic 
types are used. 
Preparation of  antigen 
A 6-8 hour broth culture is heavily seeded  on to 
dextrose starch agar (DSA) plates, and incubated for 24 
hours at 37°e. Each  plate is then harvested in 
1.0 mL of a solution containing 0.02 M  phosphate 
buffer, 8.5% sodium chloride and 0.3% formalin at 
pH 7. This thick cell suspension  is standardised so  as to 
be equivalent to 25 times the concentration of 
Wellcome opacity tube 6 or any equivalent turbidimetric 
measure (i.e 1 drop of suspension mixed with 24 drops 
of saline should give an  opacity equivalent to Wellcome 
tube 6). The suspension is  placed at 1000e in  boiling 
water in  a water bath for one hour.  It is then 
centrifuged at 8000 rpm for 15 minutes. The 
supernatant is collected and stored at -20°e. 
Preparation of  antiserum 
The growth from a DSA plate is  harvested in 2-3 mL of 
0.3% formalinised physiological saline. This thick 
inactivated bacterial suspension is emusified with an 
equal volume of a light mineral oil containing 10% 
melted lanoline. The emulsified bacterin is injected 
. subcutaneously into the neck of 12-16-week-old 
. chicken, in  1.0-mL volumes. Three weeks later, a 
further 1.0 mL, divided into two O.5-mL volumes,  is 
injected on each side of the sternum. The birds are 
exsanguinated 1 week later. The antisera are collected 
and  preserved with 0.01 % thiomerasol and 0.06% 
phenol. Each serum  is tested against the 16 types, and 
any that cross-react are discarded.  It is  best to use two 
to three birds per serotype, and to collect the serum 
from each  bird separately until cross-reacting sera are 
eliminated. 
Preparation of  plates 
The medium used  is as follows: 
Noble agar (or equivalent) 
Sodium dihydrogen 












The molten medium in approximately 12-mL volumes 
is coated on to glass slides (57 mm x 70 mm) using a 
pipette. When set firmly, three patterns of seven  wells 
each are cut, each consisting of one centre and six 
peripheral wells, each  well being 4 mm diameter, 
spaced at 6 mm centre to centre. 
Test procedure 
The test antigen is placed in each centre well and five 
antisera in five peripheral wells, with saline or negative 
serum control in the other. The slides are then 
incubated overnight in a warm humid chamber. 
All haemorrhagic septicaemia (HS)  isolates (Asian and 
African) will react with antiserum against type 2.  Some 
cross-reactions with type 5 may also be observed. 
Namioka-Murata technique (Namioka and 
Murata 1961 b) 
This somatic typing method can  be  used with suitable 
modifications to the HS serotypes only. 
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A 6-8 hour broth culture is  heavily seeded on to CSY 
agar plates and incubated for 24 hours at 37°C.  The 
growth on each  plate is checked for purity and 
harvested in 2-3 mL of 0.3% formalinised saline. The 
suspension is tested for agglutinability by the rapid 
slide agglutination test, as  a further check.  It is then 
centrifuged at 8000 rpm for 20 minutes. The 
supernatant is discarded, and the pellet is  resuspended 
in 25-30 mL of normal HCi saline and incubated at 
37°C overnight. The suspension  is then centrifuged at 
8000 rpm for 20 minutes, and the supernatant is 
discarded. The HCi-treated cell  residue is then washed 
twice with 0.3% formalinised buffered saline at pH 5.0 
and 6.0 respectively and the cells are finally 
resuspended in  buffered saline at pH 7.0. The turbidity 
is then adjusted to Wellcome opacity tube 6 or 
equivalent turbidimetric measure. Cultures that 
autoagglutinate at this stage should be discarded. 
In  addition to the test strain, it is  useful to have 
antigens prepared against reference Asian (6:8) and 
African (6:E)  HS strains, and the Australian (11 :8) 
avirulent strain. 
Preparation of  antiserum 
Antisera are prepared against the Asian (6:8)  and 
African (6:E) serotypes and the Australian avirulent 
serotype (11 :8) in the same manner as for capsular 
typing. Prior to use,  the titre of the serum against 
HCI-treated cells  is tested. 
Test procedure 
The test is carried out in 3.0-mL round-bottomed 
agglutination tubes.  Each test serum  is added to the first 
well in a horizontal row; serial  10-fold dilutions are done, 
leaving the last well as a control with saline only. An 
equal volume (0.5 mL) of antigen suspension  is then 
added to all wells in the row.  Each test will consist of 
three rows, with sera of the three serotypes given above. 
Each of three reference antigens is also used  as  a 
control to facilitate interpretation. The agglutination 
pattern of the test strain can  be interpreted using the 
following matrix: 
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Antisera  Antigens 
6:8  6:E  11 :8 
6:8  +  + 
6:E  +  + 
11 :8  + 
C.  Passive mouse protection test 
The passive mouse protection test (PMPT) was 
originally used by Roberts (1947) as  a method of 
serotyping Pasteurella multocida. It is  no longer used 
for this purpose because it cannot differentiate 
between certain related serotypes within a serogroup 
and  because other serotyping systems are simpler to 
perform and more discriminatory. However, it is 
popular as a method of determining immunity 
following either vaccination or natural exposure 
(Chapter 9) despite some limitations, which have been 
highlighted in  recent research  (see Chapter 10). The 
test described below is for the latter purpose. 
Mice used  must be from a colony hitherto unexposed 
to pasteurella and free from pasteurella antibodies. 
Serum of the animals under investigation is injected 
into mice, which are subsequently challenged with 
virulent pasteurellae of the relevant serotype. The test 
as carried out by different workers varies conSiderably. 
Essentially, there are three variables: the number of 
mice used for each  serum sample tested, the volume of 
serum injected, and the challenge dose. 
•  Number of mice per test serum sample 
- De Alwis et al.  (1978) - 3 mice with 3 controls 
- 8ain et al.  (1982) - 4-6 mice per sample 
- Gomis et al.  (1989) - 10 mice per pooled (n=6) 
serum sample 
- Dawkins et al.  (1991 b) Johnson et al. 
(1993) - 5 mice and 2 controls 
•  Serum volume - ranging from 0.5 mL (Bain et al. 
1982; De Alwis et al.  1978) to 0.2 mL (Johnson 
et al.  1993; dilutions of the serum may be  used for 
some objectives (e.g. comparing the protectivity of 
different sera). •  Challenge dose - usually 100 LD50, where the 
LD50 for mice is  1-10 colony forming units (CFU), 
so the normal challenge dose is estimated to 
contain 100 CFU.  This is  usually achieved by using 
1 mL of a 10-5 or 10-6 dilution of a 6-8-hour CSY 
broth culture. As accuracy is  not crucial at this 
stage, a visual judgment can  be made to obtain a 
dose of approximately 100 LD50. 
Interpretation 
Most workers have accepted survival of at least one of a 
group of five injected mice (i.e 20% protection) as an 
index of protection in cattie, provided all of a similar 
group of control mice die. Johnson et al. (1993) used 
a protective index (PI) where PI=log2 serum dilution plus 
proportion of mice surviving. Where the protectivity of 
sera from two different groups of cattle or buffaloes is to 
be compared, a large group of mice (say 10 or 20) can 
be immunised with pooled group sera, and the 
percentage protection can  be used as the criterion. 
In  using this test to measure immunity in  vaccinated 
cattle, it is very important to have adequate cattle 
controls. As far as  is  possible, the vaccinated group and 
the unvaccinated control group must be balanced in 
terms of numbers of animals, age, breed and sex. They 
should be managed in the same  manner and 
maintained in the same environment for the same 
period of time. Sera from both groups should be tested 
before and after vaccination. 
D.  Hyaluronidase test 
This is a nonserological test for the identification of 
type B strains specifically associated with HS.  A 
hyaluronic aCid-producing culture is streaked across 
a plate of dextrose starch agar.  Conventionally, 
hyaluronic acid-producing cultures of Streptococcus 
equi have been used,  but mucoid colonies of 
P multocida serogroup A,  which produce hyaluronic 
acid capsules,  may be  used to obtain clearly readable 
results.  The pasteurella cultures to be tested are then 
streaked across the plate at right angles to the original 
streak, and incubated at 3JOC  for 18 hours. At the 
point of intersection, where the test culture produces 
hyaluronidase, the hyaluronic acid-producing culture 
will show a thinned-out growth. The reading is 
facilitated by the use of freshly prepared plates and 
a humidified incubator. 
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In  recent years the enzyme-linked immunosorbent assay 
(ELISA)  has proved a useful technology for measuring 
the interaction of antigen and antibody using a solid-
phase support such  as a polystyrene microtitre plate, 
tube or stick.  ELISA-based systems are widely used  in 
the veterinary field for the detection or diagnosis of 
many viral, bacterial and parasitic infections. They are 
rapid, inexpensive and  can  be automated if a large 
through-put of samples is  required. 
ELISA methods have recently been adapted for 
diagnosis and monitoring of Pasteurella multocida 
infection and  have significant advantages over current 
methods (such  as serotyping and the indirect 
hemagglutination assay).  Using ELISA methods, 
infection with haemorrhagic septicaemia (HS)-causing 
serotypes of P.  multocida can  be diagnosed and 
monitored in two ways. 
•  HS-antibody ELISA - detection of circulating 
antibody to the HS-causing organism (humoral 
response). A specific antigen (adsorbed to plate) 
is  used to detect homologous antibody in test sera 
(Klaassen et al.  1985; Johnson et al.  1988, 1989, 
Chandrasekaran et al.  1994a); or 
•  HS-antigen ELISA - detection of the P.  multocida 
organisms that possess the HS-specific antigen. 
An antigen is  used in immunisation to raise specific 
antisera, which are then used to detect antigen in 
the test sample (Dawkins et al.  1990, 1991 b). 
Each of these methods is described in detail in  this 
appendix, as follows: 
A.  an  HS-antibody ELISA test used  in the detection of 
circulating antibodies of HS-causing P.  multocida in 
buffaloes (Chandrasekaran et al.  1994a); and 
B.  a rapid HS-antigen ELISA method for detection 
of HS-causing pasteurellae using antisera raised 
against the heat-stable antigen of somatic type 2 
P.  multocida (Dawkins et al.  1990). 
Equipment 
Special equipment 
•  Titertek Multiskan MC Plate Reader (414-nm filter) 
•  Plastic (polystyrene) microtitre 96-well plates 
Consumables/reagents 
(See Appendix 6 for further details of preparation of 
buffers and solutions) 
•  Culture media-sheep blood agar (SBA)  plates 
•  Rabbit antipasteurella sera (raised against heat-
stable antigen from HS-causing pasteurella strain; 
see  Immunisation, below) 
•  HS-ELISA antigen (heat stable P.  multocida antigen; 
see Antigens, below) 
•  Phosphate-buffered saline (PBS;  150 mM NaCI/10 
mM Na2P04, pH  7.4) 
•  PBST (0.05% Tween 20 in  PBS) 
•  2,2'-azino-di-[3-ethylbenzthiazolin sulfonate (6)] 
(ABTS) substrate in 0.1  M  citrate buffer pH  4.2 
containing 2.5 mM H20 2. 
•  HS-antibody ELISA conjugate (horseradish 
peroxidase-labelled antibovine IgG) 
•  HS-antigen ELISA conjugate (horseradish 
peroxidase-labelled rabbit antisera) 
A.  Analysis of immune response in 
buffaloes by HS-antibody ELISA 
All classic HS isolates possess the somatic type 2 
antigen. Johnson et al.  (1989) used the heat-stable 
antigens responsible for serogroup specificity to design 
an  ELISA system  able to measure serum antibody titres 
to HS-causing pasteurellae. The assay had the 
potential to assess  humoral immunity and provide 
rapid determination of vaccination efficacy in a large 
number of animals.  However, the usefulness of the 
technique is  limited because the assay was based  on 
101 a crude boiled extract composed largely of 
lipopolysaccharides (LPS)  and  is  broadly cross-reactive 
amongst HS-causing P.  multocida serotypes (there is 
no known HS-specific antigen). 
However, if the identity of the vaccinal strain  is known, 
the heat-stable antigen is suitable for an  ELISA 
designed to measure immunity to pasteurella in 
vaccinated animals.  Using this approach, the immune 
response and duration of protection in  buffaloes 
immunised with HS vaccines and the relationship 
between active protection against HS in vaccinated 
buffaloes and  passive  mouse protection test or serum 
antibody titres was described by Chandrasekaran et al. 
(1994a,b). The method used an  ELISA in which purified 
LPS,  formalin-killed cells or boiled intact cells of 
P.  multocida type 6:B (B:2) were used  as the antigen 
preparation to coat the plates. 
Immunisation 
1.  Suspend confluent growth from a blood agar plate 
culture of HS-causing P.  multocida in  1 mL of 
physiological saline containing 0.3 % formalin and 
then emulsify in  Freund's incomplete adjuvant using 
double adjuvant procedures. 
2.  Inoculate rabbits (1  mL)  intramuscularly, with a 
secondary inoculation given subcutaneously. All 
subsequent injections are given subcutaneously 
using formalin-killed organisms without adjuvant. 
3.  Bleed  rabbits prior to immunisation and 2 weeks 
after each  injection from the central ear artery or 
the marginal ear vein. 
Antigens 
Various antigen preparations have been  used  in  ELiSAs 
for the detection of antibody to HS-causing 
pasteurellae. These include the heat-stable antigen 
(Johnson et al.  1989), formalin-killed P.  multocida type 
B:2  (Chandresekaran et al.  1994a), boiled intact 
P.  multocida type B:2  (Chandresekaran et al.  1994a,b) 
and  purified Westphal LPS antigen (Chandresekaran 
et al.  1994a). 
•  Heat-stable antigen is  prepared using the method 
described by Heddleston et al.  (1972). Briefly, 
18-24 hour growth 011  heavily inoculated plates 
(dextrose starch  agar, or blood agar)  is  harvested in 
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1.0 mL of PBS  (pH 7.2). The suspension is  boiled 
for 1 hour at 100°C, and centrifuged to sediment 
cells.  Supernatant is  used  as antigen for 
immunisation and preparation of antisera. 
•  Formalin (0.3 %)-killed intact cells of P.  multocida 
are suspended in and adjusted to an  absorbance of 
0.25 at 600 nm in 0.1  M sodium carbonate buffer 
(pH 9.6). 
•  Boiled intact P.  multocida cells are adjusted to 
1 x108 colony forming units (CFU) per mL. 
•  Purified  LPS  antigen (10 jJg/mL) is prepared by the 
hot-phenol method (Westphal and Jann 1965). 
ELISA 
1.  Coat the wells of a U-bottom polystyrene microtitre 
plate with 50 jJL of appropriate pasteurella antigen, 
usually at a dilution of 1  :300 in  PBS.  Either cover or 
place in a moist chamber and hold at 4°C 
overnight. Flat-bottom microtitre plates are 
preferred, but many people use  U-bottom plates. 
2.  Wash the plate three times (for 5 minutes each) 
with PBST. 
3.  To  reduce background levels, some workers use a 
blocking step following antigen coating, using 
200 jJL of either 1 % bovine serum albumin (BSA) at 
4°C for 30-60 minutes or 0.1 % gelatin in  sodium 
carbonate buffer for 2 hours at 25°C. 
4.  Add 100 jJL of test serum to each  well, diluted 
1  :200 in  PBST 20. Each  plate should contain the 
following control wells: no antigen, no conjugate, 
110 serum, no substrate, and both positive and 
negative control sera. 
5.  Incubate for 1 hour at 37°C. 
6.  Wash the plate as above with PBST. 
7.  Add 50 jJL of conjugate (horseradish peroxidase-
labelled anti-rabbit IgG) per well, diluted to working 
strength in  PBST.  The developing antiserum is 
produced in  sheep using established procedures 
(Butler and Maxwell 1972) and conjugated to 
horseradish peroxidase, Sigma type VI (Wilson and 
Nakane 1978) 
8.  Incubate for 1 hour at 37°C. 9.  Wash the plate as above. 
10. Add 100 IJL per well of freshly prepared substrate 
consisting of 0.1  M citrate/phosphate buffer pH  4.2 
containing 1 mM ABTS (Boehringer Mannheim) 
with 2.5 mM H20 2. Other substrates, such  as 
ortho-phenylene diamine, have also been  used 
successfully. 
11. Incubate at 37°C and read  after 30 minutes at 
415 nm using a Titertek Multiskan MC Plate Reader 
(Flow Laboratories) or MR590 MicroELISA Mini 
Reader (Dynatech Laboratories). 
12. Calculate the titre of the test serum.  ELISA titre is 
assigned  as the reciprocal of the highest dilution of 
serum that gives an absorbance at 414 nm (OD414) 
of 0.50. 
B.  Rapid identification of P.  multocida 
organisms by HS-antigen ELISA 
Dawkins et al.  (1990) describes the method for rapid 
identification of the P.  multocida organisms responsible 
for HS  using ELISA with a heat-stable antigen of 
P.  multocida isolate 0019 (Insein)(Bain 1955). This 
isolate was selected for immunisation as  it was known 
experimentally to induce HS and continued to cause 
the disease following frequent passage through cattle. 
The  HS-antigen ELISA demonstrated a 99% specificity 
and at least 86 % sensitivity after examination of 124 
P.  multocida strains of various origins. 
The HS-antigen ELISA does not require sample 
preparation such  as  is  necessary for capsular and 
somatic typing, nor is it influenced by the wide range 
of phenotypic variants that have proved problematic 
for some typing systems. However, the heat-stable 
antigen used  in this assay  is  basically a crude  LPS 
preparation from the Insein strain; therefore, the 
antisera generated following immunisation will detect 
any P.  multocida organism with the type 2 (or closely 
related type 5) somatic antigen. While it is  known that 
few P.  multocida cultures other than those implicated 
in  HS possess the type 2 (or 5) somatic antigen, 
recognition of the type 5 antigen will result in false 
positive identification of some isolates, as was 
demonstrated with the Heddleston type 5 reference 
strain (ATS5). 
Immunisation 
1.  Harvest an overnight lawn culture of 0019 into PBS 
(pH 7.2) at a ratio of 1 plate to 1 mL of PBS. 
2.  Prepare boiled antigen by the method of 
Heddleston et al.  (1972) and emulsify in  incomplete 
Freund's adjuvant. 
3.  Re-emulsify the primary emulsion in  an  equal 
volume of 0.85% NaCI containing 2% Tween  80. 
4.  Inject the double-adjuvanted immunogen 
intramuscularly into rabbits (0.5 mL) into two sites; 
a second injection is given subcutaneously one 
month later. 
5.  Boost rabbits twice by injection with 1 mL of 
boiled antigen at monthly intervals, bleed by 
needle puncture of the central ear arteriole, 
and collect serum. 
Immunoglobulin precipitation 
1.  Pool antisera from bleeds following the second 
immunisation step, dilute 1:1  with PBS and  make to 
a 13 % wtlvol solution of polyethylene glycol (PEG) 
6000 (BDH Chemicals) by the dropwise addition of 
a stock 50% wtlvol PEG  solution. 
2.  Mix the slurry for 30 minutes and collect the 
precipitate by centrifugation. 
3.  Dissolve the pellet in  PBS to a volume of the 
original serum plus PBS volume. 
4.  Repeat the PEG  precipitation. 
5.  Resuspend the final pellet in  PBS  and dialyse 
extensively against the same buffer. 
Conjugation 
1.  Dilute the PEG  immunoglobulin fraction to 
8 mg/mL in  PBS. 
2.  To 4 mL of immunoglobulin, add 800 IJL of sodium 
carbonate/sodium bicarbonate solution (30 mL of 
0.1  M sodium carbonate and 7 mL of 0.1  M 
sodium bicarbonate, pH 9.5) and stir. 
3.  Working to a formula of 1 mg of horseradish 
peroxidase (Boerhinger Mannheim) per 2 mg of 
protein, dissolve 16 mg of horseradish peroxidase in 
103 4 mL of distilled water. Add 800 IJI  of 0.1  M 
sodium-m-periodate to the dissolved horseradish 
peroxidase. 
4.  Run  the horseradish peroxidase solution through a 
20-mL sephadex G-25 column pre-equilibrated to 
pH 4.4 in  1 mM sodium acetate, and collect the 
yellow-brown fraction. 
5.  Add the horseradish peroxidase fraction to the 
immunoglobulin solution and gently stir for 2 hours 
at room temperature. 
6.  Dialyse the conjugated immunoglobulin preparation 
extensively against PBS at 4°C. 
ELISA 
The ELISA procedure is  as follows (all steps are 
performed at room temperature with 1  OO-IJL volumes). 
1.  Coat the polystyrene microtest plates with PBS 
containing 2 IJg/mL rabbit anti-P.  multocida 0019 
boiled antigen immunoglobulin fraction and allow 
to stand overnight. 
2.  Grow bacteria for assay on sheep blood agar 
overnight at 37°C. 
3.  Harvest approximately 20 IJg (20 IJL) weight of 
bacteria into a microfuge tube containing 1 mL  PBS. 
This produces a solution estimated to contain more 
than 1010 per mL,  which is adopted as the cell 
concentration for positive control stock suspensions. 
If the bacteria are to be stored for any length of 
time, add formalin to give a final concentration of 
0.04 % formaldehyde. 
4.  Dilute harvested bacteria 1  :10 in  PBST. 
5.  Wash  the antibody-coated plates three times 
with PBST. 
6.  Add the diluted bacteria to the appropriate column 
giving about 108 bacteria per well. Add each  isolate 
to one column of the microtitre plate, giving 
octuplets for each  sample in order to analyse the 
variability between wells and  provide accurate 
standardisation of the test. Also include substrate, 
conjugate and positive control columns. 
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7.  Incubate the plate at room temperature for 1 hour; 
then wash the plate three times in  PBST. 
8.  Add conjugated immunoglobulin preparation (see 
Conjugation above) at an  optimal dilution (1:1000) 
and incubate for 1 hour. 
9.  Wash the plates four times with PBST and add a 
substrate solution of 1 mM freshly prepared ABTS 
in 0.1 M  citrate buffer pH 4.2 containing 2.5 mM 
H20 2 · 
10. Allow colour to develop for 1 hour and  read the 
plate with a Titertek Multiskan MC using a 414 nm 
wavelength. Express the results  as ELISA units 
(optical density x 100). Polymerase Chain Reaction 
The recent development of nucleic acid amplification 
technologies, particularly the polymerase chain  reaction 
(PCR),  which allow amplification and detection of 
minute quantities of DNA from microorganisms, cells 
and tissues,  has led to an  explosion of new diagnostic 
methods for many infectious diseases. The methods 
have the advantage over more conventional methods 
of being very rapid and extremely sensitive and 
specific. Microorganisms can  also be specifically 
detected using PCR analysis directly on clinical samples, 
mixed or pure cultures. Although the technology 
requires a specifically equipped facility with highly 
trained staff to carry out the assays,  PCR analysis is 
being increaSingly incorporated with ease into 
laboratories throughout the world. 
This appendix describes the general methodology and 
equipment for PCR tests and the development of PCR 
assays for identification and characterisation of 
Pasteurella multocida,  as follows: 
A.  General methods 
B.  PCR assays specific for P.  multocida strains 
C.  PCR assay for HS-associated type B serotypes 
of P.  multocida 
D.  PCR assay for the gene region associated with the 
pathogenicity of HS-associated P.  multocida 
serotype B:2 
E.  PCR fingerprinting of P.  multocida 
A. General methods 
Equipment 
The following laboratory equipment is standard for 
molecular techniques: 
•  Centrifuge (microfuge and  benchtop centrifuge) 
•  Water bath(s) 
(standard temperatures 37°C,  50°C and 65°C) 
•  Pipettes (ranging in volume from 0.1  I-IL to 1 mL) 
•  Pipette tips 
•  Plastic tubes (0.2-I-IL or 0.6-1-11  PCR tubes, 1.5-mL 
Eppendorf tubes, 35-mL and/or 50-mL Corning 
tubes) 
•  Submerged Gel  Nucleic Acid Electrophoresis System 
(mini, midi or maxi) (Bio-Rad Laboratories) 
•  PowerPac 300 (or 200) system 
(Bio-Rad Laboratories) 
•  UV transilluminator and dark room facilities 
•  Photographic film (Polaroid 31/ 4  x 41/ 4  inches) 
•  Polaroid camera 
•  Vortex 
Special equipment 
•  Thermal cycler 
•  Pipettes (preferably two complete sets,  pre- and 
post-PCR handling) 
•  Microfuge tubes (PCR tubes of 0.2 or 0.6 mL 
depending on  the thermal cycler specifications; and 
1.5 mL tubes) 
Consumables 
Culture media 
•  Sheep blood agar (SBA) 
•  Tryptone soya broth (TSB) 
•  Heart infusion broth (HIB) 
PCR analysis 
•  Thermostable DNA polymerase (Taq,  Tth, Pfu,  Pwo 
etc.) and  PCR  buffer 
•  Deoxynucleotide triphosphate set (dATP,  dCTP, 
dGTP and dTIP) 
•  Oligonucleotide primers (see individual assays for 
specific sequences) 
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•  Nuclease-free water 
(Promega preferable but not essential) 
•  Light mineral oil  (see thermal cycler specifications) 
•  Agarose 
•  Tris-acetic acid-EDTA (TAE)  buffer 
•  Ethidium bromide 
•  Loading dye 
•  DNA markers (either Bacteriophage lambda cut 
with fcoRI and Hindlll or 100 bp DNA) (the marker 
should be adequate for all  DNA analysis purposes). 
Note: Details of buffers and  solutions required are 
shown in  Appendix 6. 
Template preparation 
Crude DNA preparation from swab samples 
(nasal, oropharyngeal, tonsi/) 
1.  Inoculate the swab into 2 mL of T5B. 
2.  Grow on a roller/shaker for about 1-2 hours (or 
until there is visible growth). 
3.  Transfer 1 mL into a 1.5-mL Eppendorf tube. 
4.  Centrifuge at 13 000 rpm for 4 minutes. 
5.  Discard the supernatant and wash  in 500 f-lL 
of distilled water. 
6.  Centrifuge at 13 000 rpm for 4 minutes. 
7.  Discard the supernatant and resuspend in  100 f-lL 
of distilled water. 
8.  Transfer 100 f-lL  to a PCR tube and overlay 
with mineral oil. 
9.  Boil  in a PCR machine at 98°C for 20-30 minutes. 
10. Centrifuge (place the closed  PCR tube in a new 
Eppendorf tube) at 13 000 rpm for 2 minutes. 
11. Transfer the supernatant to a sterile Eppendorf tube 
and  store at -20°C until required. 
12. Use 5 f-lL of supernatant in the PCR reaction. 
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Crude DNA preparation from bacterial colonies 
1.  Harvest bacterial cells (resuspend one to two 
colonies in  100 f-ll  double distilled water) and 
centrifuge at 13 000 rpm for 2 minutes at room 
temperature. 
2.  Resuspend  the pellet in  100 f-lL  of sterile distilled 
water and boil at 100°C for 15 minutes. 
3.  Centrifuge at 13 000 rpm for 2 minutes at room 
temperature. 
4.  Transfer the supernatant containing the DNA to a 
sterile vial and  keep at 4°C for routine use or -20°C 
for long-term storage. 
Preparation of DNA from pure cultures 
Whole-cell DNA can  be isolated by selective 
precipitation with hexacytrimethylammonium bromide, 
or by traditional genomic DNA extraction methods (see 
DNA preparation method for restriction endonuclease 
analysis - Appendix 5); the DNA concentration is 
determined by fluorometry or optical densitometry. 
While purified DNA is  required for quantitative analysis, 
it has been shown that colony PCR (Townsend et al. 
1998) or an  aliquot of boiled culture supernatant is 
sufficient for routine amplification. 
B.  peR assays specific for P.  multocida 
General method 
Townsend et al.  (1998) have developed PCR assays for 
species- and type-specific identification of P multocida 
isolates. Oligonucleotide primers designed during the 
sequencing of a P multocida-specific clone isolated by 
genomic subtractive hybridisation have contributed to 
the development of a species-specific PCR assay for the 
detection of P multocida. The primer pair KMT1 5P6-
KMT1T7 specifically amplifies a product of 
approximately 460 base pairs (bp) in  all subspecies of 
P multocida (subsp. multocida, subsp. gallicida and 
subsp. septica) and  in Pasteurella canis biovar 2 
(originally Bisgaard Taxon 13). P canis biovar 2 was 
once recognised  as an atypical P muitocida, and 
indeed 165 rRNA sequencing indicates that the two 
species are very closely related (Dewhirst et al.  1993). 
However, DNA:DNA hybridisation supports the 
recognition of P canis biovar 2 as a distinct species. While false positives may occur with isolates from 
pneumonic cattle and  pigs,  P.  multocida and  P.  canis 
biovar 2 can  be distinguished on  the basis of indole and 
mannitol fermentation. 
Primer sequences 
KMT1 SP6  5' - GCTGTAAACGAACTCGCCAC - 3' 
KMT1T7  5' - ATCCGCTATTIACCCAGTGG - 3' 
peR analysis 
The  25-~L PCR reaction mixture consists of a template 
of DNA «1 colony, 1 ~L culture, or 5  ~L boiled culture 
supernatant), 3.2 pmol of each  primer, 200 ~M  of each 
dNTP,  1 X PCR buffer containing 2 mM MgCI2 and 
0.5 Units Taq  DNA polymerase with oil overlay. 
The thermal cycling parameters are as follows: initial 
denaturation at 94°C for 5 minutes; 30 cycles of 94°C 
for 1 minute, 55°C for 1 minute, and 72°C for 
1 minute; and a final extension of 72°C for 9 minutes. 
Analysis of peR products 
Amplified products are separated by electrophoresis in a 
2 % agarose gel  in  1 x TAE at 4 V  fcm for 1 hour, stained 
with 0.1  ~gfmL  ethidium bromide al1d  visualised  by UV 
illumination. 
Detection of P.  multocida-specific 
DNA in turkeys 
Kasten  et al.  (1997) have described detection of 
P.  multocida-specific DNA in turkey flocks using PCR. 
P.  multocida is  known to contain a gene known as  psi 
(for P6-like) that encodes a protein unique to 
P.  multocida and Haemophilus influenzae. Because 
H.  influenzae is  not normally isolated from poultry, it 
was proposed that a PCR assay based on  this gene 
could  be  used to detect P.  multocida from 
oropharyngeal samples obtained from these birds. 
While this hypothesis is correct, the identification of 
H.  influenzae limits the assay to veterinary specimens 
and excludes its use in  humal1 diagl10stic pathology. A 
further limitation is that achieving the specificity of 10 
P.  multocida organisms (24 fg purified DNA) requires 
hybridisation of membrane-bound PCR  products with 
the psi  gene. Although the number of laboratories with 
PCR technology is  increasing in  HS-endemic countries, 
routine diagnostic laboratories in  these countries are 
unlikely to have the equipment required for Southern 
hybridisation. 
Primer sequences 
(includes BamHI sites at each end) 
FWD 
5' - TCTGGATCCATGAAAAAACTAACTAAAGTC - 3' 
REV 
5' - AAGGATCCTIAGTATGCTAACACAGCACGACG - 3' 
peR analysis 
The  PCR reaction mixture consists of 5  ~L template 
DNA, 25 pmol of each  primer, 2.5 mM of each  dNTP, 
1 x PCR buffer containing 1 mM MgCI2 and  1.25 Units 
Taq  DNA polymerase. 
The thermal cycling parameters are:  initial denaturation 
at 94°C for 2 minutes; followed by 35 cycles of 94°C 
for 1 minute, 50°C for 30 seconds, and 72°C for 
3 minutes; and a final extension of 72°C for 7 minutes. 
Analysis of peR products 
Amplified products are separated  by electrophoresis in 
a 2% agarose gel in  1 x TAE,  at 74 V for 2 hours, 
stained with ethidium bromide and visualised by UV 
illumination. 
c.  peR assay for HS-associated type B 
serotypes of P.  multocida 
Townsend et al.  (1998) described the development of 
PCR assays for species- and type-specific identification 
of P.  multocida isolates (see above). Oligonucleotide 
primers designed during the sequencing of an  HS-
associated type B specific clone isolated by genomic 
subtractive hybridisation formed the basis of a type-
specific PCR assay for the detection of HS-associated 
type B serotypes of P.  multocida. The primer pair 
KTSP61-KTI72 specifically amplifies a product of 
approximately 560 bp in  all  P.  multocida isolates 
possessing the type B capsular antigen and  either type 
2 or 5 as the dominant somatic antigen. The clone, 
originally isolated from a reportedly avirulent HS 
culture, demonstrated significant nucleotide sequence 
identity to a region  in  the H.  influenzae Rd  genome 
107 flanking DNA sequences tenuously associated with 
bacteriophage Mu genes. While this proposed identity 
indicates that there is  potential for cross-reactivity, 
evidence of nonspecific amplification has not been 
observed. At present, the assay retains 100% specificity 
for HS-associated serotypes of P.  multocida following 
examination of a diverse range of bacterial species. 
Primer sequences 
KTSP61  5' - ATCCGCTAACACACTCTC - 3' 
KTT72  5' - AGGCTCGTTTGGATTATGAAG - 3' 
PCR analysis 
The 25-fJL PCR  reaction mixture consists of the 
following: template DNA «  1 colony, 1 fJL  culture, 
or 5 fJL  boiled culture supernatant), 3.2 pmol of each 
primer, 200 fJM  of each  dNTP,  1 x PCR buffer 
containing 2 mM MgCI2 and 0.5 Units Taq  DNA 
polymerase with oil overlay. 
The thermal cycling parameters are as follows: initial 
denaturation at 94°C for 5 minutes; followed by 30 
cycles  of 94°C for 1 minute, 55°C for 1 minute, and 
72°C for 1 minute; and a final extension of 72°C for 
9 minutes. 
Analysis of peR products 
Amplified products are separated  by electrophoresis in 
a 2 % agarose gel in 1 x TAE at 4V  fcm for 1 hour, 
stained with 0.1  fJgfmL ethidium bromide and 
visualised by UV illumination. 
The HS-PCR method can  also be used  in a multiplex 
reaction with the PM-PCR (described above in  P. 
multocida-specific PCR assays).  To achieve comparable 
intensities of amplified products from both PCR assays, 
the concentration of the HS-PCR primers should be 
doubled to 6.4 fJM. All other parameters are as 
previously described for each individual assay.  The 
multiplex PMfHS-PCR assay will provide a rapid, 
efficient and sensitive method for the specific detection 
of HS-associated type B serotypes of P.  multocida. 
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D.  peR assay for the gene region 
associated with the pathogenicity 
of P.  multocida serotype 8:2 
Brickell et al.  (1998) have developed a PCR test based 
on a gene region associated with the pathogenicity of 
P.  multocida serotype B:2,  the causal  agent of HS  in 
Asia. Primers designed from a 16S-23S rRNA intergenic 
spacer region PCR product unique to type B:2 
P.  multocida formed the basis of a PCR assay for 
diagnosis of HS  in cattle and  buffalo. While this assay 
generally appears to identify type B:2  P.  multocida, 
inconsistent correlation between PCR amplification and 
serological designation indicates that further 
optimisation is required before the assay  is  incorporated 
into routine diagnosis in  HS-endemic countries. The 
assay cannot be regarded as  'B:2 specific' since a 
product was amplified from isolate 0350 (E:2).  Nor can 
it be viewed as  'HS-specific', as 100% detection of all 
HS-associated serotypes was not demonstrated. 
It is  also difficult to support the suggestion that 
sequences adjacent to the unique fragment will identify 
the phage insertion site and  phage-associated virulence 
determinants if the genetic organisation of this region 
in  P.  multocida is similar to that of H.  influenzae Rd. 
The associations between the H.  influenzae Rd 
predicted coding regions and  the Mu proteins are 
tenuous, and do not appear to encode a complete 
prophage. It is therefore unlikely that any hypothetical 
virulence-associated determinants once associated with 
the Mu phage would have survived the integration into 
the P.  multocida genome intact. There is  thus no 
evidence for the claim that this region is  in any way 
virulence associated. 
Primer sequences 
IPFWD  5' - CGAAAGAAACCCAAGGCGAA - 3' 
IPREV  5' - ACAATCGAATAACCGTGAGAC - 3' 
PCR analysis 
The 20-fJL PCR reaction mixture consists of: template 
DNA (1  fJL  bacterial culture), 0.25  fJM of each  primer, 
200 fJM of each  dNTP, 1 x PCR buffer containing 
1.5 fJM MgCI2 and 2.5 Units Tth DNA polymerase with 
oil overlay. The thermal cycling parameters are as follows: 35 
cycles of 94°C for 30 seconds,  60°C for 30 seconds, 
and 72°C for 30 seconds. 
Analysis of peR products 
Amplified products are separated by electrophoresis in 
a 1.0% agarose gel  in 1 x Tris-boric acid  (EDTA), 
stained with 0.1 f.Jg/mL ethidium bromide and 
visualised by UV illumination. Positive reactions should 
produce a product of 334 bp in  size. 
E.  PCR fingerprinting of P.  multocida 
by REP-PCR 
Townsend et al.  (1997a) have described repetitive 
extragenic palindromic (REP)-PCR analysis of P. 
multocida isolates that cause  HS.  Amplification of 
multiple genomic DNA fragments from P.  multocida 
isolates by outwardly-directed primers based  on the 
REP  consensus sequence generates comparative 
profiles in a PCR-based fingerprinting method known 
as  REP-PCR.  A high degree of homogeneity was 
observed among HS strains of serotypes Band E, 
indicating evidence of a disease-associated  REP profile 
that may serve as a novel method for the identification 
of HS-associated isolates regardless of serotype. 
REP-PCR profiles of other P.  multocida serotypes were 
highly variable, illustrating the value of this technique 
for molecular fingerprinting in  outbreaks of fowl 
cholera or atrophic rhinitis. This technique has recently 
been  utilised in  a study of P.  multocida strains isolated 
from cases diagnosed as acute septicaemic 
pasteurellosis in  Vietnam (Townsend et al.  1998), with 




REP1 R-IDt  3' - CGGNCTACNGCNGCNNNN - 5' 
~ 
REP2-IDt  5' - NCGNCTTATCNGGCCTAC - 3' 
peR analysis 
The 25-f.JL  PCR reaction mixture consists of the 
following: template DNA «1 colony, 1 f.JL  culture, or 
5 f.JL  boiled culture supernatant), 6.4 pmol of each 
primer, 200 f.JM of each  dNTP, x PCR buffer containing 
4 mM MgCI2  and 1.0 Units Taq  DNA polymerase. 
The thermal cycling parameters are as follows: initial 
denaturation at 95°C for 7 minutes; followed by 30 
cycles of 94°C for 1 minute, 42°C for 1 minute, and 
65°C for 8 minutes; and a final extension of 65°C for 
16 minutes. 
Analysis of peR products 
Amplified products are separated by electrophoresis in 
a 2.0% agarose gel  in 1 x TAE at 2 V/cm for 3 hours, 
stained with 0.1  f.Jg/mL ethidium bromide and 
visualised by UV illumination. 
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Conventional techniques used to classify Pasteurella 
multocida have been  reliant on the phenotypic 
characteristics of the organism, and have frequently 
been found to confound rather than clarify the 
relationship between strains. Molecular techniques 
have overcome the restrictions of phenotypic 
classifications by providing an  insight into the genetic 
'fingerprint' of each strain, and have been  used 
successfully to distinguish phenotypically similar 
isolates. 
Three methods are described in this appendix: 
A.  restriction endonuclease analysis 
B.  ribotyping analysis 
C.  field alternation gel electrophoresis 
A.  Restriction endonuclease analysis 
Restriction endonuclease analysis (REA)  involves the 
cleavage of genomic DNA by restriction endonucleases 
at specific nucleotide sequences,  producing a set of 
DNA fragments that, when separated by 
electrophoresis, provide a characteristic banding 
pattern or fingerprint. Characterisation of the genome 
by  REA has proved effective for accurate identification 
and epidemiology studies of P.  multocida (Snipes et al. 
1989; Kim and Nagaraja 1990; Wilson et al.  1992; 
Wilson et al.  1993). The method involves extraction 
and  purification of genomic DNA, digestion with 
restriction endonucleases and analysis and visualisation 
of the DNA fragments ('fingerprint'). 
Equipment 
Standard equipment 
As for PCR (see Appendix 4) 
Consumablesl reagents 
•  Culture media 
- Sheep  blood agar (SBA) 
- Tryptone soya broth (TSB) 
- Trypticase soy broth 
containing 1.25% tryptose (TST) 
- Heart infusion broth (HIB) 
•  Cetyltrimethylammonium bromide 
(CTAB)/NaCI solution 
•  5 M  sodium chloride (NaCI) 
•  Tris-EDTA (TE)  buffer, pH  8.0 
•  Lysozyme (10 mg/mL) 
•  10% sodium dodecyl sulfate (SDS) 
•  RNase  (100 mg/mL) 
•  Proteinase K solution (20 mg/mL) 
•  Equilibrated phenol, pH 7.0 
•  Phenol-chloroform-isoamyl alcohol (25:24:1  vol/vol) 
•  Chloroform-isoamyl alcohol (24:1 vol/vol) 
•  Sodium acetate (3  M) 
•  Isopropanol 
•  Ethanol 
•  Restriction endonucleases and  restriction buffers 
•  Tris-acetic acid-EDTA (TAE) 
or Tris-boric acid-EDTA (TBE)  buffers 
•  Stop mixture (0.25% bromophenol, 
0.25% xylene cyanole, 25% Ficoll 400) 
•  Agarose 
•  Ethidium bromide 
Note: Details of buffers and solutions required are 
shown in  Appendix 6. 
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Computerised restriction fragment length polymorphism 
equipment for the comparative analysis of a DNA 
fingerprint database is needed. The database is created 
through the amalgamation of calibrated and 
standardised fragment data from multiple photographic 
images. 
Comparison of DNA fingerprints and somatic 
serotypes of P.  multocida 
Wilson et al. (1992) compared DNA fingerprints and 
somatic serotypes of serogroup Band E  P.  multocida 
isolates using REA.  This study remains the single most 
comprehensive characterisation of serogroup Band E 
isolates of P.  multocida using both serologic typing and 
DNA fingerprinting, with Hhal and Hpal/ determined to 
be the most informative restriction enzymes for 
fingerprinting analysis. Thirteen Hhal profiles were 
recognised among the 54 isolates designated as classic 
haemorrhagic septicaemia (HS)-causing P.  multocida 
(serotype B:2  or B:2,5). All 13 serogroup E isolates had 
identical somatic serotypes and Hhal DNA fingerprint 
profiles; however, the Hhal profile did not match any 
fingerprint profile of the reference somatic serotype 
strains.  DNA profiling with the Hpall endonuclease 
allowed differentiation of the serogroup E isolates, with 
five distinct profiles observed.  It is evident that the 
Hhal endonuclease yields discriminatory profiles among 
serogroup B strains; however, comparison among all 
P.  multocida serotypes requires the use of both Hhal 
and  Hpall DNA profiles to provide definitive 
classification. 
A rapid  DNA extraction method was developed to 
allow the efficient processing of isolates, reducing the 
time taken to obtain 16 purified DNA samples to 2.5 
hours. While discrimination of Hpall and Hhal profiles 
could be accomplished with the naked eye,  the use of 
computerised restriction fragment length 
polymorphism equipment enabled precise comparison 
of multiple genomic profiles with increased resolution 
of minor fragment differences. 
DNA extraction 
1.  Inoculate a single colony into 5 mL of TST and 
incubate at 37°C for 18-24 hours. 
2.  Centrifuge a 1.5-mL aliquot of the 24-hour TST 
broth culture at 16,000 x g for 4 minutes. 
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3.  Discard the supernatant and resuspend the pellet in 
1 mL of TE,  pH 8.0. 
4.  Centrifuge as above and decant all  but 50 ~L of the 
supernatant. The residual supernatant and  pellet is 
stored at -70°C until required. 
5.  Thaw the frozen pellet by adding 350 ~L of TE,  and 
vortex to resuspend cells. 
6.  Add 150 j..JL  of freshly prepared lysozyme solution 
(10 mg of lysozyme per mL of H20  (preferably 
double distilled or sterile distilled) to the mixture 
and place on  ice for 15 minutes to lyse the cells. 
7.  After lysis, add 40 j..JL  of 10% SDS and  mix for 1 
minute, or until the suspension clears. 
8.  Add 8 ~L of RNase solution (100 mg/mL) to the 
cleared suspension and mix by inversion for 1 minute. 
9.  Add 60 j..JL of proteinase K solution (20 mg/mL), 
mix and incubate at 37°C for 30 minutes. 
10. Extract DNA by adding 0.8 mL of equilibrated 
phenol (pH 7.0) to the mixture. Invert vigorously 
until a white emulsion is  formed, then centrifuge at 
16000 x g for 1 minute. 
11. Transfer 600 j..JL  of aqueous phase to a new 
microfuge tube containing 150 j..JL  TE. 
12. Add 0.7 mL of a 1:1  mixture of phenol (pH 7.0) 
and chloroform-isoamyl alcohol (25:1  vol/vol). 
Invert vigorously, then centrifuge at 16 000 x g 
for 1 minute. 
13. Transfer 600 ~I of aqueous phase to a new 
microfuge tube, and add 0.8 mL of 
chloroform-isoamyl alcohol (25:1  vol/vol). 
Mix by inversion and centrifuge at 16 000 x g 
for 1 minute. 
14. Transfer 425  ~L of aqueous phase to a 
tube containing 75  j..JL  3 M  sodium acetate 
and mix briefly. 
15. Add 1 mL of ethanol (25°C) and  invert the tube 
several times before placing on  ice for 10 minutes. 
16. Pellet the precipitated DNA by centrifugation 
at 16 000 x g for 15 minutes; decant and 
discard the supernatant. 17. Air-dry the pellet or dry in a vacuum concentrator 
and suspend  in 50 iJL of TE. 
Another method used for the recovery of high 
molecular weight DNA removes cell  wall debris, 
polysaccharides and  proteins by selective precipitation 
with CTAB.  The CTAB-protein-polysaccharide complex 
precipitates pellets more effectively than residual 
protein-polysaccharides in other methods, and 
therefore will produce a cleaner DNA preparation. 
1.  Grow the bacterial strain of interest in  a 5-mL liquid 
medium and conditions appropriate for that strain 
(for P multocida, inoculate 5 mL of TSB or 
brain-heart infusion with the strain of interest and 
grow overnight at 37°C). 
2.  Spin  1.5 mL of culture in a microcentrifuge for 
2 minutes and discard the supernatant. 
3.  Resuspend  the pellet in 567 iJL TE  buffer by 
repeated pi petting. Add 30 iJL of 10% SDS and 
3 iJL of 20 mg/mL proteinase K to give a final 
concentration of 100 iJg/mL proteinase K in 0.5% 
SDS.  Mix thoroughly and  incubate for 1 hour at 
37°C. The solution should become viscous as the 
detergent SDS  lyses the bacterial cells. 
4.  Add  100 iJL of 5 M  NaCi and mix thoroughly. It is 
important to keep the salt concentration above 
0.5 M  at room temperature to prevent the 
formation of a CTAB-nucleic acid precipitate. 
5.  Add 80 iJL of CTAB-NACI solution. Mix thoroughly 
and  incubate at 65°C for 10 minutes. 
6.  Add an approximately equal volume (0.7 to 0.8 mL) 
of chloroform-isoamyl alcohol, mix thoroughly and 
spin  for 4-5 minutes in  a microfuge. 
7.  Remove aqueous, viscous supernatant to a fresh 
microfuge tube, leaving the interface behind, and 
add  an equal volume of phenol-chloroform-isoamyl 
alcohol. Extract thoroughly and spin  in a microfuge 
for 5 minutes. 
8.  Transfer the supernatant to a fresh  tube and add 
0.6 volume isopropanol to precipitate the nucleic 
acids.  Invert the tube several times until a stringy 
white DNA precipitate becomes visible. 
9.  Pellet the precipitate by spinning in a microfuge 
briefly at room temperature. 
10. Wash the pellet with 70% ethanol to remove 
residual CTAB and spin for 5 minutes at room 
temperature. Carefully remove the supernatant and 
discard. Either air-dry the pellet or briefly dry in a 
Iyophiliser. 
11. Redissolve the pellet in 100 iJ L of TE  buffer. 
REA analysis 
1.  Genomic DNA is digested with each  restriction 
endonuclease as  recommended by the 
manufacturer. 
2.  Stop the reaction after 3 hours by adding 5 iJL of 
stop mixture (0.25% bromophenol, 0.25% xylene 
cyanole, 25% Ficoll 400). 
3.  Electrophorese DNA fragments in  a 0.7% agarose 
gel  in  1 x TBE  buffer for 17 hours at 2.4 V  /cm. 
4.  Stain the gel with ethidium bromide, and visualise 
by UV illumination. 
B.  Ribotyping analysis 
Ribotyping involves the use of Southern blot analysis to 
detect restriction fragment length polymorphisms 
associated with bacterial ribosomal operon(s). This 
method has proved valuable for the discrimination of 
P multocida isolates of similar serotype, particularly 
among avian strains isolated from fowl cholera 
outbreaks (Blackall et al.  1995). While serogroup Band 
E isolates have been analysed by REA,  this application 
is  limited by its dependence on computerised analysis 
of restriction fragment length polymorphisms. The use 
of labelled ribosomal probes to highlight variation 
within ribosomal RNA (rRNA) genes simplifies the 
profiles obtained by REA,  and allows visual comparison 
of banding profiles (Townsend et al.  1997b). 
Equipment 
Standard equipment 
As described for REA,  plus 
•  Hybridisation oven and  bottles 
(or a 65°C circulating water bath) 
•  Boiling water bath 
•  PC2  laboratory with radioactive material safety 
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of radioactive materials (if radioactive labelling of 
DNA probe is  required) 
Consumablesl  reagents 
•  Culture media 
- Luria-Bertani media (for propagation of 
Escherichia coli) 
•  Ampicillin (or tetracycline, depending on  plasmid) 
•  Nylon membrane (e.g.  Hybond-W, Amersham) 
•  Plasmid  DNA extraction and  purification kit 
(Promega, QIAGEN, Boehringer Mannheim) or use 
conventional methods (alkaline lysis/polyethylene 
glycol precipitation) 
•  For conventional plasmid purification: 
- glucose buffer (25 mM Tris  pH  8.0, 50 mM 
glucose, 10 mM EDTA) 
- lysozyme solution (8 mg/mL in glucose buffer) 
- isopropanol 
- lysis buffer (0.2 M  NaOH with 1 %  SDS,  make 
fresh each time) 
- potassium acetate solution 
- phenol 
- chloroform 
- 3 M sodium acetate pH 7.4 
- TE 
•  Restriction endonucleases (according to 
plasmid/insert requirements) 
•  Nucleic acid  labelling system (radioactive or non-
radioactive) (e.g.  Prime-a-Gene Labeling System, 
Promega) 
•  DIG-High Prime DNA labelling and detection kit 
(Boehringer Mannheim) 
•  Easytides™ dCTP  [a-32Pl  370 Mbq/mL (DuPont, 
NEN  Research  Products, MA, USA) 
•  Salmon sperm  DNA (type III sodium salt) 
•  Sephadex G-50 (fine) 
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•  Spermidine 
•  X-ray film 
Analysis of HS-causing 
isolates of P.  multocida by ribotyping 
Townsend et al.  (1997b) have described the analysis of 
HS-causing isolates of p.  multocida by ribotyping. 
Examination of ribosomal hybridisation profiles of 
P.  multocida isolates confirmed the homogeneity of HS 
isolates originating from Asia described by Johnson et 
al.  (1991), and  provided greater discrimination than 
previous typing methods. 
Classification of HS isolates by ribotyping can  be 
generally correlated with geographical origin, with 
particular regard to Asian and North American  HS 
strains. The limited ability of the phenotypic 
classification systems to identify individual strains is 
evident among Carter type E isolates, in  which three 
distinct ribotypes were detected. Interestingly, ribotype 
classification of African HS isolates varied with 
restriction endonuclease; however, the degree of 
diversity remained the same.  While the choice of 
restriction enzyme did not appear to influence Asian  HS 
ribotype determination, Pstl  ribotype analysis of Asian 
HS strains did reveal  correlation with virulence, with the 
reportedly avirulent 0131  possessing a distinct profile. 
Ribotyping analysis also demonstrated discrepancies 
among the typing systems,  as a lack of correlation 
between reportedly equivalent reference type strains 
was observed. 
DNA preparation for ribotyping 
Extraction and  restriction enzyme digestion of DNA for 
ribotyping was performed as described for REA,  above. 
Southern blotting 
1.  Separate DNA restriction fragments by agarose gel 
electrophoresis (for DNA extraction, digestion and 
electrophoresis see above methods in  REA).  Soak 
agarose gel containing DNA fragments in 0.25 M 
HCI for 15 minutes, then in 0.4 M  NaOH for 
30 minutes with gentle shaking to depurinate and 
denature the DNA. 
2.  Transfer the DNA fragments to a nylon membrane 
(Hybond-W, Amersham, UK),  by either vacuum or 
capillary transfer.  For vacuum transfer, aTE 80 Transvac™ Vacuum  Blotter (Hoeffer Scientific 
Instruments, San  Francisco USA) was  used  at 
1-3 psi for 45 minutes. Capillary transfer is 
performed according to Sam brook et al.  (1989). 
Briefly,  place gel inverted on a support wrapped in 
wet blotting (3MM) papers in a container with 
transfer buffer: 10 x salt sodium citrate (SSC)  or 
10 x salt sodium phosphate/EDTA (SSPE);  see 
Appendix 6. Surround, but do not cover, gel with 
Parafilm or Saran Wrap.  Place a wet nylon 
membrane on  top of the gel, making sure there are 
no air bubbles between the membrane and the gel. 
Wet two pieces of 3MM paper in 2 x SSC and  place 
on  top of the wet membrane. Place a stack of 
paper towels on  top, and weigh down with a 500-g 
weight. 
3.  Following transfer,  immerse the membrane in 
0.2 M  Tris-HCI pH 7.0/2 x SSC for 10 minutes to 
neutralise the membrane. 
4.  Air-dry the membrane, and  use for hybridisation or 
store until required at 4°C,  wrapped in  plastic to 
prevent drying. 
Alkaline lysis/polyethylene glycol (PEG) 
precipitation of  plasmid DNA 
1.  Grow transformed E.  coli (E.  coli containing the 
desired  plasmid) in 20 mL  Luria broth (Luria-Bertani 
media) supplemented with appropriate antibiotic 
overnight at 37°C (use increased proportional 
volumes for large-scale preparation). Appropriate 
antibiotics are ampicillin (50 fJg/mL of medium) or 
tetracycline (12.5 fJg/mL of medium) depending on 
the location of the insert in the plasmid used. 
2.  Centrifuge cells for 10 minutes at 2000 x g. 
3.  Resuspend  the pellet in 450 fJL of glucose buffer. 
4.  Add 150 fJL of lysozyme solution and incubate for 
5 minutes at room temperature. 
5.  Transfer the solution to a 15-mL Corex 
centrifuge tube. 
6.  Add 1.2 mL of lysis solution (0.2 M NaOH/1 % SDS), 
mix by inversion, place on  ice for 5 minutes and mix. 
7.  Add 900 fJL of ice-cold potassium acetate 
solution and mix. 
8.  Centrifuge for 10 minutes at 12 000 x g at 4°C. 
9.  Pour supernatant into a new Corex tube, 
being careful not to transfer any white pellet. 
Discard the pellet. 
10. Add 1.5 mL of isopropanol and  mix by vortexing. 
11 . Place  in  a -20°C freezer for 15 minutes. 
12. Centrifuge for 15 minutes at 12 000 x g at 4°C. 
13. Discard the supernatant and resuspend  the 
pellet in 400 fJL of TE  buffer. 
14. Transfer the solution to a 1.5-mL microfuge tube. 
Plasmid digestion and purification of DNA probe 
Digest the plasmid with appropriate restriction 
endonuclease to generate the fragment to be  used 
as a DNA probe. Prepare and perform the digestion 
reaction according to the manufacturer's  instructions. 
Following the reaction, electrophorese the sample in 
a 0.8% agarose gel made with 1 x TAE,  containing 
1 % ethidium bromide. After electrophoresis, DNA 
fragments are visualised by UV illumination. Excise the 
fragment of interest and  purify using either glass wool 
or a commercially available purification kit 
(e.g. QIAquick Gel  Extraction Kit (QIAGEN) or 
BRESA-CLEANTM kit (Bresatec Ltd). 
Purify DNA fragments with glass wool, as follows. 
1.  Cut off the top of an  Eppendorf tube, creating a 
tube approximately two-thirds of the original size. 
2.  Pierce a hole with a 19-9auge needle in the bottom 
of the tube, and  insert a 3-mm glass wool plug 
in  the bottom. 
3.  Place this tube into a second Eppendorf tube, and 
load the agarose pieces in the top tube. 
4.  Microfuge the tube at 6000 rpm for 10 minutes, 
collect the effluent and store at -20°C until required. 
Random primer DNA labelling using a_32p dCTP 
cDNA probes are labelled using commercial random 
primer labelling kits (e.g.  Promega's Prime-a-Gene® 
labelling system). All reagents are supplied at working 
concentrations and stored at -20°C as directed by the 
manufacturer. To  prepare the nonradioactive dNTP mix, 
add together equal volumes of each of dATP, dGTP and 
dTTP.  Before the labelling reaction, cDNA template is 
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immediately on  ice. The following reaction  mixture is 
then prepared. 
•  30 iJL of denatured DNA (25 ng) 
•  10 iJL of 5 x labelling buffer (includes random 
hexadeoxynucleotides) 
•  2 iJL of unlabelled dNTP mix 
•  2 iJL of nuclease-free bovine serum albumin (BSA) 
•  10 units Klenow fragment (2  iJL) 
•  40 iJCi  [a-32Pl  dCTP (DuPont) 
Incubate the reaction at room temperature for 1 hour, 
then terminate the reaction by adding 2 iJL of 0.5 M 
EDTA.  Before use,  purify the radiolabelled probe using 
a Sephadex G-50 spin  column prepared as follows: 
1.  Insert a 3-mm glass wool plug at the base of a 
1-mL disposable syringe, and carefully fill the 
syringe with autoclaved Sephadex G-50 gel slurry 
avoiding the insertion of air bubbles. 
2.  Centrifuge the column encased  in a 10-mL 
centrifuge tube at 1600 rpm for 4 minutes. 
3.  Discard the eluant, and  again fill the column with 
Sephadex G-50 gel slurry. 
4.  Centrifuge at 1600 rpm for 4 minutes and  discard 
the eluant. 
5.  At this stage, spin columns can  be kept at 4°C with 
the tip submerged in  10 mM NaCI,  10 mM Tris-HCI 
pH 7.5, 1 mM EDTA buffer (STE)  and the other end 
sealed with paraFilm. 
6.  To  purify radiolabelled probes, first wash the spin 
column with 100 iJL  STE and centrifuge at 
1600 rpm for 4 minutes. 
7.  Discard the eluant, and add 50 iJL to the labelled 
probe, mix and then add the sample to the top of 
the column. 
8.  Centrifuge at 1600 rpm for 4 minutes and collect 
the labelled probe from the bottom of the 10-mL 
centrifuge tube. 
9.  Denature the eluted fluid at 100°C for 5 minutes, 
and chill on  ice prior to hybridisation with 
membrane-bound DNA. 
116 
DNA.DNA hybridisation using a 
hybridisation oven 
1.  Pre-wet the DNA-bound membrane and  mesh  of 
similar size  in  a container with 2 x SSe. 
2.  Ensure that the membrane overlays the mesh,  roll 
both into a roll and place into a hybridisation bottle 
(Hybaid Limited, UK). 
3.  Add 30 mL of 2 x SSC to the bottle and unwind the 
membrane/mesh by gently rolling the bottle along 
a flat surface.  Release air bubbles trapped between 
the mesh and  membrane by gently tapping the 
bottle in  an  upright position. 
4.  Remove the 2 x SSC and  replace with 15 m  L of 
hybridisation buffer (Appendix 6).  Use 15 mL for a 
single membrane in a large bottle, 20 mL for two 
membranes.  Incubate for 1-4 hours at 65°C in  a 
Hybaid™ hybridisation oven (Hybaid Limited, UK). 
5.  Denature salmon sperm DNA by boiling for 5 
minutes, and chill on  ice for 7 minutes before 
adding to hybridisation fluid. 
6.  Denature the radioactively labelled probe by 
boiling, and  cool for 5 minutes at room 
temperature. Then add to the hybridisation fluid 
and  hybridise overnight at 65°e. 
7.  Following hybridisation, wash the membrane twice 
at 65°C in Wash solution (0.1  x SSPE/0.1 %  SDS) 
with vigorous shaking for 10 minutes. 
8.  Blot dry and  wrap the membrane in clear plastic 
film ('cling wrap'). 
9.  Analyse by autoradiography by placing the 
membrane and a sheet of Cronex IV Medical X-ray 
film against a Quanta III  Cronex intensifying screen 
(DuPont) in  an X-ray cassette. 
DNA.DNA hybridisation using a water bath 
(If a hybridisation oven is  not available, DNA:DNA 
hybridisation can  be performed in  heat-sealable bags  in 
a 65°C water bath.) 
1.  Prepare the prehybridisation solution (about 0.2 mL 
of fluid  is required for each square centimetre of 
membrane). 2.  Pre-wet the DNA-bound membrane in a container 
with 6 x SSe. 
3.  Slip the wet membrane into a heat-sealable bag 
and  add the appropriate volume of prehybridisation 
solution. Squeeze as  much air as  possible out of the 
bag,  and seal the open end of the bag with a heat 
sealer. 
4.  Incubate the bag for 1-2 hours submerged in a 
65°C water bath. 
5.  Denature the DNA probe by boiling, and chill 
rapidly in ice water. 
6.  Working quickly, remove the bag from the water 
bath, and open the bag by cutting off one corner 
with scissors.  Add the denatured probe to the 
prehybridisation solution and then squeeze as much 
air as  possible from the bag. 
7.  Reseal the bag with the heat sealer so that as few 
bubbles as  possible are trapped in the bag. 
8.  To avoid radioactive contamination of the water 
bath, the resealed  bag can  be sealed inside a 
second, noncontaminated, bag. Incubate the bag 
submerged in the 65°C water bath overnight. 
9.  Following hybridsation, wash the membrane twice 
at 65°C in Wash solution (0.1  x  SSPE/O.1 % SDS) 
with vigorous shaking for 10 minutes. 
10. Blot dry and wrap the membrane in  clear plastic 
film ('cling wrap'). 
11. Analyse by autoradiography by placing the 
membrane and a sheet of Cronex IV Medical X-ray 
film against a Quanta III  Cronex intensifying screen 
(DuPont) in an X-ray cassette. 
C.  Field alternation gel electrophoresis 
Field alternation gel electrophoresis (FAGE)  involves the 
analysis of large chromosomal DNA fragments (up to 
10 megabase pairs in  length). This  is  achieved by 
suspending and lysing bacterial cells within a solid 
support (agarose), which provides stability for the 
chromosomal DNA preventing it from shearing into 
small fragments. The method is capable of 
demonstrating heterogeneity throughout the entire 
bacterial genome, providing a complete picture of 
strain variation. Townsend and Dawkins (1993) 
published an  extensive review of the technique and its 
applications, illustrating the versatility and increasing 
importance of FAGE  in the field of molecular biology. 
The combination of FAGE and restriction endonuclease 
digestion of chromosomal DNA can  provide important 
information regarding genetic variability between 
strains, allowing the examination of DNA 
heterogeneity throughout the entire bacterial genome 
without the complexity of REA profiles. FAGE  has also 
been used successfully to construct physical maps of 
bacterial genomes, and to provide definitive estimation 
of genomic size.  However, the greatest worth of this 
technique is  as an  epidemiological tool to determine 
the clonality of outbreak strains, because FAGE analysis 
has demonstrated greater discrimination than 
ribotyping or REA.  The spectrum of bacterial species 
examined by FAGE  has increased dramatically in the 
past decade, and the technique has become an  integral 
component of bacterial genetics and epidemiology. 
Equipment 
Special equipment: 
•  Pulsed field gel electrophoresis system (PFGE): 
- CHEF-DRII or DRill with Pulsewave switcher 
(Bio-Rad) (preferred) or 
- Gene Navigator (Pharmacia LKB) 
Consumables: 
•  Culture media (SBA and heart infusion broth [HIB]) 
•  Agarose (low melt preparative grade, Bio-Rad) 
•  Agarose (ultra pure DNA grade, Bio-Rad) 
•  Molecular weight markers (Promega or Bio-Rad) 
•  Lambda concatemers or Saccharomyces cerevisiae 
chromosomes 
•  EDTA 
•  Lysozyme 
•  Chromosomal proteinase K buffer (see Appendix 6) 
•  Restriction endonucleases and buffers (Iow- to 
medium-frequency cutters such  as Apal, 
Smal, or Notl) 
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•  TAE or TBE 
•  Ethidium bromide 
Analysis of HS-causing isolates of P.  multocida 
by FAGE 
Townsend et al.  (1997b) described a method for FAGE 
analysis of HS-causing isolates of P.  multocida. FAGE 
analysis of P.  multocida isolates has confirmed the 
homogeneity of Asian  HS-associated serotypes 
observed following examination of protein, 
lipopolysaccharides (LPS),  ribosomal and  repetitive 
extragenic palindromic (REP)-PCR profiles (Johnson et 
al.  1991; Townsend et al.  1997a; see Appendix 4). 
FAGE analysis also exhibited greater discriminatory 
power than ribotyping by further distinguishing North 
American isolates of similar ribotype. These cultures 
were thought to represent re-isolations from the 
original Buffalo 'B' strain following in vivo passage to 
retain virulence (Gochenour 1924). Studies by 
ribotyping (Townsend et al.  1997b) and  REA (Wilson et 
al.  1992) have been  unable to distinguish these 
isolates;  however, FAGE  analysis demonstrated 
relatedness but not identity between the cultures. 
Preparation of agarose plugs for FACE analysis 
1.  Grow bacteria to log phase in  HIB at 37°e. 
2.  Pellet bacteria by centrifugation at 
3000 rpm for 10 minutes. 
3.  Resuspend  and wash  the pellet in 0.05 M  EDTA, 
pH  8.0. 
4.  Discard the supernatant, and  resuspend  with an 
equal volume of 0.05 M  EDTA,  pH 8.0. 
5.  Prepare molten 2.4 % low melt temperature agarose 
(in  0.125 M  EDTA,  pH 7.5) and cool to 50°e. 
6.  Mix the agarose and cell  suspension in a 1:1  ratio, 
pipette the mixture into a plug mould and allow to 
set at room temperature for 30 minutes. 
7.  Remove samples from the mould and place into 
chromosomal proteinase K buffer (0.5 M  EDTA,  pH 
8.0; 0.001  M Tris,  pH 8.0; 1 % N-Iaurylsarcosine, 
1 mg proteinase K/mL of buffer). 
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8.  Incubate overnight at 50°e. 
9.  Wash the plugs with 0.05 M  EDTA (pH  8.0) three 
times at room temperature for 30 minutes each. 
10. Store the plugs at 4°C in 0.05 M  EDTA, 
pH 8.0 until required. 
Restriction digestion and electrophoresis 
1.  Rinse plugs twice in double distilled water for 
30 minutes at room temperature. 
2.  Wash twice with 50 x volume of TE  pH 8.0 for 
30 minutes at room temperature. 
3.  Wash once in  ice-cold double distilled water on ice 
for 30 minutes. 
4.  Wash once in 250 fJL  1 x restriction buffer on ice 
for 30 minutes. 
5.  Add 40 fJL  restriction enzyme and 2 fJL  BSA 
(1  mg/mU and stand on ice for 30 minutes. 
6.  Incubate overnight at an  appropriate temperature 
for the enzyme. 
7.  Add 12  fJL 0.5 M  EDTA pH 8.0 to terminate the 
enzyme reaction. 
8.  Place plugs and  molecular weight standards into 
wells of a 1 % agarose gel, 0.5 x TAE. 
9.  Remove any trapped air bubbles and  seal wells with 
0.8% molten agarose. 
10. Place gel in  an  electrophoresis chamber and 
equilibrate the gel and buffer (0.5 x TAE) at running 
temperature (14°C) for 30 minutes before the run. 
11. Use the following conditions: 
- for 7-400 kilobases: 0.5-35.5-second switch 
ramp, 170 V,  24 hours 
- for 0.1-1  megabases:1 0-150-second switch 
ramp, 180 V,  24 hours 
12. Following electrophoresis, stain the gel  in 0.5 x TAE 
with ethidium bromide (1  fJg/mL) for 30 minutes. 
Destain in double distilled water for 30 minutes, 
and then visualise with UV illumination. Preparation of Buffers and Solutions 
When preparing and  using buffers and solutions: 
•  use the highest grade of reagents available 
•  prepare all solutions with double-distilled, 
deionised water 
•  where possible, sterilise all solutions by 
autoclaving or by filtration. 
Phosphate buffered saline (PBS) 
For 1 litre, use: 
NaCI  8.5 g 
1.07 g 
0.39 g 
Make to volume with double distilled water; adjust pH 
to 7.2-7.4 and autoclave. 
Citrate buffer (0.1 M) 
For 1 litre use: 
Citric acid  21.01  g 
Make up to volume with double distilled water; adjust 
pH  to 4.2 with 10 M  NaOH and autoclave. 
EDTA (0.5 M) 
For 1 litre, use: 
Ethylenediaminetetraacetic acid 
(EDTA).2H20  (MW 372.2) 
NaOH pellets 
Double distilled water 
186.1  g 
-20 g 
800 mL 
Adjust the pH  to 8.0 with NaOH; make up to volume 
with double distilled water and autoclave. 
Tris-EDTA (TE),  pH 8.0 
For 500 mL,  use: 
0.5 M  EDTA,  pH  8.0 (1  mM EDTA)  1 mL 
1 M Tris-HCI, pH  8.0 (10 mM Tris-HCI)  5 mL 
Make up to volume with double distilled water; 
autoclave or filter-sterilise. 
Tris-acetic acid-EDTA (TAE) 
Make stock solution as 50 x TAE 
For 1 litre use: 
Tris  base  242 g 
Glacial acetic acid  57.1  mL 
0.5 M  EDTA,  pH 8.0  100 mL 
Make up to volume with double distilled water and 
autoclave; store at room temperature or 4°C. 
Tris-boric acid-EDTA (TBE) 
Make stock solution as 10 x TBE 
For 1 litre, use: 
Tris base  108 g 
Boric acid  55 g 
0.5 M  EDTA,  pH 8.0  40 mL 
Make up to volume with double distilled water and 
autoclave; store at room temperature or 4°C. 
CTAB/NaCI solution 
10% cetyltrimethylammonium bromide (CTAB)/0.7 M 
NaCi.  Dissolve 4.1  g NaCI  in 80 mL H20  and slowly 
add  10 g CTAB while heating and stirring. If necessary 
heat to 65°C to dissolve. Adjust to final volume of 
100 mL. 
Salt sodium citrate buffer (SSC) 
Make stock solution as 20 x SSC 
For 1 litre, use: 
NaCI  (3  M)  175.3 g 
88.2 g 
Adjust pH to 7.0 with 1 M  HCI;  make up to volume 
with double distilled water and autoclave. 
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Make stock solution as 20 x SSPE 
For 2 L,  use: 
NaCI  248 g 
NaH2P04.H20  (or 62.4 g NaH2P04.2H20)  55.2 g 
EDTA  14.8 g 
Add about 1600 mL double distilled water; adjust pH 
to 7.4 with NaOH (about 6.5 mL of a 10M solution); 
make up to volume and autoclave. 
Tris-HCI (0.2 M), pH 7.0/2 x SSC 
For 2 L,  use: 
1 M Tris-HCI,  pH 7.0  400 mL 
20 x SSC  200 mL 
Make up to volume with double distilled water. 
DNase-free RNase 
For 10 mL,  use: 
Ribonuclease powder (usually 1 vial)  100 mg 
1 M Tris-HCI, pH  7.5 (10 mM Tris-HCI)  100 jJL 
1 M NaCI  (15 mM NaCI)  150 jJL 
Make up to volume with sterile double distilled water, 
and heat at 100°C for 15 minutes. Allow to cool slowly 
to room temperature, dispense into aliquots and store 
at -20°e. 
Type IV gel loading buffer 
For 20 mL,  use: 
Bromophenol blue  0.25% (0.05 g) 
Sucrose  40% (wt/vol) (8 g) 
Make up to volume and store at 4°C in  1-mL aliquots. 
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Chromosomal proteinase K buffer 
For 100 mL,  use: 
1 M Tris-HCI, pH  8.0 (0.01  M)  1 mL 
Sarkosyl  1 % (wtlvol) (1  g) 
Make to volume with 0.5 M  EDTA,  pH 8.0;  add 
proteinase K (final concentration, 1 mg/mL) to an 
aliquot of chromosomal proteinase K buffer when 
required. 
Salmon sperm DNA preparation 
1.  Dissolve 500 mg of salmon sperm  DNA in sterile 
double distilled water to 50 mL (concentration 
10 mg/mL). 
2.  Stir the solution on a magnetic stirrer for 2-4 hours 
at room temperature to allow the DNA to dissolve. 
3.  Shear the DNA by sonication for 15 minutes at 
5-minute bursts (i.e. three bursts). 
4.  Check that the shearing process  is complete by 
electrophoresis of 1 jJL of single-stranded (ss)  DNA. 
Sheared  DNA should be between 400 and 700 base 
pairs (bp). If incomplete, sonicate again. 
5.  When completely sheared, denature the DNA by 
boiling for 10 minutes, filter through a O.22-jJm 
filter to sterilise, and store at -20°C in 1-mL aliquots. 
6.  Just before use, boil the ssDNA for 5 minutes, then 
chill quickly on  ice (ssDNA needs to be reboiled and 
denatured before each  use). Vaccine Production and Quality Testing 
Vaccine production and quality testing involve the 
following steps. 
•  Production: 
- seed  management; 
- dense culture production; 
- culture inactivation; and 
- vaccine formulation. 
•  Quality control: 
- validation of the production technique; 
- in-process controls; and 
- testing of the finished product. 
Seed  management 
Usually, a local isolate from an outbreak of 
haemorrhagic septicaemia (HS)  is  used. A good seed 
culture has to be well capsulated and grow rapidly, 
producing large translucent colonies of around 2 mm 
diameter on casein-sucrose-yeast (CSY)  blood agar in 
24 hours. Colony size  is often a good indicator of 
capsulation. The colony has to be stable, and consistent 
in  its characteristics. Cultures should  be stored in 
semisolid nutrient agar slants at room temperature or 
as deep frozen or freeze-dried infected blood. 
Periodically (say once a year) a mouse-passaged seed 
culture is inoculated to a young antibody-free calf by 
the subcutaneous route.  Ideally, blood should be 
collected from the jugular vein of this calf when the 
calf is  moribund and about to die or within 1-2 hours 
of death. The blood is collected aseptically into a sterile 
vessel  containing an  anticoagulent. It is often not 
possible to observe this stage, which may arise at night. 
In such  situations, the blood is collected within a few 
hours of death by puncture of the jugular vein. 
Following culture of the blood, a few good capsulated 
colonies are tested for purity and agglutinability and 
portions of these are inoculated onto either sterile 
defibrinated ox blood or ox blood containing an 
anticoagulant. Either the infected blood directly 
obtained from the calf, or the ox blood inoculated with 
pasteurellae and  incubated overnight, is tested for 
purity by blood smear examination; if pure, it is 
dispensed in  1.0-mL aliquots in  sterile screw-capped 
bottles and stored frozen at -20°C or below. 
Alternatively, for long-term storage, the blood may be 
freeze-d ried. 
It is  best to use a fresh  bottle of blood for every batch 
of vaccine. One or two subcultures may be used, 
provided there is  no sign of dissociation as evidenced 
by reduction in colony size. The thawed frozen blood 
or reconstituted Iyophilised blood is  plated out and 
single colonies are transferred onto a suitable liquid 
medium in 10-mL volumes in McCartney bottles and 
incubated at 3JOC for 6-8 hours. These bottles are then 
transferred aseptically on to 500-mL volumes of the 
same liquid medium in 1-litre flasks.  These flasks, 
incubated overnight, will constitute the inoculum for 
bulk culture production. 
Bulk culture production 
Media 
A variety of liquid media have been  recommended in 
different countries: 
Medium described by Bain et al.  (1982) 
The medium described by Bain  et al. (1982) consists 
basically of three components: (A) acid digest of casein; 
(B) autodigest of pancreas; and (C) yeast extract. 
Complete medium is prepared by adding these 
components to a basic medium (D), as described below. 
(A)  Acid digest of casein 
1.  Weigh out 200 g of commercial casein  powder and 
place in a dry 1-litre conical flask. 
2.  Prepare a mixture of 170 mL concentrated (10 M) 
HCI and  110 mL of distilled water. 
3.  Pour this over the casein  and stir briskly with a glass 
rod  to ensure thorough mixing before the casein 
swells and  hardens. 
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Do not plug with cotton wool, as it will be destroyed 
by the acid on  heating. 
5.  Put the flask in the autoclave, raise the pressure 
to 15 psi  at 121°C and  maintain at this level for 
45 minutes. 
6.  On removal from the autoclave, cool the digest 
to room temperature and transfer to a 3-litre 
pyrex beaker. 
7.  Using cold 5% NaOH solution, adjust the pH of the 
digest to 7.0. When adding the NaOH, put the 
beaker in an  ice bath, as the temperature of the 
digest must not be allowed to rise above 30°C. The 
volume of fluid at this stage  is approximately 2 litres. 
8.  Add 30 g of activated decolourising charcoal and 
transfer to a suitable Florence flask fitted with a 
reflux condenser.  Boil for 20 minutes. 
9.  Filter to remove the charcoal. 
10. Add another 30 g of charcoal and repeat reflux 
boiling for a further 20 minutes. 
11. Filter through a clarifying pad to remove the 
charcoal. 
12. The pale amber fluid obtained is the stock casein 
acid  hydrolysate. If it is to be stored for later use, 
add  1  % chloroform as a preservative. 
The acid  hydrolysate can  be obtained in dry form as 
'casamino acids'. The process destroys the aromatic 
amino acids,  which are added in the form of an 
enzymatic digest of casein. 
The scale of production depends on the apparatus 
available. A digest from 400 g of casein  is sufficient 
base material for 24 litres of medium. Ordinary 
commercial grades of casein are adequate, but dried 
milk powder cannot be used. The acid digest is easy to 
make and filter.  No difficulties should be experienced, 
provided a good decolourising charcoal is  used. The 
final product should be a clear amber colour without 
any suggestion of blackness. 
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(B) Autodigest of  pancreas 
1.  Take about 5 kg of pancreas (pig, sheep, ox or 
buffalo seem to be equally effective). Trim off fat 
and loose connective tissue. Mince or (better still) 
disperse finely in  a blender or disintegrator. 
Measure the volume and add half the quantity of 
tap water. Adjust the pH to 9 with (10 M) NaOH 
and  place in a water bath at 45°C. Correct the pH 
every half hour (it falls conSiderably during the first 
few hours). Use an automatic stirrer and leave for 
5 hours to digest. At the end, there should be little 
left other than fibrous connective tissue. 
2.  Remove from the bath and adjust the pH to 4 with 
HCI.  Filter through muslin.  Heat the filtrate to 
boiling and leave in the boiling water bath for 
5 minutes. Cool and store in the refrigerator 
overnight. 
3.  Heat to 80°C and filter through paper. Adjust the 
pH to 7.4, heat to boiling and  leave for 5 minutes 
in the boiling water bath. 
(C) Yeast extract 
This may be prepared in the laboratory from dried 
inactivated yeast powder that is available commercially 
wherever yeasts are produced for industrial purposes. 
1.  Weigh out 450 g of yeast powder. 
2.  Suspend evenly in 5 litres of distilled water, 
avoiding lumps. A large vessel such  as a 20-litre 
stainless steel  bucket should be used,  as the yeast 
suspension froths greatly when boiled. 
3.  Bring the suspension to the boil and continue to 
simmer for 5 minutes with constant stirring to 
prevent boiling over. 
4.  Cool. 
5.  Recover the fluid extract of yeast either by 
centrifuging or by allowing to stand, decanting the 
supernatant and filtering through paper pulp on a 
Buchner funnel. About 3 litres should be obtained. 
6.  The clear straw-coloured fluid is the stock yeast 
extract ready for use in the medium. It may be 
preserved for storage by the addition of 1  % 
chloroform. (0) Basic medium 
Tryptone or casitone 
Sucrose 
Disodium hydrogen phosphate 
(Na2 HP04  12 H20) 
Potassium dihydrogen phosphate 
(KH2  P04 7 H20) 









1.  Mix items A, C and D (above) in a large vessel  in 
the following proportions: 
A.  acid digest from 400 g of casein 
(approximately 4 litres) 
C.  5 litres of home made yeast extract 
D.  5 litres of basic medium. 
Make up the volume to 24 litres with distilled water. 
2.  Adjust the pH to 7.6 with 10% NaOH solution. 
3.  Autoclave at 18 psi for 10 minutes. 
4.  Remove from the autoclave and filter through 
paper or pulp. 
5.  Adjust to pH 7.0 with 10% HCI  solution 
6.  Transfer to a vortex tank and steam for 15 minutes. 
After cooling, 1 litre of pancreatic digest (item B)  is 
added via a seitz filter and the medium is  ready for 
inoculation. 
Note: The production of components A, Band C is 
laborious and is  not practised in modern production 
laboratories. A range of dehydrated media of 
bacteriological grade are available instead. Commercial 
'casamino acids' (an acid digest of casein, 
supplemented with enzymatic digest of casein) may be 
used, together with commercial dehydrated yeast 
extract of bacteriological grade. There is no simplified 
method of preparing item B (autodigest of pancreas). 
This ingredient, however is  not used in many modern 
media, because substitutes that provide comparable 
growth promoting effects, such as yeast extract, are 
available. Furthermore, the use of material of animal 
origin is  not encouraged, as  this could result in 
transmission of pathogens from the species of origin of 
the material to the species on which the vaccine is to 
be  used. 
Hence, items A and C can  be replaced by 500 g of 
casamino acids and 100 g of dehydrated yeast extract, 
respectively. Item B can be omitted because adequate 
yields can be obtained without it. 
Medium used in Malaysia (Thomas 1968) 
Peptone (Oxoid)  150 g 
Lab Lemco (Oxoid)  150 g 
Sodium chloride  75 g 
Sodium bicarbonate  75 g 
Glucose  30 g 
Yeast extract  60 g 
Autodigest of pancreas (seitz filtered)  750 mL 
Distilled water up to  15 litres 
Medium used in Thailand (Pakchong vaccine 
laboratory,  1988-89) 
Tryptose  20 g 
Yeast extract  3g 
Sodium chloride  5g 
Dextrose  1 g 
Distilled water  1 litre 
pH  7.4 
Medium used in Egypt (Geneidy et al.  1967) 
Casamino acids  500 g 
Casitone (Difco) or tryptone (Oxoid)  120 g 
Yeast extract  100 g 
Sucrose  45 g 
Magnesium sulfate  25 g 
Phosphate buffer 
Na2HP04  175 g 
KH2P04  45 g 
Distilled water  25 litres 
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(Arawwawela et al. 1981) 
Acid hydrolysate of casein 
----









Dipotassium  hydrogen phosphate 




Potassium dihydrogen phosphate  1.36 g 
(KH 2 P04, anhydrous) 
------
Distilled water  1 litre 
The first three ingredients are prepared as a 
concentrate, filter-sterilised and added to the bulk tank 
containing the other ingredients, which have been heat 
sterilised. 
Bulk culture methods 
Various methods are adopted for the production of 
dense cultures in bulk. These include the use of vortex 
tanks with vortex aeration and sparger aeration 
systems. The former system is  now obsolete, and 
vortex tanks are no longer manufactured. Sparger 
aeration can  be done using simple, improvised systems, 
or by the use of automated fermentors. 
Simple sparger aeration system 
The inoculum is  prepared in 500-mL volumes in  1-litre 
flasks. The system requires at least 4-6 such flasks 
tested and certified for purity. The medium used  is the 
CSY broth medium. 
A diagrammatic representation of the layout of the 
equipment is shown in  Figure A7-1. The growth vessel 
consists of a 40-litre glass vessel  (F),  placed in a locally 
manufactured water bath (G) consisting of an 
aluminium vessel fitted with a heating element and a 
thermostat. The three glass tubes passing through the 
tight-fitting rubber stopper consist of a filtered air inlet 
(D), air outlet (H) and opening (N) for introduction of 
presterilised liquids and inoculum. All openings are 
controlled by stainless steel clips. The air outlet tube 
passes  into a foam trap (I) that collects the froth that 
passes through the outlet tube; the outlet stream of air 
passes out through tube J and bubbles through a 10% 
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formalin solution in flask K (to prevent infective 
aerosols) before passing to the exterior through tube L. 
The current of air from a compressor is delivered through 
tube A. Tube B,  controlled by opening or closure of the 
clip, helps to control the flow of air through the in-line 
filter C before passing through tube D to be dispersed 
into small bubbles through a filter candle E,  which serves 
as a sparger. Tube M, which also passes through an in-
line air filter, may be opened only when an additional 
current of air is required to pump the sterile filtrate 
(yeast, casein  hydrolysate and sugar solution) into the 
tank (F)  through tube N and also the inoculum. If the 
aeration of the tank is started before the above 
operation, the positive pressure built up within the tank 
will prevent the entry of an air current through tube N 
when opened, and will help to avoid contamination. 
It is important that the whole assembly, including the 
filtration set-up, is adequately sterilised in a large 
autoclave at 121 DC  for 45 minutes; if contamination 
occurs, it is  usually due to understerilisation. The use of 
a large inoculum (2-3 litres of 6-8-hour culture in the 
same medium for 40 litres) and early harvesting 
(18-20 hours) help further to obtain a dense growth in 
a short time, with no chance for any contaminants to 
multiply. The entire process should be carried out in a 
relatively clean room. 
Preparation of the bulk culture 
The inoculum prepared with the seed  culture is 
introduced into the medium in  the 40-litre vessel 
through tube N by building up a positive pressure in 
the flask by introducing sterile air through in-line filter 
M. The volume of inoculum (i.e. the number of 
500-mL culture flasks used) is about 10% of the 
volume of medium used in the bulk culture production. 
The temperature of the water bath (G) containing 
the 40-litre culture vessel  is  maintained at 37DC.  The 
introduced culture in the 40-litre vessel  is  incubated 
for 16-18 hours with adequate fine aeration through 
the sparger (E). 
At the completion of the incubation, the bulk culture 
harvest is obtained. A sample of the harvest is  collected 
for quality control. The bulk harvest is inactivated by 
introducing a calculated volume of formalin to give a 
final concentration of 05%, by opening the mouth of 
the vessel  while aerating. During this process the L  J  ~D 
f,=-==F= ......  o 
A 
G 
Figure A7-1.  'Fermentor' apparatus for bulk culture of  P.  multocida (see  text for explanation of letters A-O). 
sterility in the vessel  is  maintained due to the positive 
pressure built up in the vessel.  The added formalin is 
thoroughly mixed with the harvest by aeration of the 
vessel for another 30 minutes. 
The inactivated harvest is then transferred into a 
50-litre sterile can through tube 0 of the 40-litre vessel. 
The collected harvest is allowed to stand at room 
temperature for 24 hours to complete the inactivation 
process and then stored at 4°C until formulation of the 
vaccine. 
Use of fermentor 
A 1  ~O-litre fermentor will have a working capacity of 
about 80 litres. Assuming that the growth gives just the 
required density, a batch will yield 80 litres of harvest, 
giving rise to 160 litres of oil adjuvant vaccine 
(equivalent to approximately 53 000 doses of vaccine). 
Often, the density is  higher, and the harvest can  be 
diluted, thereby yielding more vaccine per batch. Most 
manufacturers of fermentors will modify basic 
fermentors to suit customer requirements. 
Desirable features in a fermentor meant for this 
purpose are: 
•  an in situ sterilisation chamber, of adequate capacity 
for the scale of operation, with ports for inoculation, 
introduction of filter-sterilised fluids and harvesting, 
and a few extra ports for use if necessary; 
•  rapid  (3D-minute) cooling system 
from 121 DC to 37°C; , 
•  automatic temperature and pH control systems; 
•  manual air flow control; 
•  panel indicating all  relevant parameters; 
•  built-in fluid filtration system; and 
•  steam generator and compressor to match. 
Preparation of the medium 
Heat-sterilised components 
The heat-sterilised components (sterilised in the 
chamber in situ) consist of the following: 
125 Dipotassium hydrogen phosphate 
(K2HP04, anhydrous) 
Potassium dihydrogen phosphate 
(KH2P04, anhydrous) 





72  litres 
The mixture is sterilised  in  situ  in the fermentor chamber 
at 121°C for 1 hour. The sterilisation phase is as follows. 
The chamber temperature is set at 121°C and stirrer 
speed at 200 rpm. It takes around 45 minutes for this 
temperature to be reached.  This temperature is 
maintained for 60 minutes, at the end of which it is  reset 
at 37°C. The time taken to cool from 121°C to 37°C is 
approximately 30 minutes in most fermentors. Thus the 
sterilisation phase requires a total of 2.25 hours. 
Other components 
The other components, which are not sterilised by 
heat, are as follows: 
Yeast extract  480 g 
Cane sugar  480 g 
Casein  hyd rolysate  160 g 
These are added to 8 litres of distilled water, heated to 
65°C and stirred until dissolved. 
The mixture is then sterilised by filtration using a built-
in sterilisation system with a 10-litre vessel and 
cartridge-type in-line filters or a 1  O-litre capacity 
filtration vessel for positive pressure filtration using seitz 
D9 filter pads or equivalent membrane or cartridge-
type filtration systems. 
The 8 litres of filter-sterilised solution is transferred to 
the chamber through a separate port after the chamber 
temperature has dropped to 37°C. 
Inoculation of the medium 
Eight litres of the inoculum (pretested for purity and 
agglutinability) is introduced into the chamber through 
a separate port under positive pressure. The process 
takes about 15 minutes. The total volume in the 
chamber after inoculation and the commencement 
of incubation is approximately 90 litres. 
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Incubation phase 
The chamber is  now at 37°C, containing the additives 
and the inoculum. The stirrer speed  is set at 50 rpm. 
and the air flow is adjusted so  as to permit adequate 
bubbling through the liquid, without undue formation 
of froth. The total incubation time is  18 hours and the 
bacterial harvest is obtained at the end of this 
incubation period. 
Inactivation 
The bacterial culture is  inactivated in the harvest by 
adding 0.5% formalin (36-40% formaldehyde 
solution) to a final concentration of 0.5% and stirring 
at 50 rpm for 5-10 minutes. The harvest is then held at 
room temperature for 24 hours. 
An air pressure of 1 bar is  built up in the chamber. 
A sterile tubing system  is  connected to the harvesting 
port. The  harvesting port valve is opened and the 
harvest is collected in sterilised stock cans. 
Formulation of the vaccine 
The type of formulation depends on what type of 
vaccine is  required. It is important to ensure that the 
required mass of whole bacteria is  present in the 
vaccine. Each  dose of vaccine should contain 2 mg of. 
bacteria (dry weight). The inactivated harvest must 
therefore be standardised. First, the dry bacterial mass 
of a dense harvest must be determined. After this initial 
determination, a relationship can  be determined 
between dry bacterial mass and the turbidity of the 
bacterial suspension, and dilutions of it, measured 
using any standard turbidity measuring system. Thus,  if 
broth bacterin, alum precipitated or aluminium 
hydroxide gel vaccine is to be prepared, the harvest is 
standardised to contain 2 mg in 3 mL.  For the oil 
adjuvant vaccine, 2 mg should be contained in  1.5 mL 
of standardised harvest since a 3-mL dose will contain 
only half its volume of bacterin. 
Alum precipitated vaccine 
A 10% hot potash alum solution (i.e 1 litre of potash 
alum to 99 litres of bacterin)  is  added to the harvest to 
give a final concentration of 1 %. The pH  is adjusted to 
6.5 and the solution allowed to stand overnight. Aluminium hydroxide gel vaccine. 
To the standardised harvest, 3% aluminium hydroxide 
gel  is added to give a final concentration of 0.3 %. 
Oil adiuvant vaccine 
The original formulation (Bain and Jones 1955) 
consisted of equal volumes of bacterin and mineral oil 
with approximately 10% anhydrous lanoline. This 
vaccine has a high viscosity.  Newer formulations that 
enable less viscous emulsions to be produced contain 
either lower concentrations of lanoline or other modern 
adjuvants and emulsifying agents. 
Some of the formulations of the oil adjuvant vaccine 
currently in  use are given below. 
Formulation used in Sri Lanka 
Mineral oil  48 parts 
Anhydrous lanoline (BP grade)  4 parts 
Bacterin  48 parts 
Formulation developed in  Thailand (Neramitmansook 1993) 
-------




Experimental formulations developed in Pakistan 
(Muneer et al.  1993) 










(ii)  Mineral oil (Marcol 52)  63  parts 
----.---~--
Arlacel 'A'  7 parts 
Bacterin (containing 5% Tween 80)  30 parts 
(iii)  (medium used  by Shah et al.  1997) 
---------






The emulsifier used  is a blend of Span  85 
(sorbitantriolate) and Tween 85 (polyoxyethylene 20 
sorbitan triolate) in the ratio of 54:46 (vol/vol). 
Emulsification process 
Emulsification is carried out using a turbo emulsifier. 
The oil and emulsifying agent mixture are added to the 
emusifying vessel and  sterilised  by heat. The emulsifier 
is then switched on, and the bacterin is added slowly 
through a port on a side under positive pressure.  If a 
40-litre vessel  is  used with 20 litres of oil-emulsifier 
mixture, 20 litres of bacterin is added over a period of 
8-10 minutes. Emulsification is continued for a further 
10 minutes, with sufficient formalin added to give a 
final concentration of 0.5%. The stability of the 
emulsion is  improved if the cans are left overnight at 
room temperature and emulsified for a further 
10 minutes before bottling. It is  also recommended that 
the bottles of emulsified vaccine are stored for 14 days 
at 4-8°C, before release for testing. 
Quality testing of vaccines 
Quality testing can  be broadly divided into three 
categories: validation of the production technique, 
in-process control tests, and tests with the finished 
product. 
Validation of technique 
HS vaccines produced in  different countries vary in 
their production methodology. Variations occur in the 
composition of the growth medium, the seed  culture 
used, the formulation and the bacterial content. The 
composition of the growth medium is  more important 
than was  recognised  in the early years of vaccine 
production; it is  not only the bacterial mass that 
matters, but also the quality of bacterial growth. There 
is  insufficient information to define the growth medium 
that facilitates the expression of a full complement of 
important immunogens, but once a medium is  proven 
to produce effective vaccine, it is important to adhere 
to it without deviations. Micronutrients in the medium 
may also playa role in the type of growth and antigens 
expressed, so it is desirable to standardise even the 
grades and  brands of chemicals and  media used. 
127 The complete production technique, which consists of 
growth medium, seed  culture and formulation, should 
be tested for stability, potency (including duration of 
immunity) and shelf life. Tests for stability should 
include storage at 3JOC,  and  measurement of electrical 
conductivity. Potency should  be tested in  mice, and 
there should be a duration-of-immunity test in cattle 
and buffaloes. As a measure of shelf life, the above 
tests should be carried out after different periods of 
storage at the desired temperatures (4°C and tropical 
room temperatures). If any change is made to the 
technique, the new technique must be validated in 
regard to the above parameters. 
In-process control tests 
The seed  culture plate, seed  culture flasks and final 
harvest are tested for purity by smear examination. 
As an additional test, the agglutinability of each of the 
above is tested  using rabbit antiserum. Testing for 
inactivation is  carried out with the harvest after 
addition of formalin and standing for 24 hours. The 
turbidity of the harvest should be matched against a 
standard equal to 1.5 mg/mL and  adjusted. 
Tests with the finished product 
Tests  for sterility 
Tests for sterility and  inactivation of the bacterial 
agent are carried out by plati ng out 0.1  m  L of the 
vaccine on blood agar and  Sabouraud's agar and 
incubating for 24 hours. 
Safety test 
Ten  mice are inoculated, each  with 0.5 mL of the 
vaccine by the subcutaneous route, and observed for 
7 days.  All mice should survive without showing any 
adverse effects. 
Potency test 
Selected  batches (approximately one in five) are tested 
using an  active mouse protection test (AMPT). Of 100 
mice, 6-8 weeks of age, 50 are given 0.5 mL of vaccine 
by the subcutaneous route. After 14 days, the 
vaccination  is  repeated. One week after the second 
vaccination, the 50 vaccinated mice as well as the 50 
unvaccinated mice are divided into 10 groups of five 
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each.  A 6-8 hour culture from a local field strain of 
Pasteurella multocida is serially diluted to give 10-fold 
dilutions. For each dilution a group of vaccinated  (5) 
and a group of control (5)  mice are given 1.0-mL by the 
intraperitoneal route. All mice are observed for 7 days. 
The median lethal dose (LD50), measured as the 
dilution of the P multocida suspension tested, for 
vaccinated and unvaccinated mice  is calculated by the 
method of Karber (1931) as follows: 
log LD50 = 0.5 + log H- sum of A 
100 
where: 
H =  the highest bacterial concentration (eg -1, if the 
highest concentration tested was 10-1) 
A=  the sum  of the death rates (%) at each dilution 
A minimum difference of 4 log units is  required 
between log LD50 values for vaccinated and control 
mice.  For example, if the log LD50 is calculated to be 
-1.9 (ie 50% of mice die when the bacterial suspension 
is  diluted 10-19), the log LD50 for control mice should 
be at least -5.9 (ie 50% of the mice die when the 
bacterial concentration is diluted 10-59). 
When the approximate LD50 is  known, the number of 
mice used can  be reduced slightly. The AMPT is 
preferred over the alternative passive mouse protection 
test (PMPT) because the latter, which involves 
vaccination of five cattle or buffaloes and  inoculation of 
mice with vaccinated cattle serum (five mice for each 
animal vaccinated plus five controls), is  both 
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